var title_f8_25_8592="Pili torti";
var content_f8_25_8592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Pili torti",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This flattened, twisted hair shaft was taken from a patient with Menkes disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8592=[""].join("\n");
var outline_f8_25_8592=null;
var title_f8_25_8593="Tubal recanalization c";
var content_f8_25_8593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Tubal recanalization C",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 331px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFLAfMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0y+urhbycCeXAkI+8eOTVOe8uccXEw/4Gamv/APj9n/66H+dUbgfKea60lY+bcnf5lSS9vN5Aup/wc0sd7edTdT8df3hqq2d59c1IBhcdzRYfNLuy0t7dn/l5m/7+GrEd5dBebib/AL7NUoxyMGpjwMU0kJykWfttzjm4m/77NV5ru7/5+Z/b5zTQ2R2pHHy9ORQ0gUn5kRvroE/6VP8A9/GpjX12FIFzP/38aopfvn3puRjmlYpSYpv73OPtU+P+ujUgv7zbj7XPx/00aoWGegFBbAwTzRYOaXcl+3XuP+Pu4z/10ake/vcf8fdxxyPnNRKfWklG8cH8KLBzS7sJL68KD/TbkY/6amqx1G+2ki+uc/8AXVqkkjzFjtVNhtBxyKVkNSkJc6nfj7t7c5/66tVCbU9SDD/T7vPr5zVJOATzndTCm5fpSsWpMSLUr8ZLahdk9v3zf41Kuq6hnJvbvnp+9aq7KAoPGc8e1OUYXIxkdqLBzS7smbUtRBJ+33XPT981J/a+oYx9vusHqfObioCrNkEjHfiowByABkHvRYXM/MnbVNRXOb+7x2/fNToNV1Bmwb67P/bZjVU5YjA4+lSpHtOFGM80WHzS7mjDqWoLyb65+nnNVmPUr7GRe3OSP+ejVloNz4weK0YoeFPp1ppCcmTw3l+x3vfXIVef9a3NU77WL+Risd7crj/pq1TXUoSEjIAPWseVlY5X8TSaEpS3Jm1PUVXP9oXeT/02apbHU9REvz390Qe3msazzuxg4NPteG3DH+BosU5M6MarfA7Rd3A/7aNViPUr0gZu7g/9tDWQrKxU96tIeAR90etFiHJmkl/eMebucAf9NGqU312AMXU//fxqz1YdPfNSMw25J6U7IXMyy2oXfH+lT/8Afw0xtRvOALufP/XRqqs5ZsCmMduc/wA6LIOZ9y02o3YGftdxn/ro1RNqN4Bn7Xcf9/G/xqo8mQCOT6VXlkK54NFkNOXmXH1a7Bwby44/6aNUMmq3quMXlyc/9NTWdI53EHG09KhmkwwHGfTNKxV33Z0Nrrt5G4V7yfnpmRv8a6C11OeVQRcy8/7ZrzWZjvV9xBFb2iXzblV888ihJEyv5nZS3V0ycXE2f981nzTXmSRdXH/fxv8AGrUDB0H0pzRg+lVYhTkjIkkvcjF5ckf9dGqF9QntzmW/nHfmVqsapKYoyI2AODzXBancM87ZZuh5NJqxcXJ9TqLrxSIF+W7unx1Ikaqg8dOv/LW5x/10NcFd3DLnaxPPNVSS43dsUty0j2HS/FouyoF1MCfWQ/41vm9uCBi5mxjs5rwvSbjbcKFYgAg161ps/m2UbEknbzQiJprVXNR7m6OSLmb/AL7NQS3F2QR9pn/7+NVaa9EEqiQfK3Q+9WlZXXcOaqxHM13OW1+TU4mEkN5d7SegmYY/Wudv9R1ZbZpF1C9Xb1/ft/jXos8SupDAEGuP8ZwpBpcvlqAT6UOKLjUkcTca3rCpuOrX4AGT/pL/AONc9e+K9ZDHbrOpAD0upB/Wo9WvisGxs56j2FcvdSMznpjPT0rJ2R20lLc2X8WeIHBA1vVB7i7k/wAagPirxCOP7e1b/wAC5P8AGsmM4O73zU1wok+ZSCP8/wD16VrmqbL3/CVeIf8AoPat/wCBkn+NKfFfiE4/4nuq8cf8fkn+NZDKd5zTxgDoBRZBzM1m8U+IgvGu6t/4GSf41D/wlniIf8x7Vv8AwMk/xrKd8jr0FQEH0/Gkyotn1X8JdRvbv4faVPdXl3PM/m7pHmZmOJXAyc+nH4UVR+DY/wCLb6P/ANtv/Rz0VBsegX//AB+z/wDXQ/zrPuehrRv/APj9uPaRv51nXPQ11ngv4vmZpHzcHvUqjsPzqA53kjPWrCjAGPWmNksK4+tPJyMUi5Uc9+tMY85B4NArXAEkjOM5xSyH5cA80LjGTTZAccd+aAK0n0qPaCCcVO+Tkd6gOcEcVI0NKgg5qMIF69Tzmpk6EGmMDnOc/wBKChjdz/k0xQDyOM05uDzUQzk46D9KLgK/QAdMc1VkQg8Hj6VbPJwOoqKYY57ZpAihInzYI696DHk8VaVMjd29KMBVGcUDuVGhySDjNIYQgz2q267fmOKrTszDn6YHegERN/sgc1C0IGCMbsVOgJYEYGf0ps6noO/6mgZEoUfLx/KpIlDKATmkiiB65JrRihigAklIHcZoBsdaWxIBIwo/WpZ2KLhfpVS41WNThCMVUk1JXOAaGxJDr0kgAk4PNUX4GPw4p93cpJt5HT8qgR0KgA0mykgZtxxuAxTrZir4AHPFRMhPIxx/KpoFJwTjHpTA0IGwcnJq0jnIyDj+VVIjgf561PHIM8jBFBLRdVs4I6DilZmOc/hUCEkcZ6Z4qZCSuSB0oCwAnbnikc569fajOCMAYpjMR2PpQKxC5AY4zntUEjZHTpx+NSTcMBx9ahkB54ODzQNIglbkZ4FU5B+8JzxnNXHU4PGcVWkUsTigpEG7cOc/T1q9pMh88DmqiwuxBA/+tWxpUKRPmRhkUAzrdOyYxmrMxIU4qtYSBkAAwKS9uPKQk44qkzFq7MnVkLg56VxmrQHcxAI966mbUhIzKVGBmsq9EVwhA64PFI0Sa3PP7z/WdTxn2qK4cmPKnkdPet2+0osSVXrzWFcRmNmBxu6VLRqmVoZnimWQE5zk17D4PvFutNQbssAM145KmCrZwRzXU+BdXe1vVSUnDHGM0k7ainG60PS9WtjPaHbnevIqHSbkqoRj2rXjxNHkYwwzXN3R+y3zIOnUfjVvUxWuh0bEMuR0NcT8Q5hDpvI6sBXW2MhkhyT2rg/iszLZRD+HfzTT0CC1seSa5J83B/risNsMxxjGa2bseapyOv6VjOpVyDnIrF6noxVkSrGB1PHU1OiIFyCfz7de1QrJhWB+bP6U4MfK4yOp6/ypDCQru+UHOetVpSS2OARVncrqxC4AqBsbsihsNiIruPOc0/yyOP8AIqQISAVXv+dPKFmbAP5UWuO59IfB8EfDrSRx/wAtv/Rz0U/4QHPw70n/ALbD/wAjPRU2OuOyO8v/APj9uP8Aro38zWbddOtaN/8A8fs//XQ/zNZ110zXQtj59/EUEA3cf/qqdRyKhiGCcjHP51ZQDGT0xQNiMeMUwdTnpQx7UqjIx+NAWsOHpikkG1c1KoBHGM1FcAkcdKbBIr5yTmoJAVY4Jx1qZVLHB4xSSj5qQ0RgcE88801iQDgDNSnAj4qMrgjGMClcZEcEc1ERgZFTOpJIGAajZR2z70AC574HNRXC7Y3faz7VyFHU45wM96sBccDB+tNPJwelAHkuifEyS88Wiz1C3Sz052MSK3343zwWP6EdvfGT6ngAHjJHSvHfjP4U+yTjXbFcRSkLcAcbW4AbHof511Xwn8UjXNF+xXjg6haLgk9ZI+x9z0FRF68rO2tTjKCqU1pszsZcsecVCV3McnAHHSrEoHOMY61A/KgKCBVnIiPeoyFxx7U5UDDcTxUL4Q88+9Vrq4KLlCcn3ouO1y1NdRQZIwzCs2e4knJLsT7VXDl5MuR6fjUjPj5eKVxpFdwS+OQM5p/JJ9BjHvSyFcjOaZ1J6560AMuz+7DAnrVVZSvIPv1qzkHK5GDVCVSrkEnrkfShsaRq29z5gAPXvWnAQR0GD+lc1C5RgwznPFb2nyhypBHPWhMTVi8ynPFTQR9zn/69LtDde3SprcDA4PFMlssIox04p+zK1JDGTzkZqfairQSyr5WBTGXrx2qaSQ4OOn86pTTEZ9KASGylSecYAqs0oII9KbJKW4A/Kq7s2eSOTQWkPkkC9AeagaQLlmABHH1pDJlcZ5BqB2BJXPvSuNIkW7AcjbtBqzYSF56znwT71paTDvfeSQoP0pg9jsNN4iB7YrN1q5w5UN9cdKd/aCRIEQjgYrn9Uuc3hGevOaL6EJXeo2QlmJA6iqgJBJDHI6VaVsY3YGaDBuGR0IpFlISiQbXYZzisDWrco+4Dk/qK27i3aN9wBI7+1QTYuE8uQHPY0AcdNHk5blj15osXeK8U5IIPY5rVv7ERcnoTUNlZmaUDnOeKTRd9D1jwffvdWID54GKb4oi2yRTrwM4Jo8O2/wBi06ND9481Z1nFxp7qcbu31FUtFZmD3uR6LOHjxntXMfFSPdpSP6P/ADrS0GchmDfw8GofiND9o8OSsM8YPSmtRpWaZ4pJjBFUbmMMhY9QP1q+8TMVHOeajeLaTnJ479/asmjvi0lYyEOF4HOT/n3qaJg45Iyc/wD6qWYEZSNeOoqOOPEhPGRg/Wk9y7WIpSUyoI9eKZkv1I4HrROpWVgcHnNNI54OaHuKxaTkYyGBGR26VZjjXbxnk5qrAcOvHQflVtG+bsSODz0ouxpdj6K+Eg8v4faUuB/y2P5zOaKk+FhH/CB6X9JP/Rr0VJ1ReiO0vh/ps/8A10P8zWfdfdNaN9/x+3H/AF0b+ZrMu/un17VutjwGtWUVOW79atL9z2qpHkHPPJq4Advan0G0RDG45p6Z3ZqNgc+hFSKduD3oAlUbT9ajkGRmnjPWiThaBW1Kw9ahmbax9DUzNgEj/wDVUDDcTk0mVYaFyuT0pMg//qqRgAuMcDmoWbIwaAQMN4J9KYDngg4pYz1Ge2RQwbPBoCwpJK5AHFREEHJPNS4+XnOajbJ60XGirqFpDfWM1rdKskMylXU+lfO1/b33gHxkrRFisTbo2PSWM9v5g19GnknJHFcf8S/DS+IdDYwqv263y8L468cr+I/WonG+vU6cNVUHyy+FmzpOqW+q6ZBfWbboZk3Af3T6exzUk0wVMGvF/hZ4lbSNRbSr5iltO2BvOBHJ0/DPf8K9buHGCAacZXQq1H2c/LoR3U4A5GDWdPI2ASTjvVichkyTyKpMWJHTHrRczSJI5O45p5YK24k+1QIQGIIODTnBPSgLD5JBvBPIpQcrjPPr6VEFAPJFI7EdO1FwsOYdwRkVDLH5q8ZDdqQyZIpyOc4OOaAsUyTG/Ocg81atrhlkyDwDRPGJTgkbuxxUSWsqkjB+tAzqLO68xR05rVhzgHjjFYeh20hILAge9dNGm3G4cVRDsieL5Y8Ack5qUJleepqJWCkOenSnfaAwz0xQRYr3IK4PNZs5w3JrQuHLfjxWbMCWOQM0ikirNIUbAxXK+KfFljoeI5i01wcERRjJA9T6fzNdJIhLnGefeuJ+JPhh9S0839tEftduCThcl0x0+vpSk2lob0FBztPqdJb3UdzbxzQPuikXcrDuDUqozHvn0rzb4W69tm/se6kwrktAzHoe6/j/ADr01nVThSemCaUXdXCrT9nKz/pCOqxLubBPpmopr6QqET5Vz27U2Zs9c4PU1UlYAEqeaZnY0JLp0hDZPBqvLd+YQxzkde+arC4GwpJg5461HFIm11PUdKLgkaMd4cbSenat7RSlxE5YjC8VxUs3IKk471tw3jWWmR56yZJ9aEwaua18qjcowaxZk2tyRkdMUxdXSTGSBn1rL1vUdrgRAn36Cm2CT2LU08bMEYBhnH0rf8PaUryi4YAr2964OzuPtNwkanBJxXqui4t7GJCBnApJiloi9JKqAAD2rH1q/EFszA9BzWtcBWjyMetcD40mkS3YKevAqiYq5oaZfRmbcmPm962daUXvh+5iySdvFeW6FqEiTKHOcn8q7yw1RHjaNm6jB/KknZ3LlHU81aHa2HHIPFUrlMAk5re1ZfKvJTg/ePbtWXLtlVtuM+gFJ6aGsX1MCRRnK/0pj5SIsAD7Y/StCW1YEnA2/rVSSNwSoxycHPpUNanTzJoymO5skfhSo21skVfurYhOBWew2sQe1DCxIjMWyCBnjmrcB6kkegqivHUmpULbWJz9PrSFsfTPwofPgDSj/wBdf/Rr0VB8ID/xbrSc5z++/wDRz0VB1x2R39+f9Mn/AN9v5msu6PDYzketad//AMflx/vt/Osu5OOa6FseDb3ioh+arWRgVVVstx0qcHjincbQ1zhuelKjA4+tJIMqQegqENhuD0ouCVy4GwaXO4dagDepNSK/zYFFxWGSINuKqNwx7Yq7KcgmqcpAGaGxpDzho6rMM8DtTlfDcHg04qc7gOKQ0RRrxkn86f0HJ700scEccU1unJ5oCw12YkimbiBgn8aOrcEUj/KPXNAyNvvZPFQTPg9gKe5G3mqsrEnH5UXGkeNfFjw4bG//ALXslxBM2JQoxsf+97A/zrofAviL+2dJ8qdyb23AV8nlx0DV2mq2UWo6fPa3ChopUKsDnuOvHOa8GlF34O8TuF+ZoicDPEiH1/Cs37rv0Z302q9Pke6PYZJOeTwOoqrJN6ZxmuX8Ia9da9qN+bjbGiqpSJeijJ/E9uf5V0kiY9eapO+qOapTdN8rJo33Kc4qUScDuBVWHKsfSrIycZx1oJaGkkHI6ngUHKjIPBpS3GCKcvLDPQ/yoAiVSRuxwTk05QBweRUpwB8o5pqIS3I6UwbFUd+vb8K0rBBITnmqKfK/StOzXbg7TzQiWjbsIwqDmrjnCj2PHvVOGURooxyB3qWWXzFA4pkvVjjI2w5JGKbbyHPzEEdKiVsA5xxT4Rk8AYFFwsPumCJz+FZk0mCcYzV69bcACelUJIieV5obGkVzJtfcRyKti8jkt2SRBnB/Kqb5AwQfeoXKgHgjj86Vx2ueOfEHRDoutC+sQY7ady6kH7j9SP8ACu88Ja4mt6OkpIFxH8sq+/r+P+Nams6Zb6vpctnOOHHB/ut2P1zXj+kXlx4T8SPHcK2xW8uZf7y+o/nUP3XfoztX7+nZ7o9klddvI6cVCwG0E4qWMJcwpLCQyOu5T6g85pRFjBbGBVnHaxl3CbhwTweDTBG+QMfrV65CZGPug1GHCYYgbT70DMy53QTYyMHnr1q3qN8stjCwOGRcEZqpfSxyvtJGD+lYt3MYDtDFlPTnrSuNK5YluQzjYRwcYzUkkxdV7noKwZnw+RnJ/ShLh2ZcsQAfXrSuaez7HU6JEGv4yMBs+tenRA7UAII4rx+1naG4SRGHSu/8Lai9wQHJx2ppmM11OqdmReScdK5fxVaie3JUDGOK6yTDxYI61jajblo2Xb14H1q0yE7M8nhBiu8Dgg/Srs920EgdHIHH5+lJq8D2t4zMp6ms6edHHlkg5/Q1D0N0rmjcXq3FwrjB3AZwc05NNZklljwBjJrAgykhGTu3ZA9K7rRUE9ntbBLiheYpLlOPkBWRkcDpz71RuY8nI7HPFdRqVkoZ8ABhWFJE6vyoCj9aGVGVjMkYkAEHB61RvIlBBXHOc1fu+WIBxg9qou6qCRzkg1L0OhW5SmMdzjFSwt8xwRk460wIWY4/nipYMqcDB9cUgTsfS3whXHw80kcf8tv/AEc9FHwl4+H2kj2l/wDRr0VB1x2R3N//AMfs/wD10b+ZrKvPumtS/wD+Py4/66H+dZN30NdCeh4LWpTBZRxzU6cKCetVgefp1qUHI9qExtEjMDnGetRyAYO0CjuCBxQWHY8jrTCwmeAe47VOp46DFQhePeljbqMkUBYsEhlP0qpIu4GrCkMpBPPeoj1PpSYJFAghjirURyMH86qTjax9P5VNat8o65/lQhtCyr8386rsT271ZmHOarsduaAGAc596V8Fe9IxOAeOaFbIINA7FaXHbFVWHPOeKsSde2eTVdzgEnrSGkU75Xkt5Yo5mhZlwJEAyuR154rw3xd4X1bT55bq4Z7+AnJuF5I92HJA9+nvXuTruXqc+/eqUqBVZSeD7VMlc6KNV0tldf11PHvhlIV8QSoD8rwt/MV6eU3fe9OKzU8OWFvqqahZx/Z5lyGRPuOCMdP4fwx71rgcA9zRFNKw681OXMuxDHH9eKmwAMEH/GlVDngZNSrHkHPBH60zHcrNGWAwPzNCRkct/wDqq4IspkCgKM85zQBXZcc0+PGQT3qV0BBPOev0oij4wenWgViRI8tkc1oQggZFVYTtG09PSrUR2gEdqYNFsNuORTw4zyB7VArZAPY/pRJneMDj60CsO3ssvrmr6EKhwB+NUEBaQdwOtTs+E4Bx060CauMuWLHPaoVPYdaazHzDyMe9NbIOeKB2JZPmGGA/Kq8ka9SB+VPXLepBodfkxnpQFiqyAZIHb0rg/iX4fF/Zi/tEJuYB84A5da9AbA7Cqk4BVgRxgg+9Jq61NKc3CXMjzb4X+IsL/Y92/Ay0BJ/Nf8BXoc53Abeo4rx7xnpD6DrC3VllIJG3xFePLb0rqbXx7bzQ2Maxs15Myxyg8KmSASD3qIytozprUud89NXudTcp85I6Ac1nakxEQyen6VryKZCcYINZmpW5ZcAgDnNWchzV0zGQ/NVGaXI2nJ21avY9hJB+YE8Z61myNtGfXv61LNoq4sjFlGc5FJGynGQOP50AjAI5BprKu7IJx1xQaaG9ZwZRWABGPrXX+HH8pYyvBJ/SuU0BmER3kHnvXX6YFNxGiAYJ5xTRzy7HZrKcZ9aikYv1A4P50ySQRbAe9PEysuVxxxmruZWOY8VaabiFnjj7c/WvNLqynjmO5SMGvZdRulWBgQCPfvXnGrLJJcsVJKEkYxSeppCVjDkTy0EqfeHX2960ND1NobhAXOwn6URQhX2MBhuDxWXfWz2lwQAdp5B7VLRoknozuNThDsJc5Vh29a567iIPOdh6Va0bUTdWQjlb94nH1FTuM5yowfXtTTIty7nKzWoaY4JGaqXNr83BPHP1rq2skbLxAH+lVLvTmOMKemaTVzRVNbHMLECwwBx7VKsQDjaME9eK0ms+GJAXH60nkEx8A7ugpWLdRHu/wqXHgLSx/wBdf/Rr0VN8LkZfAmmAjkeZ/wCjXoqbHZGWiOv1A/6Zcf8AXQ/zNZF7905rWv8Ai8uP99v51j3pOCM1qjxGveKIY4OakDrjioFbAYH8qUdOD1p3KsSknGcmlRg2Oce1QscL1NOQjORilcLFtSAO+TRt7+tRo/salRsjn1p3Faw5VGOtRyOMkCpwOCfWqdx8jEnHP60mCRFKoZc9/wCdQREowqUNuX2qFT85x24oKsWpDwDmq7DPJqU4MfU5FRk8ck+lFxWG8EHA+lMwFPFPKgHrQiEsAMc0AV5ELMcEfWqUzopxtB+vetK9PloVTBYj8qyJVy4OKCkgaVSDlBj+VU5oTKrGMg56irJTKkehxzVeRCASMikUkUHt5V6qfyoEL56HgelXRcOmAcfj3q3BNG6/vFUH1oBmWqYIbBBqVcY569+K30s45VzwQaglsSHwqjAoEmZYT8KQKTjOMdK249LeUAkBRjFWIdC5+ZyRnNFg5kjnVjIx15oCYJz24rq/7DiI4ziopdBXACMRimHMc4q4GBUsYOeeg9q1pNElQfKQ2O1VhptzGTujJ9O9KwXTIc9OBg051bqAMGpvsspODG31qeG2cD5lODzQBXRQi9waY5Ow8HOauSW7A7ipx781CsDliMHH0piuU2XIyc80qj5u2D+lXRZyuPuNj1x1oFlJuA8tuPakFyqU2nINMk+72x9KutauDgqcD2qs8bKSDnn9KYIpSDPQ/T3qrNkhumavFfmPB4qCaPachTzSKPLviTLqjRGL7Io04EEyr8xJ6891rzq3kaG4ikXqjBh+BzX0RPGMsrA45zkdRXDeIfBFreu8unMtrPzlNv7s49u34flUSi27nbQxEUuVqx11q2+NWAPI/pVfUVZkJJwDU2moYbSBZhiRUCuAQRkDHbj/AD+FSXxDQnaowOeatHI1Zs4q9X96y4OM96x71DkqhPFbt8GklYAHg/lVO2tmmuFXac5Ge9J6mkHYzYYpCArDB7Vchtxu5zkda2bi1WOfgA7Rg8e1RQpukOFOAeaErA5tljSbctKFGcDn611Wlo8DNLtIRRjNUfDtuDKrsDtJrpdXg8iw2wAAHr700ZN3K8eoiaQI2CR/KrIl2RZHHU1x1tI8F5uckHP5iutkXfbJKudrDr6UJiasYGq6gxl4b5eh56Vm322RRJGecc4qTWY0VvlwTnFZsMjRoRmhspFYy72ORhs9amv4muNP8wjLJ7e1U7sDzwwYDPP41r6EwmRoZMFWGKSdmO3VGDpCvHKzxg5XqK22myFLdT0qbS9OeHVimMoTg/Q1DrFs1jetCwOD0J9KLWBu7JIXKsGBwCasiVJBkEZHUd8VnsfkAJ6D86ruZI33KD/jRcVrmm1vFNk8Z7cUGyTAAAzxUVjIz4ypHb0xV4uwU/3ccU7hY9c+H8IXwjYLxx5n/oxqKPAJb/hErDn+/wD+jGorM9KHwo3dQP8Aplx/10b+dY18eDitfUf+P24/32/maxdQPykAnNaLY8drVmeGGTjtSqx6496jU8cHr+tIrE5GKCrEwPc5wRRnAFQMxA5x/hRnGMmi4i2jjoDViJyOD1NZwYZwCeasRPgADPFFwaNJWwBk81UvDnPHbilR84JJ68U27OVAFMEtShG53FScUo+8QD0/WnlApzznt7VEGxMRSHYsocoajOcHBPNTRAbDz2zUZG3Jycmi4WIywBqWEhVLHpUXAbtzUzcQgUBYq3JDNk96ouNzcEelX5huTntVJxtJI9KBkLAgHHb9agmJ249asMwCEmqsj7uvrQNIrsueRRglTnkipGXk7e9NPAxzmgdi1Y3kkPclT1Fa+nyG6mJYYA5xXO7gOg69au6feG3lXDcZGRRcTjdHaQoMDip1XjiqdncJNGrIQRiritTM2rDgvtS7falBpQeKBWG7OKPKGeg5qQdaXFAEIhXuB+VKYV7gVNxSGgCIwqRggYPtSCBR0UflU9IaAITEBxgU1oxx0qx1ppoArNCDnIFVpbKNjkoKvkYNMcigEZcunxYOEH4VlSxwwOVfHHIzW/cSBUJJHFcnq9yrTHZzjNJlxTYt5JatH823BrDu4YiSYmGfQ96vrbNNBkZJzmmRaTIzF5SVFBSSRmeRIVwFOcVHcKIojuYFu3tXR3Gz7OEjxuTgH1rmrqJmkIJ70DWpzN5CVmygJ3V0nhPQsK11KOACcEc1Z0vSjd3KgoCo9e3vXXy2ZgtPLiUgAY4oSCTPM9RiaO6YhCQWOTj1NR28X+kKMH5j6d66W+s5Q+GUncfSr2l6OjyI5UEg56Umht2KlnYNG6uc7VGMDvW3rcDNpcckakkYB47etaF5ZhbcIn38gmrlrEs9k0EgJyMGmiG7nm11p8s43Kh3HBHFdNo8LjTDBcDnb09DS3MX2RnRj93+VULK+828cM5C54z2o2G9Uczq0bxXjDB2Z71TABRnOOK63X7QHMgAIPP1rjZlkMgAGEJ/KhlLUyL9HRy2Bz7dK0/Djk3CZz2z9ak+wvcRng5Bq5oWky/a1yCADSaKvodZFY5vUmA4Ze3saj8baObm086MfvU5GO/tXV2Flm1QEEkCrF5brJCVIHIIqjK9noeJrllC4IPT6VLGpC5YemDV3W7RrPVpYh90nIHYZqOIF22sKlqzNFqh9rCWIbBBP61dC/LhgMjgVEmFwDirCqXG4HkcfWi4j1fwGuPCliOf4/8A0Y1FT+BQR4VseP7/AP6G1FQelD4UaGon/TLj/fb+dYOoNgECtvUj/ptx/wBdG/ma57U2IPJxVnk21KeQDjvSl+MHH4d6rmQc9fWmPKFHJ5NFxpE4f5TjGe9NL4Jz+FUzMeo/GlMm9cADnv6Ux2LsUi7sAc9anSQnp9ay0kEZODyPWrSOcZ7n3zRcGjVifjgipH+ZCciqED8gDqOtXEO4UE2IpM7Qc5INVLobGViOnNXZB6etQ3SZhOM9KBksDhoQwxTGPJwaisG+RlIpz5yTk88DigAVSzVO0f7oZIqFpCsYxgZpXY+SCSeaAGSIcHBFUZR8xGBVokHHJqrckeZx270rjSKkv3SM9DVfORyRx096dKxx0HWqsjEAgEUXKSHM5DYBGO9Nab5sflURJLcD604jjJHI9KLhYcrg5qaIZYk9T2x0qEOijdxmnR3K5JHBHtQFjb0y6+zNhidp7V0trcpLGCrA5FefvcFjlev5VPbX81u4ZWOfT1FBLjc9EU5Ap4rC0rVUukXIKsfWtiNwcYNO5FmWB0pTUYOacDzRcVh3aikzS5+tFwsBoNIDSE0BYdTSaQnmmMwANAWBiOarXEyopyRxTLq5SJSSRwK5zUr7zjhGO0UrlKI/Ur/zX2KTjpxVa2tFZg0xH061QL4O7tSx3RU8Ggvl00OkthDGu1AM1UvyxPAOKyUvykuMjitTzVngDg8/1ouKzRnNGQ4ODgVE1kjSsWxtPP0q5Iu4Yyc/zq1bWf2gqW/1YGPqaY7iaa8FrFhAWb2q4L5WGCjACriWMYQKoAGMVG1giZ2k5+tBJQlWO4BCEE55FFujwybY1yByTUl1ZiP97HkMvNUBriLOISBkEZagLXNEvMZNzgDPbrWnZptUZxk1BYvHOobGc9K0NoHTtRcTOS8ZxbCjqwXfwfeuZsYyLnlMqepFdz4qtxc6Y+QMp83PtXF2DbJwoPy5/OhsuOqOhvbRbmzXbjGK5e404h2VUyo/WuzhZTAN3HFSW0MMnBAbNIRxkMSIFBhP+FdDo9tEXBCYP0rVk0dGbKge3FW7KxEHPeiwN3LcMYVMD0qOZcggjrVkDjFRyjimQkedeNrLF1DKoHOQeK514wAD6da7Txwv+jI3TBri1wehz3pM1jqiSNQwGO3Q1dtY8kAg9aggHHGOKvRYzkjmgD1XwcgHhyzGf7//AKG1FP8AB5z4cs+B/H/6GaKzPRh8KH6l/wAftz/10b+ZrnNULYOAOa6LUz/ptz/10b+ZrnNT6e9WmeZbUyg218HPvVeeUGQjPTvTpmXdhjyT61mTyESHruJ6ihspIsNNhzjJApRNtHAPFVPOChgwHPWovtEbHAPtTuNovluM7v8APpU8UpUg5J56ZrOilTaAWGTmrEbgMGBGMUXBo27aQZzk5rRhkyf/AK9c5byESYPT+dadpOc4HbpRclqxpSYJ4NMfmPmmeaNwJH1pxbcRjoaVxWKkRKSYGeatTfdXHX+dV2BEh4PHSnO5yAc8UXAcGRkw/BFMllDDAxtFVnc59aI2LdRzTuFicNgbiRgCqMzBsnOfxqW4lXZtHA7+5qjIwHehspIguieCM5quAScHoalkbIHIqpczrGeozSuVYkMiRjJwM1UnuizFVIA74qrLL5hJJ4PvUDyKoHcmkCRdRywIB7jmpUU9u3esxJ1U8Ec9qU3hX+IjPSgLG2ACBlgPep1ktogDI4J+uc1zL3m4E7j+dQy3W44B46etFwsdNda0kZVYG2AfrXUeG9cjvY1QsN49T2ryyX5o8jJxWr4TuPL1SE7iDkge9NMUopo9ljYEVKDVO1fci59KsqaZk0SA0uaYDzRSuFhRSk8U0mmO+0Ek8DmncLAzgAkkcetZWoakqEohy3r6VW1O/ZsiMjb3NZLkt83ODQ2Uo9RbudpCdzE8+tUW+UHk8VYccdOc1HKvBpNlpFRm3Gqc0hRuR9e2atPlSRj1qjOCxAOfWgZG8hLZDVs6POQNjkYPSsRVJbpwTWlYoVcdiD+dFxNG+I8sWAyMVp2n7uJAMdqq2gBi561Yhb97tp3JaNJHODUEr5J9amjU4qvMoR8kjbnvQTYiDNJlGB54rkdSsY7bUmDMck5Ax6120bLtyvUVzXiGIyzeaikOBijcpbm1pTokKKvatfOV4rjtBuJNw35HbBrrInBWhMUlqMvYxJbSLwcr/SvL5CftL4bG0kY9CK9Uc/u2z0IryPVn8jVJwOm8/nmhscF0NrStQc+ZHIcnHFPsdYEF8QSduf8AOa5m0nZLoMC2T1FRXkh85ihIDHnmlfQuyPY7K7iuYQ8bAgjn2q2COxryvw3rcllIqOSYifXp716NbXKzRqykYYZoTuZyjYvZzUcpwKUNn6Uxhlic9qdyUcx4zhMumORnjnpXBWgBGwgFh2r0rxCQLCVXxjBrzWJP3pIyMHNDZpFF6KPYQMEelW4MMcY6VFFiRATnI61ZgTkYxSuOx6p4QAHh2zH+/wD+hmil8ID/AIp206/x/wDoZoqTuj8KG6of9Nuf+ujfzNcxqrEA9ea6TVDi9uf+ujfzNcxq2cEg+340XPPS1MN2LMc9vWq902E3MOR0qaXepGSMg88VQuCC+5icCi5djGvpWUkFmHtVaOSQsCNwyeatXzRvJ159qjtmyWAIx6UJjsIJmVxljitW1uRxyDmst9pcgLnoMkVbghYKD0xTTBo3opV2g7hk8VftXwdw6ViWsfHI5zWnbyYBGadxNGm8g8vI/nRFc+WoBJ5rOeXA6570GfjHUikKxpPfJ1KnrTJJg8mQMCs1keQEDPrTjOUAU9RxxQFi6TlgD36U+7kEUYVcZPSqyEswY9Bz9KpySvNMeTkdPpQCRI8p5BNQSOdpJzk1ftbeM4MjEn09KmvraNrZvLADckH3obGc5d3QiQDHJFYF5dlmOc5qbUZnDsGzkHn2NZEjFpMc4/8ArUrlJF1J/wB2Bzk9Pao5ZSwwCcjrioN20446VEHJbI60XCxK8h425qQEEAHPSmx4YAnPFSDG3hfWgLDdqgDGc+1NCHPXinhdoBHb1pwG4Db3ouFhYkO08ng4rR0CHGqREA9cmqKgq/NdD4YVTfRkgetCYnselWefLX6Crinp7VVtwNg9MVYFVcyaJAaXNMHFLnikKwrHvWVq90Y4ti4LNx+FaMjbVY56c1y95cB7hmY/LnAoKSuyu4LA9cGpoo+ASOKRLhMYAFBmXbtzzQVYWSAFQV7c1Wkj3Ejvmr0TZ4HSrKQI43EYoBaHOXa7G4AwKou5GTgVuajaZJKkfjWBdwsp+8oAouMfHtbn/OamSTawx0HesxJ1jJB3MfypzXrlhjAXvSuOx2OmPlFJPJqx5wW6wATg1h6dfJtGGGQK3dBkjuA7nBbPJ9KdyWrGxE+UHB6VmaxKV2gda0ZGVFznrWJqp+beTxinclIhsL10kKvkg+9WrqWN0J6j6dK5oG5S4LpGzRH/ADmrcOpIr7JsISe9IpxLMVwqShY0Oc+lb1q52c5x61gpfWsZ3M6AZ65ps3iKAgpA4cg4z2oBo6OaYH5fWvNfE8JXU5AFPzHIrrNOuzM5Zm5PvXE+Mrxl1VlRhnH5U73CK6Fe2jb7Rl8ZANNeEtIM5x1qlHfSpGzsM4/Ci21pWYiWMgCpuXZ7mikIUg4HB47V2Xhm+xD5Tt06VyEMkF0B5cgyR0z3rU0gPHP944+tDYmr6M9Ht5Qw4qcetY+nykqOTmtOJ89apMzaM/xFEG02ckdFzXnHl7Dxya9S1CMTWroehBFecTQlZHBHQnNDehUSOIsu0YIJOPrWpbp8g9zVCIYcHHTjNaduQqDuaVx2PTfCIA8PWn/A/wD0NqKb4S/5F60/4F/6GaKg7Y/CirqrAXtz/wBdG/ma5fVJACQcfnXQeIJvJuLtzniRv5mvKfEXidIbjac/jTucSjd6G5MwPGRWReliCvGO9YkXieFiAWGcVPHq0VypG4cn8qZXLYa6fOxIyPTNS24VSdqj1PPNDbHGFYZIqpOWRgq8+pFK4WNCNkUkEDn17VKt3GpAHY1gvNsBy/A5qW2cuoYk8H9KYWOmjuAyNyMdQelWredeO+BWBFISoAAx3rU0mIySHAJ/Gi4rWNBYnkclckHmtKysM43AnmrNhakJhsZ961Yo1UdqLibKotI0TG0cise4tgJGI7GuhlHB56VQliDK5OM0XEmYT3PkSADJPTA9KtRx5jDhMEjPSq8NtnUyW5UDNXbi5+zuQw4/Oi5TWpUc3GSVVgPpTI5rgsY2BIPX2NWY9TRm+YfL3x2pZdQs40Zg659KA1OB8QP5d7KhPy5z+NY6TEN1zmr2uzNc3ssqqcMePYVgSSOkgwDilc0Sua0kgwDznFNQ5OT36d8VDbkyjOMitOztVdwDkA0E2sRxLgE5PIFTJkgYIA57VYu4PLbI6EY6VVkJHQYwPWi4JD2BKnOSKSINnGDimK5K8EjIq1C2V5xzRcLDlIDgEDNb/hr5tRRRjFYapwOASa6DwqMX4JH0zQmJrQ9HgGEHtip196rwfcH0qbPFO5k0PHtSE8UhPFITxRcLFPVZGSzkK5Bx1riWmZievHXNddrcojs3JPOK4p0JYkMOevvQXEliklaUbTxWkykAEA57+9VLJRwBjd0rUVMqAKBsltAWxkVbnkEaYH40yACJeaoX9yASMHigVipf3BZTzWLOS5PXnpVuadCD374qq00YPII5pXKtoZlyhjYdcGoycj+tarxxzjDMAO3tUbaemCVlHtQNaFG1neGThuv6+1dp4YvFWEKVw2efeuSW1XzRkjFdBD5exPKO1k96EJo66WQSLgdSKxr6OSeRIzwo5+op0N3ymSOeDV5WRhubGRTJIxbrsVcgDFZGvaOlxaOyj94ASGHFaVzOI1djjGPyotbpZYirkc8c0Jgk9zyO985C8blhtzwe9GkkxlixIB6c123ifQ/PzNEoyvPFcaIHicjac0Fp3Op0e7KyAFuDXL+InabWZiM4Dc1dtJGR+TjAzWfI5ub9mPJJovoCWo2RCLT5qxmPLADnNdJq0WyFVHHFc5IuH4HI9utHQpDkd42VkJBzmur8L6q0kwSfkDgH0rlVXdwep960tG3QzhuQO9K4NXR69auNilTkGtOFuRXIaLeYUKSSPr0rpraXOKaZi0aLcqfcVwWqxCLUJR2Jziu8U5H4VyviSDbdbgPvD0pp3CO5goAcgA59PSrsAOO3FVooyG4xmriKQQD0NSWekeEjnw/an/f/APQzRT/CQ/4p+0/4H/6GaKR2x2RheLD897672/ma+f8Axcf9MOOuTXv3i1j5l6P+mj/zNfP/AIubF6wPc1Lepy01qc25YgletT287wqDvIPbnvUJzkkenFDKzMDkYxyKE7HU0nuakWp3C/MHP496nXW5TgNg9KyY846GmFtgJOT6U7tGbgmdAL8SZzjP1q3aXWQyByM9MVy8OZGCrncTjHcGujstIvHjDohGBz700+5EoqJrwXPlBQzA56810mgXMRuVCuM5rjH0nUJCAE4z69K6Hw1pNx9p3SboioGT600zNpW3PSbbAjJJyScip0cgjg1liUx7F3Dbxn3rQSZPLJyCAKLmdiSaVVDE9qotI8qkRIcdyaaha6lJJ+QdK0IwigKCKB7HOsJ7a+V5E+QjGa03t4rkBgASRzV2eIOrDAINY7efZSEqN0ZPryKLgiwtjHtOY159qyNX0NHQtH8rdfrW9bXscqjJ6jvSTyKwK9qTBNo8+1LTGRVbHXArMl0fcuSucmvRJrVZY8YGAcVRks/LJBHHUUFJnK2ulhFACgetXIbDYwIAroYLYHkAc9ama1GMgcUAcrqEDIuccVnbAQCVIJzzXW39rvQqR/jXPz27Rll59aBozZomGNo4J5qWFSq4Ixz+dPCsBx0q1CivjIPHFAMSAZYgitjSX8q7jxjO4D6iqSRKvQcjr71PZZ81SPvbhgfjTuJo9LtzmNT7VMD0qraE+SmTzjn8qsA0XM2h5OaGPFNzSFqVwsc34nuAqCPPJOfyrnFlJGQOeBWn4mO/UQhyPlzmo7DTy7A7gR1+tO5a0G6au52bnH9a3baPjc3Q/rRBZxwjjHNOkcAYGPSlcTEuZODXNatOQ2Mmta6lwOvWuZv5WMhJIxRcaQ0yZQ5JBqtcOfWkLEg9KrXEuTjjHehspImEpCjBx2OKRZuMhjz2qGGVdu3PJppHzfKTgetA7FrziOhPFWreaRTkMc1nb+RkdTVyL7oNAmjUe6k8qOSM/MDyPWtjTLma6hLeWV7fU1zsbFoGC5+Xnp0rp/DsyPZDOM5wadxNaGJreo3EbGJoyo9fWjRLmacMvPArp72wt70fOoLdqhtdOW1A8sDr2ouK6JJxm0y/XaQfrivNr5wJCFPO6vRNVkMdo7YJ2qfxNeYXTnezMCp57UDiizbYuZdgAVunpmtSy0dLUmWX5n6jviuYSdkkBUncK6nT703Njl/vDjOetIbMzWMM3GefWsdrUscnFamqSfNgAVTjJI5J4602xpWQyK1VTkjNTqDj5RjnikAJOQeKcWJ4NIDa0a4IkCkmu00+XOOa88sWMcwORzXcaNKXK5oJaOqiOVrE8SKCik881sxHisfxGwES59apMixgIAp4FWYgDyc+lVl6DB4FX7dBsBPU0mymj0Xwon/FP2nH97/0I0UvhgAaHajP97/0I0UjtjsjlPGDbZL33kb+Zr5+8Vvuvmz6/wBa9+8aH57z/ro38zXz14o5vnHODkGs2zCkveMdXOeQKkLAj2qJVGeCOT39akAy1UzoaRIhz06fWt7QvDL6kvmTErEf1qp4e05r++RNvyAgt789K9TuUTT9L/dAKQAAKa0VzCctbI5yHR9N09lUIPMXHfmtizmVxtAAXv24rlJJnkneQMT1yao3OtTsPKgOxRkE+tF7EKNzuJdQhhk2RAselOj1J1lRU+63865DRWkkP7xzzzuPcelbluslxIPJU+UmRu9adxW6GxfahtIJYk8celX7TUHuGSJFwuBk+tYUlu5jLzAYXkcda0tBH75ZBnZ0GfQihMTR0lzL9mthjgms+y1MFiJGPWtO4g8+NAOmapyaKNwYHjqRQJJGvby7lVs5BqWWFZF4xk1l2DvbuY5AdoPHpWqGGMigT0Mu6tCpOwc1DGr/AMWemK2JXGDkVlXcmMhc7jx9KLjWpNa/MWT0p89uGXOBx0pmnpiXv05rTK8YNJsTVjLSAqD6/wA6R12jnPNX2jAOaY8YZeadwMyRFcHIFZF5bnnAHUnNdBIm0cAVSmQOv0pXKRyz2+HwRSrAQeM5HpWvLa4HAPXmqskRVhzgii47FNVYetW9P+W5jLAcsKa3Q5wKW1UGZcHndTuJo9Btm/drzVjPNUrM/u19hVoNxRchofmkY8c00txUbtSuFjlvFa/6RG4FS6NIWiJPaovEhLTx4yBzUlm3lWwzjJ5ouVYuTXO04qpNdKSenIqvcT5B55rOlkJfBzjNF7DSLtxKGAAP61g6kME4NX5G+Xjr2qndLuTPGDTuNKxSlysWTycZNZ0uck8//WrX8pmGCOMVFPYMxyVIx0wKQ0ZUYYNuOelWY3DAMCPepbiALle+OTiqzLtPyng/jRewJFqNCCSeh6VbibAIweKrRvuAFWAeOnWi4WJbZ9kmDwGGPxp9lfSWc7KM7c9M/rVWSTYdw7Us3IWXHBHJHai4WudVbaumB+8HPrUsutRoCS6n2BrjgfU80+KPc4JY+1O5Nje1DVhIFBBCfXr9azNQtYbuAsoGQOD6UzUIwqAk8Co9OdpFdR0xxSbHaxzU0W2Q4xkZFami7khcdfWqtxGBcSdeuK1NLjAhYd8HpxQ3qOxl3JMkzE4/OmqMEccVLNHiU4Ixmmlcg7c4+tDYWF6gjjHWm87zT1RuMkAU8IAMg9aVwsSRIcK/ocHiuu8Nvl0ORg8VzUG0IVODnpx3rf8ADqMsig+tFxNHcR/dFYfiY5CDnJNbkZ+UVgeJQfOi54wapMhLUyoFJYZzWgvBqnajDc9KtA9eOKCmj0Xwsc6Dan/e/wDQjRTfCh/4kFr/AMC/9CNFB1x2RyPjU/vL3kf61/518/eJ0LXsgOMZr33xsf3l76ea/f3NeB+IyDevg9Cenes76mMFqY6qM4HWpdvTOcD9aYDinopdwAaZs2z0P4f2gFv5pXlz174rc8Ttug8lSc45p/hC3EWnwgD+H+lVPEzbZSzdM+tVJ2Obq2clfSra2jA9W4/OsNCmDnGSa6HWLRptPUgcg5z7Vh2dqZJlUAYyPeknctWsb2hQPdMd7DYnUA9a7S0mhhgEYQZHYdjXNR2f2W3jjgYiSQgt9K7TRdPWG0QsgZyMkkUXIZl3VwHjaMgjPt2pdKkEU2wEbWro5bJZVO5FwR6VmrpptrtXVcrnP0oTFudNbBTEpHcVMw4NQWzqUAGKmBGDRckqyKGbBFMj3pJsXkdeankXnIqMSKj4Y8AZJouOxJIuFO88nsKpOi5yKbPeh2PPApIWMjA54oCxftRyTVsVXh+VABjmp1PFAhGHXmo2GDj1qY0xlBoHYrOoIPFVnj54FXmHP1qJ1/Oi4zOkiGc4GaqXFspGfX9K2GjHp9KikhyOKLgc3cwbQQAeOaq28ci3CMB0YGujmtsnkVAINrAn19KB2ubtkxMS59qug+9U7U4jFWA1BLRITUch4NLmo5Gx6UXCxz2uA/aY/Q8VBLKFjwD0GDU+qOHuhjHyfoay7iRmBAzRcaQNIWPQHFRsSCc+tESMxAGatRWjyEbhxRcdiFVMg4zzTltGIAPetO2tNoxV6O2AAwBRcGZEdkMLgH06VJLbBEyRzitlYPUUk8G5DkUXEcFrY8ljgfe4rEQtnv8A4V03iq1ZWVgpx61zKZ3FaTZaRbgwOMnFXVcFeBz0qjGh3ADPSrKcChMGhzjdx6/rVm1UOhifGCOPrUHGCT1FWbWM7w2OlO5NiN4mUkEdKt6ZEHuF8wDCnP1q3cW/mRZA+fFVIAUbAJyKLhYtatBHMSFIBFV4Yo7S2bLDJFTXkZEYfJORzWWtvcXEhGSEHPPbFF+oWM6dcSM3HzHNXtKYHIJySKpXmPMYAfKOPrirOjr82QKGxtEFwP3rADp0piqSMDvU94cTED19aiBODxzQCFEeOpHFJ5YwME9fTpTww7j8KkLcggChAWNOhZplJUHHcV1GlQFbknHHHbtWLogLygnG3NdhboF2kY5FK9xPQ0Yz8orG8SLny269RWxGcgdKzNfXdCnsapMlKzMe1UBMnvU4AC8d6SJNqqvFXbW3MjAkDH86V7DO48LRH+wbX/gX/oRoq94dj26PbjHTd/6EaKZ1x2R5345P7y85H+tf+ZrwPX2zfyA17t49bEt5/wBdX/ma8D1vBvnJB6/1rO+plTV2Z5faTkjipFcgqR1GCBUDE88CgdKq5s10PbPB90J9Licddoz9aXXrRLhCSD04rkPhrqWJntJG7ZXP8q9FeNZ4mUnmnLXU5muV2OIilWMtDKCw6fhWRJbrZ3+6MnY3I4rf12wkhcNGuc9qpNGlzbbTnzEBFSmFizpEn2m8YsSQhAH17V2dvfeXIsb8HGOT1rivC9s4v5Q4IXAI/Cug1u3dog8ZIkU8Y4yKdxdTroZQw6Usqhl5xWJoN559uFkyHXg1sMcgZ6ChisV4vMgmAGTGTWkr5FVByABTwdo5NFxWJHfAJPasO+vMuVB5J5+lN1vVlt12RnLn09KybYvNhyDluaLjS7mrGBKB1zWlaRhRWdaKVPIOa04TjHNFwZeQ1MvSq0Z5qdeO9IViQ0lIDmlobAay0wjj61KelNbqKAsQstMKHPNWKQgZ4oCxVeMZOKhaL2q8yg0wqM8CgY6LG0dKnAqoxCdwPxqeGUMBnH+NArE2Ka8e4YpwalzQBz99p0nmMygkE1VSy+b5gcj9K6ogdxVeWFTyAKB3MaKyA6CrUVuARxzVsqAfpTlC8YNFwuRrCB0FSrGPSpFHFOGKLgNCjNIyArg1IBxSUCsZt/YR3cDRyD6H0NcVfaJNaznKAr6gV6K+CeKq3UayJhhTGeemIRnlT09KjbHIAIxW3rdv5Z47d6w5ASTjOKRSFA9xV23O0rjGTiqEWQ2DWhZpvuFHp19qYWNwA+WHABI4x6VUeEFiy4XPXinXFw0Q+XIqi2qsh+ZFb07UBY0oLfeApOVByTVPWLlIk8mADGPmIFVn1WSUYTCqfSoG/fJz1J4z2o2FYyyCTlgMjNXtK4c5Haq80JRju5/z1q3pihWPB56570FFS5YNcNTN3AHpRcsBM2MdaiDN0A96GxWJkHJ9etPHzYGDmoo2PerMEZeQZzRcGjc0SPYF6c106vtAxXO2GI9vTAHNakE4kkAGOKEJo2oTlRVLWBuRB6tVyDhBVe9TzJFHpmhMmxTt4dxBPQfrWnboF6AVFGoVcYqxD93PrRcHqdvoH/IIt/8AgX/oRoo0A/8AEot/+Bf+hGiqOqOyPKviC2Jrz/rq/wD6Ea8G1gg3j4AxmvdviGcS3vP/AC1f+ZrwfVObqQc9Sf1rJEQWpSYZOVx/hSYIGfpTlXBOfp9acRkY6U0bXsTaTetY3ySoTuQj6V6vpWuJPFHKpBU9R6V5AIyDkY9zV/T9Qls5Q0bHbnkZqr9DKceZ3PcGWG8hBwCOv0rKuNEAmLwEDPJrnNE8SQlQplCnpgniuhXWodm4Tp+YNJoysWbGykhcZABJ5NaE8Ktnccg1inxBbZAMq8H1qd9cs9oBcEnoB3oCxYs7aSO4Z4wcE1rLKUA3ZFZI1yztbfzJXVAe3FY1543tiSIlZh06YzQFrnVy6hHGCB8xHpWRd6vcOCqqFJ4HeuPu/FNzMf3SrGp/WqkOsTmUMzZzzQh8tjrreyeVy87FmPJ5rVgjSMACudstSZ4wc8nmtKC5MjAgnHpTFY24SOnFXYyBg5rJgbGc9auwyFjjtSBo0om+YVZU1jT6lbWg+dxnsBzmnW2tW8vAfH1oEbIPajIxVE3sWOXFVp9Xt0PDgn25oCxqs6qOSKp3Oo28RKvIAfesK91oMhEXU9/SsWSYsxZmyTQOx1Ta5bodocH8KjOvRZ4IxXHsckk5zSA88nii4WOquPEsKHCqxNMj155ASIzge1c0kO75vStW2CCMAgDFFwsaU88l1CpLEetTRSsqLtJyOOtUhJtACY44qWB+T70XGb9rP5iZzz3qwsnNYVvIVYYPNaEcjEgE0EtGirZFKx4qCI5Xmpc0risV51J+YdutRo/HNWXGQaw9TnkilwhAB56d6Y7XNlJcY5FPWVSeuDXLDUJkPJyPekl1SUg7QAaA5WdaGHrSM+Oa4s6vcxtkSHA5xjNFzr08sGwfK2QdyntQFjrZp1jUliAB+lYs+uW+7huBXPXmszzWxiYjrgt0OPSsl5+O1FxpG9quqRXKAIDn6ViSSEk+uaYzkgYFS20DXDgAdaGxpWCxV5rgIATk8V0cNsLZQzD5iPyqTS7BLSPewBf1pb6UYNJA9TMvpMvgZ5/SsuXGT61auZTk8cjgc1mzOQTkmncLEkUiI3JyaLi7aP7p/KqcL7m3N3yPrVe+f5wM8D3pXCxeXUwSVkGR2rW08q0MkikYArlYIzI3JPNdLGotdM6Hc1MGZ7pl2O3v1qQEYxtFQRz7WwTjNWQVk5Uj6UAxUX5sADJ61fs0OSSR1qkp+fJA9K0LdwqDA+tFwLbSlF4IHp71oaTksM+vNZO7c4xnHrW9o8Lbd579PehsTRuw/dA9qjf7xPpUiHanPpULEk/WhMmwpJNWU4Wq0fLYq1mhsGjs9AP/ABKYP+Bf+hGik8Pn/iUQf8C/9CNFUbo8p+ISM817sHPmuf1NeC6kcXb5Hc19CeMeby9GP+Wr/wDoVeHeJbDF3JJGOp5H9ayT1CLsYTHnvQv3jyM009SD2o7YqzaxOrVGxO8hcULn1H408qAOMZ70yNEJGSMdAasJMc4LHj3NQAc8dRS7TnnrSE+5aEzZ4NWEu5P75yBxVADnGDmnxkqeh60XFa5dMrup8xixHTNRtJgjODmoQ+SeRimu2TnIouCiWfO+nFS28wDZNZ4k4wO1KGJYY70bA1c7fSCkigl1x3reS7trdRmRa81t2cZILD8avxMxABJoZDVjupNet0H7sM7e3FVJtcnl+SPEa+3f8a52MjjJ5qzExyAe3FK4rWNITs53OSc+tWYWIxgmsuKT5sHFX0fnrxQDReaUkcMcfWonmOTimbj0GcVEzYbJ6UCJRJx+lNZ+TzwKhLHnFCvk8+nNA0iQsMZHcetMJBPt60HknH0oUjPIHJ5oTCxpWgDR4AHAqychRjOc/lUNkuCABwfar5QIOfyoAWNQyjPXFWIAMse+KhQ7gMY+lWbccfpQ2Fh8Kng81cRwCOpqBQScDpT1IDBRyc0hNXNONsoP5U7fUQYRx5J7VTnvMA7MZoFa5fd8DnrWbchJ2weoqpLcSHJLHmnLcKoxj/69A0jOu4/JfHqaqyEgYHUVdmkDsWbOe1VnRGGTmgZQlORVZztyefetGSONSeuaqyxxt60XAoSn5sjOCKiwGbHGKtvbgD5XGaatowOQQR165ouBGAWOAB6Vv6FGN4OBgdayraBnkCAHriuitYhaw8fePWgC1cS7c4rJupN3erE77zkZqo6bic+lO4WM2UNksfXisq53M/GfSt+5h+TAHaqAtsnI6UBsUY4jt4xgelVZ4Gd889a3EtW28DmrVppbStjaTk/pSvYDM0fT3mmXAIA68Vqa6PKhVRwAOK6K1sktIMBRurm/EhJHFNAc+GDHgcipI3KkEGq6Al+M/Sr9taPJjCnFDY7FmIeYARj34rRtoGf7oPPr2qXT7AIoLA1rwoqkYAoTE0Q2diq4LDkVu2qBVAA4FVIl5GelXoRSESyNtXA61GDxSOdz56gcUo69+adxWJoR1PpU2ahjYBevNPLccEUxNHZ+Hz/xKLf/AIF/6EaKTw7/AMga3/4F/wChGimbI838Xti+vScf61//AEI15TqyLJcsQQQc5FepeMTi+vef+Wr/AMzXlV9/x9PjPJzWSFY57UdPKtvQEA9vWssoQ3Ocd/auwKrIMHHoc1m3enB8sgwfaqvYqMmtDBAYHvTt2DznNSzQPExDA8GoyowAetUXe4K4xSiXJwBzTQCAQOTTdpxxQCSJfNB64x2+tPWQkcEdKq9OuaVOD3oBxJzIec/WkJ3dzmownTBNSooP1NCYmrCxrnGQcVNHHyD6etORc9O1SxryM54/WhslvQmhXnAxjvVyJSKqxfXirUZOOtJsllhOPT0qxG3IyeaqLktg9vep4uvfA60riaLIORkVcgY7R6GqKvjuTmrELEjk0NhY0Q/Axjihjnqee/NRKeMjtSMSMY7UXCw4+lIQR0ppcHqP0prN6Z4ouCRIhx3xUsKZYNzjNVcknBHXpV3Tz+82t0PtQgaNezXawIHQVcDg/K3U9KhhTaQR0xmp9PXzNQU44AJouDRJDEQ2ShFWUAI44rQ2D0rMuH23pRePWgW475lJANWIVAw3eqwILVJNcJCgyRQFrialeCNQuecc1mJOXbPr71n390007EE4zjpTbeblRzQNI2mbI7dKrOy5PXNHmfJwc4FVHkIJ9DRcNiVm96jZscg1XeTkgZqNpMjg0XGSSvjOef5VUeTc3TrU7JIUyo3CrNlabhvkXAHrRckprGzAfIcE/nVmO1Y8tlRVye5jiUBAMj2rPlvXZuKB2NCKSO3T5eT0zUVzqK7MDGT71mNcO3QVVlSR34BPHp0ovYLGnFeBzyRgmrsMgftWRaWk7MCFPWuhstPkKgsCKLjGGIMvA4xTILEscAHBNb1vZKo+bFWkgROwpXE2ZNtpY43VpxwLCgCqM1Px2pHpoTbKVwpwcVzmrWol65rprjBX3rB1E5bOeKBox4bJEYfKMd6uxKq8KBUYxjJ71LAMtx3xQFjStx8nPQ1Yjxn2NV48hQKsRYzx1oBotwDkYNXPuRk1XthgZNOeTc3HSglq49Oefxp+OaauMDpThjNANEsSDGTz7U5wOMUkf3fakdsH8cUAdt4dH/Ent/8AgX/oRop3h4f8Se3/AOBf+hGirNkeXeMT/p15x1lf+deWX/Fy2M5z+depeMub699BK/8A6Ea8tviRct0wTWS3IYkRDHBAyfarCQfPg4/CqUDHdyRgnFW4ZQpycZz0BqgGS6aJm5AxWRqGjPET5YOOuK6uDbJFz154xVedS+e47UgTa2OElieNyGBGDUeBkkCusu7SOUEEDI68Vi3OmkH92cc079y1JGU4OeBSDgZFWpLaVOqn8KYEPemmUncYpOM+tSLkHBJx/OhVwc08L0OP/rUwuSI3pnIp6tyMnPTimBT2xUiqTggD/Gl6kuxPGfrV2IfL3zVJOvpg1ajJwM5xSJepOnJIqzGwUY46fnVVSMdamQg80thFgsM9OlTQtg8Y9KrA5IqxCMjINAFxCdvPekZiCMdKAcRjrgUxmwSR0o6gOY8gkikEqqOmc1Wkk+Ygf5NNUs2eeTQMtiQs2V6elXbCb94c9uay4zhvp1q1bPtkAPpTuJo6WK4zHvDDGKvaE2+4YjHT9a59XUqqqcY5NdB4eXAkYewpNiZudq529uMai2cYBroM/lXJXz5unYY+/wA80JgkahmVVJJAxWZeXPnOMMcDvVLUbhh8ozgnJqpFMV4OCP1p3CxcuI8Pu5xgGpIYxkEHvUSPujBBJFWrYEjnGOtILE4O2PrzVOQ7u3fNWZDwQOlVpM7iAO1AyJye2Tn2qNVZ2AXPX86soqkZbtVqDZGcqBk0CsXdNtwiAyd+1XpoUkTAGMelZ8Mpz3q4sgxnPNAyhLphZiQQaaNKJ9MVo+Yc4zShzkZpAU4tJRcFiM1ajsbeMk7Rn3qUsccZppk9TTAnjRE+6oH4VOjciqSy8cc09ZMDORRsKxoK2RT9wxVJZDj1pRLwMUBYt7qazVCJOM96a8nH0oCxFdPhTjrXPXbM0vt0rYvJMofWsWT5mJHWmFhpQggnvVmEbRnFRxjrn86sRdMcYpXGTw/Mw9KuQqD7VVRh6VYViVAB4oFYts/AVMgfzpY8kjrVdM4yOlWIiOpp3CxYWnA9qiDd/WlVsHmkItj5U/Cok+eTrSSTKUwCaS2dS59SOKOgWO+8Pf8AIHt/+Bf+hGijw9/yB7f/AIF/6EaKo2Wx5f4uI/tC+Bz/AK1/5mvLtQCea5AIOfWvU/FgDX14T3mfP5mvLr8DzZOKnlFylFQNxABP6Yq1bx7iM9jxmowqiLIHNSRnKgnrTsLlLiyMsg27cD09afI/OeKgt1Gc9/rQScmiwcpFdnHXPPXtVF8YzkdatT8nmq0igE4GKLByiFYyuG61A9pE57CrCKCCT1qMEhxilYEmiA6aCCVz7U1tNcDgnnpWqPuiphTsxpM5/wCxyL1XgUeUV6g4HIrfIHPFIyLzwKLBYwh9KmjYg4OauTwx4J2iqsqgDgYp2YcpKuDk1KowO/Peo4QD1qxGozU2E4j06DOfzqxCMdOwqHoOKtwKM0WDlJGYBABnj3quz8fTintzjNQydRTsHKxpOGB4waBLkjjHNNfhDQAKLD5RRIQ3P/6qsQS5cYPHpVdFBzmrNmo5OBmizFZmhE245HQ/pXXeHOLVyf739K5mzRdyjAxXaaTDGloNqgc0WBxJpWCxM2RgCuFvLvEjHvk13d2o8iTjqK841ADzDSsCiVbvUV8/5wadDcxtg7hWFf8A+sqS2UCP/wCvRYOU6uwkUswBGG/nWkrBFAWuasvlYYJH41tWzMRyc0WDlLOfnqNznPTrVmJFJ5Gam8pP7op2DlM0A8nnFSxEs+CKviNMfdFKqLu6UWDlEgViMYwatKpA5pIuDxVnAK80WFYiH40pO2oj9+gnPWiwcpIZcDPeo2cHBOM0h71GeM4pWHykiyZ4GMU8y4OB0qmCc9TToqdg5S6021ev4UizkgEGq8oyRTFFFg5TQjl4GTRJJxwTxUEXIGaJicUWFyle8mHIHP41SBDEs2Rjmp7gAsM1EyKWxjihofKLGVY8E471aQjcAO9V4wOnarKKAelFg5SVBnqP/rVNkZ71Ah61ICaOUXKWIulWFOB9aitwMVK45o5Q5R+7j1pSwA5xxSEc01x8tKwco1n96SJjvyp5FNkAqW1UYPFU0w5T0Tw07HRLYk9m/wDQjRTPDjEaNbgHj5v/AEI0U7GqR//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Widely patent both fallopian tubes (arrows) shown with free spillage of contrast medium into the pelvic intraperitoneal space following the fallopian tube recanalization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8593=[""].join("\n");
var outline_f8_25_8593=null;
var title_f8_25_8594="Placement lateral sutures cone";
var content_f8_25_8594=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Placement of lateral sutures at cervicovaginal junction during cervical (uterine cervix) conization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8594=[""].join("\n");
var outline_f8_25_8594=null;
var title_f8_25_8595="Spinal cord compression MRI";
var content_f8_25_8595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    MRI image of a patient with an epidural spinal cord compression",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal (left panel) and axial (right panel) gadolinium-enhanced spinal MR scan of a 69-year-old women with a remote history of breast cancer, interscapular back pain for one month, and a normal neurologic examination. The scans demonstrate a large epidural lesion compressing the spinal cord (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Schiff, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8595=[""].join("\n");
var outline_f8_25_8595=null;
var title_f8_25_8596="Severe mucosal HSV-2 ulceration in an HIV woman";
var content_f8_25_8596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Chronic, severe mucosal HSV-2 ulceration in an HIV-infected woman",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 372px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF0AfADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3uVA2VYZBGMV4HdwHwj45u9KOVsro/aLb0APb8OR+FfQkq15P8eNFa68Ow6tbAi606TcWHXyycH8jg/nTlo7hFj7C5BkHTmulhuAEGDXjnhfxKt1BGXbEinawNehWd/5qDBqWaNHVRSiQ811Okw+VbAkctzXGaOhuLmOMdWIz9K77ARAB2oWiuZS7DJW4qszU6VuahT5pVUdzis29bCsa2nQ4TeRyauGmxDagA7U41qNDTTGNPPAqJjQIpanEHjDDqtUEYd6135Ug1iyrskYelYzVndFIivLZJY2yoZWGGUjg14z8SPh2hWXUdGhGRzJAo6+4r2xXqvdRBlJUAg9RVoLHxzLDtkYMuNvGO9MYKoJxk9jivW/ir4PSBn1fTY/l6zRgfqK8nlO+Qg9PpTsNIYIVKbgRkVHHGejZIJqywxnyuSeM9sVNBGXcrIh3DsKdh2RVZVLMFBwKt28CTvESMIOP/r1cit0VsNuJP8IXNa1vbRvnywAo42nvRy2C3cqW1im4o4CjsSe1bdmiKqYyroQAwXtTY7UzY+X5l7Vs2CbFVFBH4UDsFjCzK8Z3D5sgdRW9BC8McRAw2ORjvTbOMIuTy2cVpApGB9ocBR0PWnothWKksO+FlOAWOcgYwab8ixtFHtUhcE45qK6uPNbHAiFV1KFyEBHH0pJ3CyHpGNvzYLEdDUflpG3m7UznoBUyPGrIdpJHUGpTE8sbbIxtyeR6Vdrk2MiCQSSg3EQ+Q/Ke3FWGcSYyvyuT0HT6UPAwLgZKZA5qGRTDLuSQIQe/+eKLWFYV43SWR1iGAMZbsfaqMtzvbDAAhcEgd60pdSEMe1iXPRieSSaxXneYlGj8uLGcgct2ov2DlJZJxNCTK7BwcAdseoFVrW9kYyK8aIU+6O5HvTzJ+5aJW2yLgKQBk81TmhRLjDu/mZw2KdhJXJ5S5Q4jfGMkgf4VMLIJHHJGQzYw2etJo/ly28qsWBDYGe9WHZ/MIjaNvUEUJg0jPvY0ikjUljEfvPVXyEWzjLKVbrtB/HNbdwoaM74WYcAY/nWOY3eciWRWQdARyPahgl0KMplMOInjZ3GFDZ4/Ss57VxIxMeeOSODWxqFwYVChOcYB7iqiys/zuWXnkHr+FIaRlS2AYYV2RsZxVvRNPju9XsbNlyZJlUll6880+a4JkypVxj1rR8FSJ/wl+mZ4JnHFKWiG0e1a9pamFPLXG0Y4rlZIJYcqM4r1CSESxcjNc/f6WWclVpSVyYu2hxkUMpOWyasrEQOlbh051ONtPTTHP8JxWfLY05jFSNs8Z6VahDqfatZdPI6LUq2W3qKLFcxXtmwemK3bB9wHNZgt9var1iCr1UdGS9TZX7tNdgOaQkBeTXMeK9fFlEbe2YG6cf8AfA9a0crbiSuyj4v1slzYWbkN0lZe3tWBaRdKq28ZLF2JLE5JPUmtiwi3MMDisG+ZnRypI1dLts4JFdNZwbVFUtNgwo4rdgjwBWsTCTuxY48CpNuKlVaXbVEkeKQinkUhFMRNMKy9WsYtQ0+5tLhd0M8bRuPUEYrYlXKmqjr1FJq4I+Ndcs7rwp4lurCThoJNvpvXqCPqDXoPhLXFuoUw3THeul+P/g99Q0+PXrGPdParsuFA5aPs34fyPtXjXg+S5Gs29vbBmM0gQKPUmiFNzfKty1K259WeAoDLC92w+X7qf1rq5m4qlo9oum6Vb2q9Y0AY+p7mpZH61NVpOyM92RStSWRBu4/rUMr81DbzbLyIk/xCuaL95FI64HikJpAflphNdIhzHtUbGkLU1jxQIjZsGszUBhgw6HitBzzWfqZxAzH+Hms57DRS34o8/aOelZcuoxr3rA17xNBp9rJNLIERRkkms1JRVy2a/iN7I2M5uXVIyhDbjwRivlySJZb6UW+4x7mCjH8OeK3PE3ia/wDEt7tDPHak4SPPUf3jUNpYlLc7Y+OhI61pHmesgtYpQWpZGcsQE684q9FEzOZQNqAcMe9TJpcsxXDY28+9alto1zKyFY3KqcEnoK2SYOSRQjiO0FztzyBWlZQFiuSozz+Nai6T5e4XBG9egz+lK9lDEgKOdx9ulJ6grCW6snPAYcVp2hdiWVMIvLYNNs7dCxDHfkcD+tSyh4SUQfeGMelZstIsCbyoiVOST27Gq5me4c7ySvfNMaURJzkYH61UiuAMq7fM3ejcHoWWnWNwoBK55pYG813eMABfVqz5nAHycH1NSafKVhcqeSeRWiM33NHzygzJGWP95ecVs2Usc8a5YHAxjA6+9c+ZRNE/lOyvjgevtSpeLDAVkXZJ0AA71V7C3OgltF+1RhQm7hgBnBFY+pJ80g+UDqARzU63EM+4vcHcF6uO+OmarXaOsX2gIJFxnKtn6U73AyJnUsqHCt1B75qveGOSeFSWQAYbB4p809vNIpkDpgHG4dD9ar6krtbPKmHUfdYng1NgEk2B3/cmUAY3A4+lCyMGUyDzZSuEyeEHGM1XsJgSHBC57VHfl1uCVcMpwcqvH50asdjRCi2tto2zKy5DqBx6/jREQYS8WCw4UHrVV4nQBmyQRkENxk+1R28UxlVhIoXPUcHPvTd0JLuTmVj+5lZwBydpyWPYewp4iQEtEm1Twd2Dinx2Ue5/MnDshxtwOR9aLe2e4aUbisWcY9aNtgsij5yMJBPFlX/iVc1m3bwFVERc8YxjpXSzW7rEY40AjHCrnBrO1CwCM2YT0y46baYROfVmjYsUyGGCxAyKk0m4Ww1yyuWYKkcyue3fmrciJ5Sg8kcD5e9Urmz81cYwfRu9S1fRFWPqXS7qO5to3RgVYZGKuNCrdcV4X8M/GslncJpGquVI4hkY8MPSvbLO7EyAqc1lGTXuy3M2rEwtI8/dFO+zp6CpN3FRvNt71dwSEa3X0FVpIFBp8lzgfLzVd5mbNFykhrxx9+tINkfzEgKKy9X1my0uMvdzAN2QcsfoK828SeLL3VS0Vvut7U9gfmb61LkkUos7DX/GSb5LXS/nlX5TL1Vfp6muXhV5ZGkmZnkY5Ysckms/R7fZbqSOTya3LZORjrWbblubxSSLFtbljwK6LTrIriq+k227BrqbS3wBxVqJE59CSyh2gcVqRrUMUeOgqyq1ojJigUuKXHFFNCGEU0inmmnpTAuMMiqkyYPSrpFRSLkdKCUUWjSVHjkUMjjaykZBHpXiieCV8JfFjTLlU/4k11MTC3aNyD8h/HpXt7Ltam31lb6laGC6QOhII9VI6EehFOEuWXMhtXRYeN25XkVWkSQdVNPtpHhxFKckdD61fVww5rJpMRgzBvQ1RkDh1IB611bRKw6ComtoyeVFZOnrcfMXbeTzLeNvVQaC3NMhwsYUdB0oJrYQFqaxpGNMZqQxjHNU74boHU9wRVktiqd64ETHPapewHj+v60um+arn94rFQPU15nq15fa/dqZIytsv3UJ6n1Ndd4n0ma/8QXjXR+XzN0LBuMe9Ja6XboQruGOQpwcflUU4bNlOSMLSNGiMyKFLyepHAroL3S44rSORJBtJ6Z6/Src/wBjsrlIog5dSBICfrnkfhVK6lj83cEVI84Vc5/KtvQPMS3txuUovzE8VuXFtLFaqHd1BOTGGwGNRaWsKpvu3CKhBGP61tyarpk7LDMvmKcguv8ADTZLbvoZelW1pJHKLwuJOi7TmqbwFGOOVzgHHGM1fnENk5JdLi2b7uOcex7ir00cEUCmzkt7mFx1VuUPoae4zNNsyiIrnLY5ApdSIgCKrb88MT1J9KnmvEs5I1ikERLEqJDuTHoaqeKLyGSCNHCpdx8lV+6QeuD39aUuW1ilJoy53ywzyBnI9KoycnKnj+Ie1OilzcorMNjDgntViWAAecOcDp6jvUxXQG7u5BLF8obceetPt5FSRA685wfcVFLLtRGXBQ9MjFVJJzI6sTjBziqbsSbhUM+1c4xnIHWmX4kmiRHPC8gmqdnqLxzrIGB2gg5H3h71sx/Z9SheS3yjbcmM8FT6+4pqzFexmRzmKAJOnmR8A4PIq3FPYGZPKdlcnBjA6/Wqk8e0ll5OOhPFYsojdHYqySAfK6noad7aDsdTdWomiEdxGBnIIPrWJPpAXKxysmc8A5U/4UujeI55ALfVPnTIUMeuB71s3UWyJZo2SSNlO1s/zpp3Qno7HDTu9jdRxlSnJB5+XFWsxwJnLKG6sGyp78+laeoWcdxIqXI8qb+CQH7wrJvrKazUhtzqoOCuBjmi3VBcngn2u6xOSrfiKTY8s5WL5WQfPnjNZ1rcvFdKYXVHz8rEcZ9KlkuplmdZ0zOWycjhvcGkhvTY2LC1ilmO/tzycVspbIIl2Aqo6YY8VhacZXXLkAyE5BOcD0zWvbzlv3WNrL6nrTE3YHZROX252Lz34qlPJKxd8nD8EHqKuzW6TAOxAPQqT19xWZcDbJtVnHv14pajRRuGlYrDt2puBI9TSXKsqFVG5D3qyY03fIS+Bk7utPvEWOGJVwwPP0pFnManC3lo+0gg5BBwR+NeofC3xyk0QsNUmVJ4xhJHOA4+vrXDX8YkVQwKgdM81jvabTll+UjHHalKHN6isj6lXUonUFZYyCOzVDJfQ9WlQf8AAq+W2WTblJHVehIeszUUlQgiZyvozGp5ZBax9UTa5ZpuEMqTOP4YznFY+oatfzxssZEKn+6Ofzrm/hxpBs9AthIv7x18xs+p5rr57X5DgVMddw2OA1K3Z3LyEu55yxyTWe0GOg4NdZqduVLdqyo7ffMo645NZyVmUixaQ7I0XHatnT7cs444qC3tyzAV0+mWYVRxVJFuVi7plvtHSt2FQAMVTt49gq7Ea0Riyyi9KnAqGLmpwOKoQGmkUpNNJqgEIqNzgU8moJ2wtCGawprLmkRuKk60GZRlXBpIzirEyd6rgYNIpD5ohKvuOhqKF2VtrjBFTqaHjDDPf1qWgJUbims1MU44PWmyGkySzE2QaCajtjkNSsaVxoGaoXalZqhdgBQMa7YHNcd4+8Qx6Tp20SKJ5jsjGeprX1/XLTSrR5ryZY0Udz1+lfO/jPXJvEeufaUZkt4siFT19zj1rKT5nyoaR09sJXxLI5Ysc59fwrWl0pruzDmIhh0bpXD6ZqVzDEVDZJ/iPataPWtRWzNuszBSSST1Na7bC5WRvC8UxVh8wPUdKsog2/OOeoGKhtgZUJBPIySxqdHSPG8NgYBPaqK1JpADGFbehOMFeQaqZEM8bAlgThsDtU0k8Rkby5C3oGFTXVlezW0L/Z38pQMMq/4U7X1C9iaCaCTcoTcp4rZsdJRoRcWzOJk6gDpXNQIIJAsoZVz0YYau38Ki2kIEdyAxGcM3X2+tK1kW3c4rV7GWe8dpkcMTkkdR+FYtzBcW5P8Ay0hyee4A9fSvZ7rS4ZZtzoGI7jvWbe+H7NC08YIzwRnikpRW5LkeSw3AaQAHIBK/1rag3vAH3N8p/DFZOu2wsfEBRUxE7cY6ZrotFUXETxYBwC2AcEjHOKcbNie1znJGbZcQngo5289qYgLPknIxUl6Nt7KiZO0YyepqW3hV1bcQAOfr/nNFtQRVcYJAxmpLS4ljcMpYMMj8KnkEIYgseeAcdPWo9oDoFIK7s9D+tOwaFqC5HcD6Z61X1S3MeJ42BSTPOPepXiSYM0Zw2Pu9xVOWRxG0bH5M52+9N7WBFDITY+xGjUfMB1PvXT2tqn+jywz/AGi0fgZxlT6MK5hyVIGBn1xVjR7qbS5gDMTbyjggcEjqKE7DaudfNAtyGtbi1SCTGY+cgj2Nc3dRXkLGNipAO3aw/wBYO4zW5Dfm6tljdpJI1xhiOVPQYNFyrXtu1vKRGyjKyPzuq9zJO2hxc1vsdd0Rj39D2/8A11Z4tmKFvMjGMbhw49vSr90kls4t75Vyy8FvuuPVT61mXGVcxSpswBtyeHHY59aVirmjvgVkNo4jVm+4x4q+jvG6CX5Qx4Vjx+BrlGZrK7wjZY8jcMD8avpqciJLE6qYZF/1bfMufUHtSv3HbU6pkGSVlw4HQjjNZtykmS8uC4OAFOMiotMuYvIWNSWcjnd0/DNK9u0kwY3ACAY2nJxT3ErlRbjkiM7T6HrSGR3YjcFPcU2e28slgQSB3PWn2UhlYiRcOPoKLFjmQqG3gqWHGelQPbAwkc4PB9q1FjJB35J561Eh+R8gru4DHvTWmonK5j3MIkbdDHsUk5APT8KxLSxlv/EFnZAgq8oU7fTvmun1EmCzMu04YYyKt/BrSH1fxVLckZjtYydx9WOB/WlUfugnY9f0m0WKBFUYAAH0rRkgylbFvpaqgANPmsWVcipjGyIucHrFvgHisi0t8OTiuz1a0LKflrGhs2UnKmoktTSLsLp9tlhkV09nDtQcVS061IwSOK2kQKuKlA3caBipUPIphHWlB9asC7Ac1bVcis+FsVowsCKaJZFIuKhzV6RARVJxg1Q0NJqjeyYBq1IwANYuoz84FGwI6SKTNWkbNZaMc1chk4pJkWLbDIqpKm1qtK2RSSIGFMCqhwamXmoXUqcU5G5pDJSoI5qJ0I4NShqXIIqWgGQjbupkjYzSXd1DaW7yzusaICWZjgAV4z4t+LDNLJb+HYgyg7TcyDI/4CP8axlOzstwSPVdS1S0sITJdzxwoO7sBXmXib4p20e+HRI/tMvTzHyEH09a8s1DUr7VrkyaldSzN1G48D6DoKiitAyZfKlTwaFCUviZdh2r32o69dPLqUzu/wDCOy59BUK2r4VTnevQ+1a9pApX5wN4/i70+6UwlGVVZT68VooqOiC5c0TR4rq3jeSTyXbOdw6+9TyWMcBw8qFVGcDPI9Kz4Fk+1LvdlzgAg9qv6lALO52LMHjcZwD/ADqyWOhhkmYCw+eFueB09jUhtLrzmU25PGMEd60rPXYLa2W2htwHXG6QDGeOmKlLPqLeVE0qIcZ54Ye9NJX0JTY2x0uBFjjEoF5/Hu5Cen41pNFqdh+5iu5TA+NwDZUimwaQLJ8zJJuB+8BkfjXRafZGaJxLG4PReMU3JI2jTurswrqC2vbsPchmiBALYCn8BUqeHWtbhXgaQBxuXIxx61vNoqhGw2ZDzgjIq5bLMFAnO59uOSTgCs3UNPZxXwle2aSJESSTI71My+YGDNkGpGt1aUBjwewpLmMQjjpisZMiSR5z4z0j5RMikhWBz3HNReD4EluZ45jgouc9h9a6rV5IzBIsmCuOlcPodz5GscsUQsVY9Rj6d6ujPXUyasrFHVEUarcbWyN3Jx1qBMs5QcDOafNIZZpZJDkuxbJ680trhrjtk/rWm7Guw2SNQQecZqu77Mq4DAnGe4rYvLF2JCFSVwcCsXUTtfAHzDk8dabBalxds4PJ8373TqPaoJAJF2ODuHRu9Mil8sRzK2Wxjj/PpV5il7biRBtz29Ke4GDKCh+bqKiuGeW3dIzxw+MdCPSrl4vTAxjqTVNBl2HOD6dqVtRrYv6Rcv5eUk2KBhs/4VpSm9YBkdcZ3R4OQx789jishZYYZQCqplNjfXGM1bsWMUQE8rvGw5VRnHpVaXEzTuILjUdNKechmDBk34wG7YPv6VhbpWt5LO42iSJuFcc/QGtRHmtFMXyyWEp3Bz69xntWdNceVeNLPHvRsJj+IL0yD7U/UlIq/OLffKonBGN46r2/A1qeH9ItbpJTdXBC/wACAZzkd81nSpFEcxTTtE/Dx4wcE9Rzz9KqmSewlW4sDK8Cnccr+hod+gNFi5iax1BhE7KqDb68U+C+hjUlL7yrg5G0jg+1LqV+NSm+0bTECgU7sfMR6e9UbKDzi0yqCVIBz1FD7j1LsMjld+TgnjuM1ctY8MxIJVuuT2qoGKgnaSp64HFan2ae1VEcqQwD7SeQKZSJnZtoP3l6Z64+tIyEqG4kX2pRIsYUqRtf1PNI2VJfO3jBB70XFbUxdRuAsbrG3U/cbtXqnwI01bfRb28KbWuJsfgo/wASa8m1GU5CtGhA55HJr3/4Z2v2Twbpq4wXj8w/8COf61lN3aRL2Ozi6VOBuFVENW4uaogiks45fvKDVGbS4s5VRW1jimOM0XGYn2fy+AOKUDArTeIHtUDQ0rFplFhTMc1daI+lRNFSsUmhkRwRV+BuKo7MGrUBoW4mXgeKqXY2nI6VPniopTkEGrEjIvLkKpFYM8vmSHmtPVwEzisLODzUz0K6HaYqSM4NMNCnBoJL6NxUwNVYmyKmBpokkZQwqu8ZXkVYBo4NAbFVW9akzmiSHuv5VHyKRW5neJdHg13SLiwut3lyrjKnBB7Gvl3W9MvND1a50u6i/eRHKt2ZexFfWTNxXA/FLQE1DS/7RhiDXVp8xIHLJ3H9alpJ8w1oeKWULPGrzLh/cdq2DZGNQyNlG7gcZp63MM1kYmUbsfJx2pmmzM9ukYfncQQfXNXZXBtsgWNiH4OQc5qURLLFtm79MVu3Vi0kkbR4QuMtu6ZHORUL6SRGzltjgZGTxQ4kpmfYfZoQqzozuj5DA9BVzUHspJVa33bFJJZhkk+lUWtZGZtgJxyRTbVXkBiDcEg/WhXYWIwjzEOgySc8DkV6B4Zs/MtIRsZZc5De9ZWjaUBv2jk4B+tdnpcMlgAzkSRgDC9Me1bJKCuNe89DYaAzs0s23cxwynqMAcmpHjX5QrcDnFMtXd5JJGAJc4wewFOkmjhjeQggr/DXDJ3ZuotOxSkllhuWDqDH2xUGqTFWi8voecipINSiuJCs6bCTkZGBUtwlvJxlSw5xVxSOhxs1dalYM0qq8bFiRjP0pNQZo4FZz82OQatwIsESjgqvpWZq15FLGwTB21nUtYymrvQ47X7xMspOCa4phm8PfntWx4hcM7kHpWBCymTrznuKildMVSnZFmQ4B7YNbvgiyhvdYUTEhV71zE0rGPOD1zV7w/qSWl05l5G3hfU11QetzBp2NHxBqIgnjkhy6NP95TglQcc1FrcUN3ALmEggjLBaoeK2c2tlLFtDMWyOo5p/h+5jkiIdss45Tn8xWltbErYzbfLsUJA29GJ5HpV+y/0WQr/AeCSPxqmqeRdSgZ54I/H/AD+VXPvAbRjk859KSXQbVwvIgDncMdMY9axJztlZTxg10DMJIcDG4Hb+ArD1CIlhIDyOCDxQ/IafchuAJY/MGc55HrVuAr5YKBhkHzBnjFVIGwGUgEdqIDsyGORnBI9KOlxmjcCaJQX5hcAjB4YeuPXrTp5Y5LUJHGAynKy/xY9D2qkGEdz8h3IePWpfkt0YLIWYt8oI/h9aBcpGTGEaF5dsnaTPyn2qJLm5SJY0kPP3cnt6VeWNZERL1G8pjgOg5HT86zLqHyZ5IrdzMmcKx4yO2R2o8x2VxFhlY+YkZIDYdecA5/SiGJWlZVk2nqoLEZ9q1PC91GuqJ9pyBsKgk5HXmptetbSO6cwlXR2zkfwnFNE3s7FWG4uYrWNAuIHOXb1IqxsJdDE67mAchTk47VJa3twNPW08qOWJCSwB2s+eck1FZbneWXYVwcHb1/H/AD2qktALSTJeSxxqDHIvONvWlvGjUsmE3pncvTmjdI8heJvmA4kHUGjVYLV9KjlDn7ZwJFUc896ltoDm5pBLIEYEdxivqHQYhbaRZQj+CFF/ICvlu1hlbUIIwwIaRVw31xX1Va8QoB2ArF/EEi6jVdtjxWcp5q5C2BVIhovZpKjQ5qTgDmqEBXNN2Zp29aQyCgBpjGaY0OaeZRSecKBkLwU1I9tSvcKOpFVZbkHgU7D1J2cDionbioBLnvSPJx1pjsY2tOC2KxY0MsyovUmr2rSgymotMXlpD1PArKersVsjqz0pDSZxSFs1bQixbPyRVoHis1H2sDWipyBSRLJAacDTBSiqEPzSMob2NIKWkMq3CFRkj8arMqTRNG4DKwIINanbmq0tqpYtHwfTtSGfOvjXR5/DmtLEy/6G+TBJjgj0PuKqWTRydBgk53CvdfFehwa3pU1ndr1GUburDoRXz4yT6Rqsthd/K8bkH+h/Gou07Fxs9Dpre5d4TAZD+6bcueo9cVpXGHiC7hhh8wU5/CufhZSwcMQcfnVm0d5pmiJLBj261al0E42NtTHFoN2m1lulzyuNu0+v61z2jqv26NTtYN6dqt6kwtop4hn5htyTkCtDwXp4nSS8CLKYcAqegz3rVe9K5mkdTo1uquyswwW5+boav3TPDujLF0PTFWdMhRbV0mVUP3gQMk89M0SQkzLJEfMiB4ZuD+VRUn0OilHqM0242KI3DYB5atCWEMwIwc1QkLRysNuIzyR2Jp1nqhWTZPHgZ4PYiudOx1cresTK1KIO7FXO8HI9z6VHZee4dHj+Y9CT0q5qirJcTFeMjcMetQ28bxwMzEsBySOtG7uzrUrwNTYZIPlOSRgj3rl9RY2qyRsCWb2rXF75doWhwQRXH6/qUyOsgw2R8wNRUephClKUmjDuZI7i9EUq4BOOaytds0sLuIp0cZ+lWb+8ivJVbKRvnOScYpt3JHqNvKqTxSyQryVyPxGRzShpoia9NxszHkLMDweB2rPuJ9snBwM9anmcjbyRn0NVJ1DzgcbW/Q10R1OKWj1OjuFd9Ct7leY93G4e/H8qzI3eK9hKDAyOAO2fSti6jtrfSo4g6s4cqAzDI9DjqMjPH0rL1aWK302ykVx57jp6ckc+/FayI2ZoXMW2ZmIO89cikJwwCk/X0qWPFxbR3jzRuWUD5eq4HfPfrUIYMAAQM5PP8qrQNhxAQbmycEdDVK9XLHgiNjuqzOQpJH0A+tVLqQ7duBg/pUMaM848xQMAetS+WFucQ53HGF6gmooQVkR8j1A65/CmyqVIZu5I/GhPQHqyV2Doyldrqf4RjPNXIbycJFDPEssBztZx7evWqilCw3EHK1c+aNUGD5PQemamwNF/T2VVlhYHy5OdxXOPpUV3YNs3W6uyHOGCkDj1NS20kYZVOVXfg9xXb+FHt3uRYvJlH5DHAx6gc8VUbdSXpscHbxGMNJNbKWwR5mev04xmoGtIShaBmZzkMH4IFeo6h4QFwTcRXpVsHCupAOPeuDnsHtr+ZJD8ynaxHQ/5zWnLYlSuZjOEjVhEVKgKQnTHv3pjsyZe2lALdUJ6/WtA2jCTI5AHBPaontSWJ4RsihrQE7k8k6Lp9lAoYyYZpsDHU8Cs+/udkW1jyejAf5xV6CGSSdhHG7sPb9ag1i0u7aHzZYGVWGQev51OyHoZekzI+s2IYg/v0/8AQhX01avlFr5VtW8rULW4YKuJVYAexFfUWmvvhRs8EVg9JDkaSNyKtI3SqSfeFWh2qiC/GcLmoJJcnk1PbEFcVWvI9jZ7Gn0BDDIfWmmVvWq7Nio2kpFpFlpT61G0p9TVZpKhaX3p3GkWWl461EZveqbze9QNISetPUqxoif3plzdBYzz2qh5m3r1rO1C5xE3NUhGdqd9umKqcknFbVswjhQDsK8+nv0/tSEO+FMgA+ua7aKX5RWT+Ic1Y7VhSYpy0rYrRkIhbg1etH3Rj24qk+MU+zk2ylT0NSDWhpCnCmKaeKZAtLSUtAwpQaaaaTQA6RVkXDDNeX/EzwBc6pcJqejqklwilZIicFx2wfUV6bupQ/rUtJj2Pl0rPbTtBdLJFOhw8ci7cVaFwy7GRwr478Zr33xN4X0zxHCBeQgTqPkmTh1/xHtXjHi/w5daBeNFOgaB/wDVSqOCP6H2qHozRSuY1xeGVSkjfMOOefzq94a1K4tJ2EEjIGG1gvcelYTplxtcj3PNamhKC5D4yM4NaQepNtT1TTr2WaIDAdcYyB92p43uIn2GQYPOKo+GxGls77W3nGealuXEsuI2AJOfp+NTU3O6ir6GrvDx4kIyRVWYDCCRcqeBVeIiAtuJlbqfb6VehulmiXKZQfnUGjTi9NiG5jTyiCpBI6gfzqF4zb2bbN7IQAwYVoqEclkzk0XwZLFsYY/wg0pIOdqyOWkjdYzHuKRN8wBrDvMIzpKmeMAnvXUTEfZP3oIcHvXG61NvkUB8En1rJs6INzZyupWjBmwMEelYd5K9uj7eD047/wCcV0l8cyuRkjpya52+UG5I3fK3ftntRB6jraxGW07SRAgZOMGnRzwmJ45n2MTwxHSmxBrfLyL8rHkA9ajiEM05VRklv4lyBXVBNM8ibT1J1ukactczGSNTnBbJf3PWqWsStfHzgu2KMfIi8ADNdJaeHdPdkVppMkfN257461opoemQw+UshdpOBu5z7Vra/Uy5ji9KvCdqFyo55zgH2rorPEtu7HBlGTgHoO1c14g02fQ751dSsTn90/Zh3pmm6pObpY1Zfm444H0qb23GtdTpblmOGGef51TvbmWaUvMcsRgYGO1dXcRQ/wDCPK6R75duAqdhgc5/M1xzOA7FlJbjHp+NKRUNRbUiN1YrnHNU9QvDh0TAZn3hj29qvqxDIF6kcjFZF/E7z7lXOX6DtTWwSRehuSAjPHGTjHA6Gui05XltnWRdxeszSrFZFBcMxHXA6V12n2hUAopAUdqSNIUmzDW2mjcjbwD3FaGnySrKEQYlY8HPQ1v6baxTXDCZcsPmAPeqk+m41mNVBWFm5x2qZTtsdEcPF6M6VoprbTbeRbySZtuZYyxwPpXPNp5mvxBhsO+Sc81savNFaiGGI547mqNndGC4+0qw8xegP8PvWlOdzkqUmo3SM67s2S5kjjb5FbGSOo9Kz7tWKsY1XIIBGRjrXX3ckcmnvLj/AEh2LN7mucW2t7uVkklEDFS3zHqR2rbRq5i42KdtqNxYiT7NMgMgxj72KwrzV7+SUrPIJF5+XFdHqPh2SKyLgnIGeBwKyNA0+K8vblbudIjFEWTPUtkDj9axkh2VtTBuLRLiIeSwWdSS/PAr6A8Caguo+H7OcNuYoFb/AHhwf1r51vbS4h1GSOGT5g5XjvXpvwM1J45NQ0m4OHRvNQZ7dGx+OPzrGejTC2h7LGfmFWscCqkXJFXVHyiqQmT27YqxOnmxkd+1VIztNW42yKpCMSbKkiqrtitXVIMHzF6HrWHcNiiSNIaiPLzUDyk5qN2zTfxpIsXOTQxwKAKa/A5NWkJshkfg1ha1c7Ld+ccVp3swRSc4rxr4peLTEW0yyf8AeuP3jKfuj0qktQvbc5jxP4jeTWE+zMSkEgYEfxMDXt/h7VotT0q3uoiCHUE+x718wZIxgnr0Ndl4A8YPoE/2e53PYytkn+4fUVjNa3RNz7B3U0tzTQc9DS4xVAFRn5WDDtUoprrkUMZoxOHQMPSpxWdp79YyeRyK0BQZtWHdqTNFBHFAhCaYxpTTaBoSgUYp6LmgY+MVQ8R6PBrWlzWlyvDD5WxyrdiK1FXAp5HFJq+grnylrVndaXq1xY3KbZIXK+zDsR7YqxoikyfMc9+K9L+NWhBoIdWhUbkIjm46g9D+fH4157ocSsQFAyamndb9DWGrO90WdmhmjI6AY/KrtvKIsqclyP8AIqTTdMWKyTHylgCT3q0lghUndtK9Pes5OzO2E430HIFkjMj43E9DTYNyuFYqoAIPNRD92Pl4wfwpRClzub59394dKaZt6jtSuXtLYGN85P51k/280h8qVuT7VLqkphVYZjviHQ+lZ97p0Hleep3SNyu3pis3ds3hGDj76KurXrXMLxqxQ461y97AY2Vnk3HHGDmtK9t3imVZXKoy5yelZdyjqpCtlMnnFYy3OmMVDSLI3Ec0O3/lt0FY2tae0EYYEY6kjtWpCGWdZCDgdD61F4gljaykVcHcR3q4XODEScbpGMsRmsHWIAlAXPOcgDoK543B+15j3cHjjiuisJfKnUQsQQSDz7YxWJfWFy8jxQx7Rnlw2AfrXYr6Hk3aQsniGexZGS6IfnAQdMjvWjpfipmu7eeSQbocbTJyBjnBHpVHTtDhXMl2izOv8OcA10NnotvNGiqkKMDgIykbfrximtHcTZV1q6n8VWYt7SNpLmPMn+8c5OP8K4NjNb3LRyho5Yzgq3BGK9i0R/7B1MSGFJiy7M44H0964fx9aLd6xPqFuBsmOZAO3amwjuO0XxFfRQJCH3Q9MMOo+tdBrFg6xwu1sIUddzNnvjNcLpKlWOzG5ema9P8ADdw91pUh1IhkQcZpWuO9jnpNltZ7ERvtEh+ZyPur6D61UjtWmiZ1aMneOCfm6Hp+VaGqSLNds8YOzov0qfw1awz3T78cHjFK9i1pqa/h+CaC388EbOm0iuhaR0tw4/5aDnHaoIbf7M6IjAxMeQe1bogjltCcDI6CsG9TrjJLU523ZkvEEj7OevrV77XHb3BMnzf0qH7DEzMzO29TwvaqtxE7lhgk0nK+p3RhGWha1B0kkRyoKEgA1JNZRnyzCwVm6g8jFU7MZG1yB9elWXu1jjbYgyvfNCZM6bWiNvUbOKTR0ihljSRMZPTIrl0s4zdwPG+8r9/86t297LLKWwWJ49hVyKwzyzGOTuccVtGppZnJOjy/EzV1u6hfSZILV97quWymMdBj+dcInh95FMjLgtyDXUtiC5EYcMuQXPr7Vrm+tzCU8hQp5XnpVc8UrHI4cp5xrPhqWJ0mUb5ABu9zWL4OvZNF8f2jT5XzZDE+fRun64/KvS9TuUCOeoAzXkOvzTS6ut3jlCCmB6HP86yvzpmdj6jgfO0itCMkrXP6Jdi60+1nHSSNX/MA10EJylXHXUhoeOtTxNVY5zTo2wasRclUSxlT3rl72MpIynqDXTRvx1rL1qHkSAcHg090ODsznZBg8UzJFWXXmoihqDa41TUc7gLUjfKDXJ+OfEcGg6VJczN8/RFzyxrSKbIbOb+Jfi5NGtDDCd13KDtUHp7mvBppJbmd5ZnJZySS3eptb1GfVNSlu7t2Z5Gzyeg7AUkKlgMgADnHXNEn0Qt9ys4I9iOpxTsAKOTyKtGMsQNrZIyeOlQynamM5bvjtUjPt6Kbb9KuRyK44Nc6sktnJ5VwSUzhXq/FN3B4qVItxNegjNVorjP3qshgaom1iIExShh2Na0b7lBHesqRM9KsafIcbD26UhSWlzRFKRTVORT+1MzImpoFSEUgHFA0IF5qZFxTVFSgUAKKXHFAFLSEYfi3Txqfh+/tCMmSJgv1xx+teB6BnKxBSZSePrX0pMuUI9RXzldIbDxTqEC4HlXL4HoN3H6Vne07Lqa0jvrNr0KVvF2soGADkGrbOzbSQSBweKo6LfC4dVm78DmuvWKOW1UQoDjHAXn6motqdHPyu9jnL0BzGkajAHLD+tWrXUZLOIKE8yFj80Z4B/8Ar1fkhhVTvTOO2KgktFnQoisgFUk1sac6as9jB1WSK91PdbqfKZhlH6Ke4rPaVWvPvDyicFe3HpVnVNlvvgjP7w8Z6Vmrp91FEsm04Y/Wou76HfTtyamnqUEF1EoYgkDgY7Vz1/ZxCECH5XrdhhkuDhmGQMHPB/CsmWM2eoZkw4BIA7UpK7uzBScdEzFv7M/YgQAXx2rmNUspRpj3LqRGrBCx9TnH8jXb6pG5t3KnAx271y07iUm1kwcxk4YfdPUY/wA96Ib6mFWo3FmNpsHl75WHB6A/zrWBt1O6fcEx98c4qrbxhkOWyR1xzUz23mRqrtHsBOTt5I9DW6ZxytsdJ/aOhNDZwiyBtwpyxPzs54BOOnqBmsqdIbceWzsvmIXQFRlR+dUFsYIVDhN3pyafdzXtwBM6bl+7uVQPzxWikRpshs00/kKqK/lDnLDnPsayr5FlJEm5k4yD2rWt5ruIEOpaJx/HkjHr7VHcAMWbqvbIobGtdDG8P+HZdS10R20e0PIFVFPXJ6A12ep6e2kwT2kyGNkkKiI8lPqeh4qfwNJaW1y73CA4cNu8wpyOwIIIJ4Ge3Ws3xJfJPduVZnBJdmYk5Y9eTTb0FFNy1Ofum2swHLZwMVseGIZlSR4l3IuNxx05FYsb/v8ABQMM9K7zw5HDHZFAh8yRgTxxioltc3SdzRj5tx5ic0umXqNuRnGFPSr7RGO3Oep6A1x6xyQ6kxHJLHpXN5nXh4Komjp57gRgGFFK9+KbK0N1F+4b94Bk4qvNmC33n5eOaqWN0kQzGRuz0oWp0xjpoTtp0piMmMKPXvWbJblWO8Y71sXNw7BCzMw7jsKQ+XcWsuUbzcgiQtwBzkYp6bG8JyS1ILI+SwBA2jv71Z1DUN5COSAuMAd6o27pKRFECX3ct2rei02AxPc3Uis+chV4yfpTTuc9ZRi7yM20RWYvs3E9AasTxmRCSygA5AHU1PDLB9oZNu1fcVFcSW7ybFUqf7w4FM4p3vcy5kkuNwHA6YFcHqNurXrRkY+bG2u8uiY5N0YIQcZJ61g3tuhlN08YU53dMmpUrGM/M9a0CMWmmWcC8LHGqj8BXT2jZQVzNm++CIqeCoIrfsHzGK1p9DnkXm5pBSbs0VsSSo9SSqs0TI3cVXBqVGoEYNzGY3Kngg1VfAzW9qNv50Zdfvr6d65m6l25B4IqZLqaKVynqt5HaW0k0rbURSxJ7AV8xeOPEU3iLWJJWZhboSIl7BfX6mvSfjF4iKWq6ZbP88pzJg9F9K8cSIkLtU8nFaX5Y27ierGwpvfkEqBwa0lhRdgCknGeBUlla8KHXCn0HWrcUJdiWODt/Ksx6lRoSgBYn5uT7e1Z88Zy2Bwi9cd/at6UAqyclQ2C5rMaPe7swJ9FzQDZ9j30KzKVYZrJRntG2tkp2PpW5KKoXMYbIIrNo0TJIJVkUFTmrccjKOK5aWWWyud0fK919a3bG7S4iDJ17juKE76jNVZgRzUfneVKrDkd6hHSmN0NO/UTR0kLBlBB4NTDpWPpU+V8tjyOlbCc1Zi1ZhikxTzRigAUU8UmKXpSEOFKKQU4CgBrjINefeJPAthqd5dXkG+C/dtxcHIY47ivRG6VnSLi4PvUsd7HjumJNYXklrdpiWN8E+n0rvrW+iSElGDADOFPOKqeN9GAddUhByg2yAd19fwrnoziPfGTUuLkdcHGa1OqTUIpcHGC3rUV7cKiOhwpxwc1hGRpLZ9oIcdRUbNeSPFFPFuRR9/Oc0NOOh00oRk9B0QMtxJLtQqDjcau20olwYyXHTGO9S2ziFdrKAMdCO1P3ww8k7dx4AHensjSpLpYx9QuvIlZUyGHXHSsC6dZWLKSxPJUnn8K6DVtgYzR8g8MO1chqFwjTbR8pHasXK4QV9kLLdSfdYZToCRwfauZvJ9+tSSuqKF42oPUVr/2hLAhhumaWAkkIT09x71g3mJNRuJoGDrI+V4xge9VDujmrR5XqEDqhIA+Qn9fetTTmSWVFAUP947mGCPSsB/MXhR3/SmC4ETjauXRsgDt9a2j5nG7s7NIF8wSyrH5j5KjI6Hp8tWbuB4kSR5YgJAWJiUZH/AR+Vclb6hJLMq3Dq0T8FQ2GUdeCen51q3GoI90m2JUjCEg7u3bJ/zzWq2IaY2eNYmYHPlOASO/HcVmSsqo6hm25O3PU1Lqlyi3qxMGBUfOSevfFUJZiy9MA1MtdEa0433NXSAyRzTn/Vr1HHOB71j30wfOcgk54q3dzCFRCGH7tAD9TyayJ281/wB2BycVMuiLglqy1piH7WhKkrXdWWoLYaSZBAGlSXIbPVcYx+lcto8D+fl1PC9SK3Zz5tjHGg24/Umok0tD0cNQU4XkXP8AhLra+xHJE8L/AJip5ZI9ytAMk4y1ZEekSPcF5gPNI5/yK07exkDAM2FHGAaw8jRQpw+EnLrfLt3YYdQehqg9jILsKQAe5HStqbTniQCEckZ4pkzMbULKuJM44FO3Q0pzt8JnTMY9qBdwAwMVYKSTQ+XDlUPXNRS+WgCFsHrkdqeJRHJtDMU7mg0a0Vh9pA9uFC4HctVpHmku+vAGOaYp8x1SIHJxyTWglukU0YmfHI3EelUrHLUlrdlJLSZbh3mwVPTmrE9qyxxlo9m48ZPP5Vs3ELW06yxqrBjviXIc4zxmsPXbi9iuWnuoZFDnlyuBmmct3UdkPgt4UnL320xRjckfZm/2jXP37G7kuFtlxIMuEXHSpTcz6juTkKozkc5pthazO2YmMUyAkNiiMwlh2k3Lc6vwZffbdFh38Sxfu3B6giuw01tuVrynwfevY609vOR5c/fP8Q6V6haPhhVRavocdSDi7GrTgaiVs08GtjElzTgaiBp26mIk3Vx/j22u49Knu9Mi82aNSTGOp+ldZnimPggg8g9qpb6h6HxbqjXepahcXN1uMhIyCMYzTI4fnVUGQnJyOBXqXxg8Pw6VqvnWYCRXnzMg6Bh/+uuBjMcEbKwU85YjnHelUjZlR1JY7dZtoQNtbAB7mlaJQzquCV4APTNOt7h3ZGRSojAwAe9MlLA8gFsZx71BfUikTEKBdpbPA5zVd4cs4UDJGQRzn61bjTaAW2ksMY655zilk2xK+w7pDgdOgpi8j6ycVAyZzVkjNKqdqzaLvYxrywMvKiqUdtNbSb0BBHb1rqkjHcVI1ujjlRRy9iHIybWdZl9HHUVYK0XGnYO+H5WHpRBKQfLmG1v50ilO4kLGKUMO1dBbSh1BB61jOgPNWLOQp8uacXbQUlc2xTsVXglDAc1ZU1ZmKFoxzThSnH40gG96XNNJ5pCaAH1TuRiZT6irSmoLteFYdjSYxk8SywMjgFGGCD3FeZtbGx1Ce0YZVGwp9j0/SvU1GUrkNfS2XWUWUASSx8E98f8A6xScuXU0pOzMS3h3XcQViMtwFGc1tRJHO7oT8oOABVaVYIo3eIb2xVGwvwJEtowPNcnPPSsnO52JOavHoal9bKjqhI54Fcjq11IJmj3FVX+HPWuvv7MtanfJvPXOMfWuP1KEKxDKc44bNKTvodOFkm9TMN9+5eMtg565zmudvHkcHAG71IxWuLWJpGMkmB6Co5fLCNC0JPXa26sGn1O6UYx1icxcMVYu0hJzjBrOkn2ISOvf6VuJFAZPLcMrk4UyMCuffjj61zl3GBNJE+1wCQMHg47/AEramebjI2Qq3S7SGbn7x5yFzVdrt8iNJlYsMHj8qrXcsYV1RwrNweOoqrDKyuEJUqR16iulHmtG+ImPl2snltCxykykABj2LVstDaw2rxCcXUqjEs3SNFHOFJ6nI/GucjnW2MYucy2z/MYA3B6j/Peuq8LWEOqW/lOSq5by0VchDjglj+PT0rWKAypUEv8Ap0ylIwB5UbnlvXI9KracfOuGnuB+7iy7j6dBU/ido7e/GnWz+c0J2tIr7lcn0rOmlCnyYCfKxhv9o9zUyLghbqUzPLKRgsc4+tS6XatNKGHYg/SqbN5sgQdDXT6FaeVbmVx97oKzcranXQpc8lEtxx+XLsU/KOpoupfkAAwAaswKo3MwDMT0zVjTNPOoahFbrtXeSST0AHJNc/xM96MI04a9CSKT7JJBDMwAlQFXB/Q+9aX2lY49hO4/3q5rxGYpNTdbZdkMfC8k9O9aNq3n2YL5Dgfe9abVpHBOmlZvqaC6t5UmMlgKbdah5wzGPlHasyBYkTc43sDgjNXRGjyHC7WYdKlNmipwi72Gq8KP5kykqSOlRXdypJCIFB/Gp/sck8mVUso6D0qCeHYQGjOQce9FzS8R1jdyiQKmQfWtuNHlRXlz6HNZKOtqI1kXEkhAGOwrorZbdtke7JNNPocNdpu6Q6wvhFMwVcgdSep/GjVrSyuLNpUmBeQ/cxgioby28pT9nH3qW1skRFMjknv6CmnZamK5b8yKmi6W3mHjEfQE1reJNKextHaF0yADuQ9Qe1TPcLaxgxlc+ntVC61CS7YROG2Agk7N20dyRSjoN89SSl0OWvtOktoba78qdS+WDuu0Eg9j3rv/AA/fLe2MUwPJGCPQ1UntYb6yYhZHXO1XkjVflHsOP0qvodu2mXkkAbML/Mvse9a6KzOWt73qdnG3y1KHqjG+VFP8zFarU5S6Hp6tVFJgT1qZX4qkSWS/FRs/GagZ8jrXC/E7xrH4c0xoLVg2pTgiNQc7B/eNXGN3YRwvxl1ldQ11LSGQGK0G1yP7x6iuEmjjhMaISRwzH1yKz5L2S4OZZCzuxZ2PXJPWkb5TnJfjKjpUzlzPQaRopKTKGyPmI47KBUtw6EIykM5OOPWqaF1Q7xtkIyBjmpITiEFsbmBAB/hHrUo01HxAJC+5dsmduaiZgxO1GGAO/X1//VSxyLjIT5QcjngZOM1LNhiiQj51BG71J9KYj60AyalVe9IMZp4IqbCbHKMVIlRrnripFz6UiGyQAYqOa1jlXDKKkBp6kUmriMS783TxvZTJbj7xAyVHr71YtpEmRJIWDIwyGByCK03QOpBGc1yt9u8OXnnhSdKmOZQOfIb+9/unv6daztZ2LUjoVcocircN0O5qgHSSJXjYMjDIIOQRTd2K0THubazg96UyZ71jLKwPWpUnI61QrGnuo3VQW4qQTg96ALYehmDoQapmX3phlPrSCxoqQE5NeUfE7UfK8Q6bHG3zLGzkA88kAfyNegXV6lvbySzyBIkUszMcAAV8weNvFj6v40uL+FitmAIoc/3V7/icn8amWrSNKb5Xc9o0mcC3Ek0qFHGeDVO2kgj14zBwYv4T05rg/C+qm7xEZCw7c118MQBDZywOcVEqfU9KjbXXc70SLNDj+Ejg1h6nYLMrFiBgVTsdTuIpNkg3J2FO1GSZZCpcMcchTms2iYUpQlozlpljt3dXJJB4zVG5JMihckHqK1Lv99MY+QDye9EmlmEiQc+2aycT0/aJL3tzktVgki+Y42nkAda5TVopPO+8QA2R616jrKW/9ltI0ZLqMV5xq0vmsQy7TjgH0rSn7rOOvetC6WxirueEqUU4z8zcnGaiMa7l3HC57dPwqeXKqoOVweapXd5Bb4aaSMFTwO/5V1RPKlGxoSqIblFOFRQAuT94ev55pJNVuEDhLhkiJztTOPwrBl1iS8ISMMUHQnj8hW94asmvHd5sOUXKrj3rRO+iILunwXFtYz38+Q8w8uIHrg9W/pVVXAYDJx0BrX8Ql4J0gbC4UHAOR7VjjgkkZIBJqajs+VGtJNpyLNp80wHQk4ruLRNsAA6KO9cboNs9xeDg7Y+TXcKojAwDtxyDWFSXQ9fAQ05h8agktgAdaVMojOpIPsaQEuuB0qzJGPJJxjisj05PuYUbbriQydD61sabIpjWNQCTxzWN5byTMFx0PSrenNJGCgGeOuOaV9DnxCTkT3Fu8UpVs4zkYrStGSTygW7dR1qgyzSSZfLCtG0tURMq2GPY01e5jUl7urN63EcKIsZ69Wp9zbRyoclRgZ3YrFnuFWy2hsyjkYq9p0st1bgz9AOgp3scE0171zNns5JZw7AbR91quQR/ZE8+T5nxxmp74iJQ3boAKqXN4iQhW5J9ql76lRlKSSHRX808qhxj5untVqS5RZDGckYxlRnFc8txIk5I5zyDmuw8Pm0iRJZlWTBDMpOM+1JamlWCprmsc7d36GRQgIRRwTXS+Hbq3LXF7J5lxIOCTtw2Rg8H+dcpqsBnvJVtUUozkhQenPStbw9vtw1s8RZ3IClece1XHSdjatCMqWm50CXImhGBhlGCMcVm3U4UkgYcHK96lbMNygib5yMOpqcW6EZ4JPOa2k1az3PNmki3YXQngVxxkcirTNkda881/wASr4ZuDNKrS2rOEIT+E+tT6d8RdDuwD9q8v1EikYq4ppanHNJM7tXxUyycVx8njfQIoy7ajCwHZMsf0rhvFXxXMkb2+gRsgIwbiQYP4D/GtIxbIbO2+IXj218M2phgKzai4OyMH7vu1fPmrX91qV693eytJPISzsxz+VUZ7mS/vnmuHeQsfvE5LH3pbhsuMnByBxRKelo7By9SxZRl2DPhcNwP72PWtONGWfD7cEYz/dHpVSInKOxwoyBj196tNMIh867XI4Y9KgY6Z/lRMZdicsOtJIwyMjA7HGc4qJpHaVfLBAY9SPzNWo1R5lV+gyS3/wBagetyo+TJIOSE5GPWnq6ZVgG2qegPJ96JgVZipGw5+bOOM0in5gB98HjJ/T3p7AfYSLnrViOLNPii9qtJHigyuRLEKUxj0qfbS4qQKpSgLVgqDRsFKwyHBqG6hSaFo5FDKwwQe9WyKhl6VMo3VgPLZNYk8D60NPv9z6HcHdbynkwHup9q7e1u4LuBZraVJYmGVZDkEVznxE0k6x4busczRgyRjHcdq8E0bxRq3hybfYTt5Ofmhb5kPrxRTlf3ZbrqaJWV0fUYenbq4HwZ8Q9P18LDNi2vOmxjw3+6f6V26Sq3Q1o4tbgWN1OD89ahB460HHrikBZDe9NklVELOwVQMkk4rm/Eni3SvD0DPf3SeYBxChy7H6f414d41+Iep+JA8FuTaacSQY0PLj/aP9KLhY1vjP8AET7fFJo+hyBrQH/SJ1P38fwj29T3rylLjzoSVxkDkE064j3pjbn0I7VR5t5VC7sZyec9aSjYFudX4Lv/ALHJxkE8817P4ed762BX5s8+9fP+nS+ReI7/ALxCeQOCa9e8HeI4LaZUhYNCQOo+Ye31qnflOii9LLc7mNGtZt23JHrT1eWYFzH82eSB296nkkS7jSSM59B6ikcCPG2SMk4O0HJrNJNXOyM+bW2pVv8ARgLgKxKY69jVNrVY58HeYxxjOa39UlVIommfc5HY85rCmk3vtGRnisVo9ATnNaso615UtoyJ1HAFeUeILdmu26jbxj0r1C7spreZpJctH69q5nVbaKR2dFXceSPWjlvqbwtFe7qeVXkcksrJLI55/vVSbS0yOc/Wuw1mzWGRSVG5+TWPJGvlnzAF9MitKbdjgxK97QoQ2pDKsarngDFd/wCFp0sNKuZ7uMJGm3y8qMlh+H6VykEahA8Yzg5yOv4Vbn1CYqomJlRAVVXHAz3xXTFcquzktrYdd3T3ly0knVug9B6VGVfzdq5LE56d6ZZkOcngLyfeuh8MWC3F6s84Hkg9D3PpWV7u52RjpY6fwjpCxWSySryw3N9fSp7wiW5K4AUdhW3bqtvpzFVAByQPaufjbdIztgDJPWsZu56uCu7vsWYsZ46VJcgmPB6VVjuFyxGAB0zSTXXmRkbenes72O72cm7lJyFuGKkhQKW0uzE7PH8w+lZ2pSFmVRlRjk5qNLxbaFI4SHb+IUGM4c0rHVWl2xVpGAO7j6VHPclJv3JyT6msCHUQCu0YI9KtWcwZ3Pc1VzmlSad7HQQIYx5k+FLYxmte1uET5V+bjtWNEzPCvO5Aec1f0h45LtwMcDt0qWrnHKLd2x8ky3LMDkbPWqV3bSqf3WW3DkVoanMlijSBQzelYn9oXDXyYKhGGT7USdjajBy1jsX20tVtwxYLI3rTrKFHtpG3lShxjNUdSvy0axKSD61AqyqUihJLP19qTsjZQly6s3NI0n7RcAyTtGjZww5Gff0GK0bnTrvT5VUKC3UMpzketWPDzyRxBWB3AYLCugmUTx/MSZOu7rVRs/U4qleXPbdHPWyONSVpecjGAKnuJDNG4ibYAcCrcoGM48yMsBtXhmOPX0zWFcytFLiMYznch7Gt+VvUlxU9UcH8T7JzpziMkoHVmJry1grFY4c5Pt2HevWviRfRR6W1u+S74JIPTmvJJgUy6cBuBmtlrFXPPq/FYjm4eUKfljXCnHeob2PyYYY25d/vHuakEyo5M7DGQ3A7+lV4SZ5nmlG5j91R1FDaJLSDATHyhOGIFOKMCX53kkAelWoU22UqsoDgBunSlTfOxyhxwCR2zU9BlrTY1RX39h8vP8XvUlw4CAMC3BJxTYgY8ujYVTwuOhqWUsY4wwX7ufrTW2pBGrKgDBsScE5H6Cmk5yASTt+Zh+NOuZAz4AwpwucdPpTXysSD+HGcIc569aLjehGYTgbWALj5cjpQOY9yuSwXtjjmnt6tkt6A85xUTAqqAnaoH9O9DGj7cRMDpUgFLwKTdQZBjmlphcUm/miwx5pKYZKQuDRYBWqCTpUjNmoZG4NKwGPeqAJY2+6wJH9RXy3rduLfUr+2C5EVw6jHoCcV9U3YEgYGvmTxFH5vibUpLchibl8g9GwSKy5ffRrDU5Vi8M2YsqRyrDgg9jXovhX4qXthEltq8Iu0XgSKdr/j2NcrqNgQI5UDjI+YGs8WqO3JAx39a0Ta3K5OY9buvjFbKhFnpsrP6yuAP0zXMap8R9a1NWUzrawtwFgXB/7661xfkLA+CCQ3BxS3KrE42Z2d/ancfJYjvZ2md5JATuPLMcms/eVBjBHPINabgyIysA657dvesm7gkt5xvGFYcE96RLXUkidywU8rjH0pLiHEe6MKSPbNV2lJRWj5OQOvOKuRp+73hi244OO1NEmdAz5RWbCtypPrXW6JOyzI6nE4PUdDWc9jHJCFC9Bgc8j0rQ8PTMJZIJQA6t+Y9qLWKpv3j1Lwte3ckBeLIY/KVPb6VvQJe3MqpuSNhwTgEiua0C8+xxybk3h12njJB7Efy/GultZHgdXLKJNvzL2NZyjd6Hpwb6rU1r6SRII/tpNwFG1Wxg1kRSRq0jzKdnIAHUHtXSWclreoquqRuBgA/dPuafcWcMiSBY0ZMYJA4rOV4u5Mayjo0clqGq+bbeSItztx7VjW2l/aphGTtLfzrfuNMl+1BIlyCeGPYUWls9vdlrkElOVI6E0k0bc8Ix9w898b6HJZushJZV4/CuFuwxXn7p9a9f8AExbUWaBlO0/xYrzLVbQ29w8HD49acHbQ5atOTXMzGgcxEnr9e1Pmma4VVYEAcZqdYto2hTk45pHicMD0APOec/Sui91Y5owe4/TLaRpVj5JNemaHp8dvbq8uPlGRntWB4O08NC9zOp5PDNWveXLSBhGSI84HYfWsZux6OHp8y0NG91AygRQ8R9CT1NU8bk2gYA61nxXO4cAkLVk3SqB2OM4rJ66nr0YKCSRKFEn7sABe9XPskcNvubnIqlazO8oA4Bq5d3CrCQfmIqGupvPmuoo5nVYJZPlgUsWPGK5yLfjJbJJrpr2Ca8wkOSTyAKzrbTXaP7pPv6Ut4oyk1GerLmgWsc5Pnrk9BW7Zachu9oYl1P3c4rGtN1rlMFZB096mF5LFcpMD84OSR3qklY5aylJtpnVTgwROhBBxiqFlepaOdnJPbuK0ReLdxJKF+RlB3GoIrNLpyVXOe/pTfkcEJaNTRDfypdTR+YWIIy2O1NOkpIVlg3lD6nrWilk0aOvl5J/ixUlpdLaHywD+PrSavubKo0vcItOt4Srwygb6urD9mkQgfM/yqQKheRCjrwHJzuHerESNcbFLHYnOaq2hlNt6s29P2q/lZywGau6lLPBaxpDzLNnaByfSsGzikhuGdZM56c81LqEl1aahDa7yJ5T5eScEZ9+3pVRj1MFTTkrO5t6vbwRqv2eXzRHGsZCsMhx1+oznp3rnJYWhLb2JLnJPpWwLZtPtWa4iaJs7Bh9wyOtYGoXJO4swx9a2l5E3fwo8++I0Qm8ko2RuwR3zXBPaPJAZCAcjEYJ6V0/jTV1utTEUTrtiyDnnmsG7maG13JknpwOK1tokzinvqZs+lgOkSk4DAu2Sa1tHso8STMu7aSq5FRxr58Cg/KScFugJNbULpCvlRbnCqNxQdqW5NjHlQNcEEfu/uYI61IEZNxiJ2q2Gx3pnmKJZWUDytzY55J9KuWF2t0zBlRXU7iv8LYFDs3qIp2qSSiRVibjksegp8sO35UYFj1wOgxVnz3e5j8t/LBGGAGM/hTXPmRMx27fu7ieTTApKD5oOBk9AegGKZPneQrfIO478dBUiBRzIGwcAHr0/xpsqsk2wkkbt2AKTGEzl0Em0YIxkn0HQVGdojK5AYsOO/wBaUNjYSmCQRg880oeMW+ZGClupxyKT7Be59om6zR5+e9ZKyGpA5q7oz5S+Z6b5vNVQTmpFB96AsT+ZQJKYFNOCUgHbiaZI3FOPFQTOoUliAB3NDAy9evo9N0m7vJiAkMbNz344FfN1u4lkllZl3sxYn1Jrtfit4r/tljpumS5s4G/euOkjDsD6D+dcHp4/uDJPZqztd3OiKsjRP72LHAZe+OtZM1q8E2WDSIT1HcVuSRmN1jkG4YHzdOtSiNTtDN14A9KbQJox5bcSWocja47Y7Vl31o8McUnUdwK3hmPfuz5RO0tSXNq/l7GO6I8gg8c01HqW2nocss3lsDGSCOoPINV79jKm5mB/2O4+lal5aojyKM7TwD6j1rNuo5LY4lwynBDAcZpN3JtYpRApG2R8pHBPOKW0uWhlACgq33s9B71NECxYSgsjf3TjBqvcxyW8oaQ/LIcg+lNPqjNo31mV4S0ZyU9eM085WSC4SMjAzgHJYZ5/z7Vj2Z8wqiyYyQCK3bWcIPnjdpF4OTwf/r0xJs7bw/rUUywqmHUkZXvxXaQyi4I4KD65rxrTVkj1PzrNnjVwCQecNXpOgTtNhPM+YjkelCSbOunVOttrZ3BeMkKDjJFbzzPbWiAvwV2nAx+dYmhXkSXIhuo2ZSeqnp+FdJq1lDHFLlDggNF5koz+Q71jJO5pOV5JMo2pEgYjAOOcnH5Vk3kbS3AQZFaNvFKboRB4EDDdhmA98ZpbuMK5ftjOaiaStYn4Wczq6R2cW8gMzDaOK8713Thc7dowyncD7129+zTSkFiVzkVBeRwzRRrDDtdep9alpno0qataSvc8vfTLsc+TLs6BgMjNael6AzMs9+cRLyFPU+2K9H06COO3KlcHqcjrWXqNoxugcfK3StOd2sZww0JT5ehUSdPKSFECRgYAqOaNTCwPYcVJPZMJY2XHPB9qnktQEJbOQKi/c7owjDYwIxt+U0yT5JkdmwB178VNfLtYnGAKo3jgwk54pLY0k7se+vRRX3lFgIs4J9KkutTthkGYY9ua8+1ucqzbO1ULW9aYgM3CjBotzLUwWJlSnyJnqOnXay3aeVNtXpn61rSm3TcIZFXHUGuC0KRpWXkgjvWqrsJDljz1zUX0sXKDqS5mze1Bo5ViKYZvas+VSUJ5ODVcSMApU7m6cGr8cMvkb3Q+Wf4qaeo3H2cbHS6SwbSIVwOFwRWlprJExGR+Fc14dufkktieVyR9K2o0QxMQcMOeKH2PLqQs2mb11KqQ705b19K5W9uCLhZHG4E8qKvW9/mMxbDu6ZPeoZLN2kU7GYE84p9LF0f3fxGdqF48rB4wQCMYHatvw75s8IMjHywOFx196nn0/wAy2RFUhV6HGK1NOjW3gAG35RjrS8xVa8ZRtFC2YAPyAqQcgY5q1qOmyxSQTTIflUMu8cDPPXrmrduISys/HTJAzUT37xXeJZfOUHmNhvX247VpFJpnF7TXQz9a1JJLKOMoFcHghsj6VxPiy4axsjMTuLcBVPU10Ov3sUbuxVVXkjYMgV5B441kSyrFG5dPUdP/AK9bwi769Ac+WOjMK5u0eXayK8pYl3Hr6VJaTi5TfLncDtUZ4HpWW0CICquWbALMO3tWlp8TmHhflXkt04q3LXQ5uupuRx5tVTaz7VyMDnPtVa5d4FcrujUrtbP9avGZ0jiaFidq7T0NUoGiuIJTKTHk5buTRHQGzPhTY5UjIOclh2IqTT2jj/eZOBnOfanRnc3AzkghgeuKVtigKqqG6568DvU2FYlZ9xSZzmUDovcdqa+0KVwcAr1OcilR9oWRt5XPGR1pkwKFkJw54ye3NPcCS5dlbGVbGCFH1/nTJ5AWV1bcpxknriomkLDgDYpxx1amzAuxJwdmDgDGKAW2hNkMmMMCBhVYdqryoImYmMOeCA3QU92HzYcE/wAR3YwD6/rUTu+QD1xuTjtigSPcdC+LWmXCIuqQyWshx8yjep/rXcaZ4n0TUFU2mpWz56AuAfyPNfMlzp0qq2xCVb7v0rMKyq2WLYz1FUqkX8SG4dj7KikjcAqykHuDVhXX1r48tNW1G0YC3u50OP4ZCK0YfFviOJtg1a9A7ZlJpuUSeRn1p5qjvTXuVGeQK+VV8ZeIztb+17vGe79amfxz4mfcv9pSBPZVz+eKTaHyM+jtY1+x0m2ae/uY4Yx/ePJ9gO5rxPx38RbzWS1npqvb6f0ZgcPL/gPauEv7+6vpRNfXE1w56sxLfh7VPbQyzoFBOAefQ8VDbZcYJbjbZTLGfLcjJ5x+PWtXT1H3WyGPtiorXTQqh0BVgMk+uf8A9daNkAuRIWCjtjv9aafQrToXIlMMgMnzEjr1/nQbby2DRMzA889AaaInWQgjKkYIbnbSxERtgrlevzUMSEtwhLRyqAvOAR361St2ZkntZBuCHcjDsM1Y8uRrgqMbCchqqsk0eXUqWJ2nH8XtQtBvUbLaxXQkJBeQICCnr7+1Zb28kRMMsZ8vrtYVsKxSUyoFVSMMncGiXEpVc7CBnIHIpbDOWv7ZbaUtCpaFxuxjoayG2+f5jMxQckEZru5rfY8cgw6NnIx3rF1XQDch5LSXZIckpjFL0B66HJxTqk4K8r3GcYrZt5S8Y2c4zk5rEvIDbykAhWY8k9R9amtbtll2srZIwTgAYoT7ENHZaO4+VSDnICnrXoOjxbXSdZEUHCsO4968w0m7VHT5ww4Kt2NeiaPqKFELKD6r61WttC4OzO+sbTG25MmXU9c4rTlC3Fqo85zMrfd6/LgnNYunzwXKosWQW48sDn8KmeBfP3/aHjtskADDN+IyPWsPeZ1RvJ3bLkM0CyoJUyOmc85rUlCTwyR7SAxO1ickjoBxWJCu29dGIzGSADXTaeke2KS45Xd8yKOduOtRa+hNWyOc1DTo5oQrAKV6EVjLZOjSlAWWM85rtbmJWZ9ylRk4WsqVVimdV4D9qlOxpRryWhzckglyq8E1SkeSTbuUfL39a3JtNRE3Bs5biqtzAExwOKu7lqehTqRb90rW6RNCBIRvzTL222hfKye5FOdRkHGKsIA0ZbcMjjHehK5clbW5yd5bhywxXIatMbZ3jI47Gu9u1/euD1PSuM8S2hljYgfMtS3Y1V3qjgdbuFELD+M1haYczsQeM5xWprcZdHRv4eaxrM7Jd3Oc44q18Oh5NaT9qrnd6LI+QycjI4rop43aIPj8a5jwsTOZFjb51G4D1rpob1pQIpBgDgg1ktD1acrvQLc7hwMmtW31XZb/AGeRcoOCay4pBBOTHgjuMVK21yRjGRnFCi7l1FGXxI6fQbSFi0q8q4+WtK0tWDSb2A2npmsLwzeBIxbScPyyH+lah3GUuZWDSHHFLdanl1ItTaZqX0STWwEC4k6Aio7G2ltUJmlznjmqEU9xbQsqneAScd6pvfXM0bmRmUKelVoaQpSatfQ7KGdTACG3MPen3Eai38zO047VhaXcBYFadSCTwfWrlzNJIAC4VM8AVaV0c0qTjKyLFtfsIsGQKV4zjNLPIJ/nkfLN82cg/oOBUVjZpMpaQAliQvsB3rn/ABnrlvoYECY85+ABVQjd2RzScU9DM8cauIYTaQuSzH5nzwAK8nuLhbu9Eb4Qc/N1q3rusNdzlWIDH7xJ4HtWKk3nXC7EAA4Brodoqxzyk27mhp1nNJvkx8oIyD3+taoLLAkRbAYcAdjSaRloZvNBDg4I/CpiI2meRtq7SSqkcGpGkXpbiOCyRUCrxj6H1rHaMJv3lhKDng5BBqTUpIyF3Apxyx7ZqK42yCNYiS4Ayc4GR3zRdLRE7MltTscEHAXAye1SblIAwxY9CRwBk5pkSgNGEYEP2xn8Kdtfy8DbhQOe/WmtB7jjJuiKLuPIDYpy/JNKZyoXGMevFJHtQvx8xGMCmsu+RlJ5U8Fu5oXcVxiAKnmc4Vs7D/OmI3myISFJI59etTNIBFMq5AfgHA5xUEJ+zyjaoIHXPrTFYgmYqzk4AYZb/Cj/AFY3ckN8gyefbilfjaSU3bs46ZHWk+URYVSXVgRn0zSDY7J3ZPKjcuFGTz196iaxjkcoV6tkHHapzJHty2HLD/vk+lKkis0mVIVlwD1IPPSpsabKxmTaIn70d1btxxRBpMUnBcr7npmtfO+P5m5YgcfSnogy+08qw444osBiDR/nIznPQ01dMMUgBdi47Af54rfnTBjdcKjHGBzimvHlMAAyj36j0FCBabGdaaajkllJJ6+1XIrceQQqg7Oc5wDU1uHYPGH2leOTgj60RxeW7Jhht+9k8U2NtsYsDDO5cJjsc1IqqLdn+YsB1HPFOOUO2LkHkDoTSvGdy7wRnjp0FAh0boqtknDYK88Ae9OcgBRCVDOORwarGPy+eQoyCAM/jTZMqqvEo2hep7+tIZMQWZVYhxnPHGOaaiAXDxtlT2PamMkkJUomSwz1yAKjnuS8X8RdW5xzn8KOo0wlQQXfzfOSMHtn3zU+IDJG6Mxjbnax5BqhOJpYkYd8DnJ4zTrhHaEYISSMfd9qq66isXCg2PLFtPOGj6496hlwZVkib5e1MQyArJhQw+Q/0yKmtEaa4JjQHj5lpWQXMDWrCK7zJtG7rkLXK6jZypLHGUKvjjjqK9FubaURyvaD5lHzxd8e3rXO3SC5mblvMIBwVIxis3oLc5GCd9PkWJhhP5+9ei+FNViljDM33cVyGo2jzW6K6jI4VugPtWNb3tzp9yTFuXn51xwa0hLuHws+gdPvWebdFKsYDdc4x9K3Yb61WaNpG84Aj5VJOfyryXw54jtbqUeeSV25CkdD/nFdvY6iAkbxIDE3Gf8A61U6cp6nVGpFaHZpd2zxfaRFLuLEFchQPp3qxYag0sqKZWcrwoI4Gaxra9Xah8slM8/Wty2ELFSjKT345rnkuV6lS5baly4uZNxJ3Fiaw5rx5LohgwQdTiugnaJsCFGVQvJY5yfWsy7lhhgkGOMVl1HRavsVhdedjbwg5ANNlhMgLZ5PQVnWtyFyWPGKm+1uw46Vtpynpqi4v3SGTdE48wH6UojaQsyj8BUznzV+frTHk8l2RBuGMZFZlyTastzNeMM53AdetYWpWu95FZef510MqkDeejelZ93h5Nx9MUmhpNHknijTsF+MZ4zXDMvkzOpz154r2jW7JZgwx1715Zrlg9tf7WAwTwcVUH0OHGU9pot6DdS2V1HLb5JByw9RXWxXC3MjyjKhznHoawNDtPLIZgCCMc11Og6UbzV47aNsKxyfpUSZrRnFLmZPbp904781d8kNhgvTvW5e6AthKodj5Z/M1XSWzjLRMj47mnHYv26lZx1MhGeCRZImwUbINdZbNFexptYB2GRg1WuY7C40rdb7RInGD1NUdHYCTyyfmU5UHvR0ujKb9rHm2aNKSOeyn+YllBz9a2bGC3vbdpNoVwclT3qk6yXiGSNQo9Cajg86FmMblW7itXFPYybbjvZm+lkk5RZRhV7L2rJ1DbDqBjDkxL1yagk1O/t1ZsrgnPTFc/d393dXBAw0h7KOTVRpdWzmdR09zpzqa2u+WNw0KjoDyPU15Dr+oSaxq9zeNOqoDtUN3HtWxrlw0dugV3XzCUwxG7cOuFznHvXD6gRBEckMScovYeufetFHlRxylzFC8ije6YAkqOdx7mrFhZyMAEQlDkYHWoYSxTAPJOcYxitqzjdAnmkhVXcCpqZPsJGxFCsdxFBuIQqCxb1qKeP93Id20AnbuwB780lqxjcXMpaVAfu4xkU+JxMkrNAzJklO+0U1oFzLBd3dpo2Iyu7ByAKtwhEeVN27Z8272psbR7NzrkOu0EevampEI5WIDFtp3HGaAt2JUZI5CYxubKlcdRmnSKVuZVkJI3/TmkiXckjlhwOAByOKccu7KinJwfm6/U009CbD4RhC43KpBBI9cVGjGNFPl4YDIbjmpiQIlRsgAncOxOKaD+6RwQMsflI6etCC1hsyeeTGqnaE3biD161UeYYXK9cDBGcjNWY5fJuOWJBOBuPT8KqzbQZAOXA6Af57U3rqCEkEW7ZHjbnbnPTvUMz7mkYyYQfLkY5z3+lSSr97BVsqB07+1V5AXUFiioo2qPQ0h7naZaOESOo2NlT65NOY7U4Qh0cKB3pZWVolLMGxk9fx49KgimJXJYiVh1JyG+tSaGutuJrQPk5XH5VDDIEOdpGSVY4656Uy0ubhYtsjIcHAGfwpbZmVFklGArZJHXmm9BLzLR2M0ZU5jLY2+hqRVWTzI2JwD3xkVTWEmVShAB5BJ/z7VOX8yTJJDjKvz3HpUhuAG4kqQW70m7LFx/d9arMWR1+YjsG9RQxeEmXbnPJz3qtxk8c+7G/CkdWI6f8A1qkumYvhiWJ4Bz+VVxhondOCRjGM8U15mWLbG/y9CD29KBMlhxJGySN+8TjPp70jpKtuCFBQMRkdaHtwi+erbtwyQOf0pQ5wnzcqAdo6H8PWgLakJuMyn75jycnOeaaq7ZX2c4GCP8KddKFdgr7lcbiF4OfrTXgQurxMwL88noaLAn0J7YfZdquGKA/MGHAFVwyyXT4Z1jbIUEfpSLI8kWfNO5Rhu5/KnzfM4LgAq275uCaBlK6juY7lnQLkjuSDWhZxMYUkLlm4D7R/nioLiRop9zE7CeARkMKLOcRXWF4U8ZBpx1GzVkgVtsisUmJyTWdqNoZLj7TysrDrjjIrRhaZpFyAQQCCDxirE8TqS8sYYMPunoRSavsTzHIasnnWRRsFk+9jqDXLpHHK/lzr0zgseRXoc9pHHmSCIvHnEgbt7/SsbV7CD7XFJEoRHU5HvUNdR6HKBXhuWa3f/U4IRV5YfyrqvD+uSrKglBTuAV4rGvrCSNw6dhkY7elY8zy28wltyVIIJU9B+FXCdtw5Wme66beiZlZcNnniurtGKwh1OV6mvEvDWvNBCslwSisevYn2r0zQdVTULcNG6vgDIU9KdVqSOiL0s2dY90xQgEbe9YepajFJGyRck8ZNPvr2OKDaHVnYdAea51t7FioIA554zXNy21Z2YSEL3kXLZiMggk+tW45BuwaisLa5gkjFxCR5oym8EADpmrDQf6SyBlYqfmIHGfamttD1FUi2X4V81Rxzmi6tSoBUjpg1JCBGFGQRT7vmLeTlR1rXk0OaVS0tHoYpbClW6dBVW5hxnj3FXbh45ZEEY5zzSSqGOG+UYrLlbWo+Y564tw0bMV6d64rxTpaXCjA56ivSZ0UK6tXJa1BIpGwDBOB7VOhlUTkc3p1mYIQsmARzjuK07SGRUNzayFZYznIqO5XZLGxJyV+bPrV+xj/dlYjy3FTJWephTlaJuadq1zq9g6XGDIorPnhbPz5Vh3PeodOuJNLleN1DKxzkdq6cC3vtPG7aWxwe4pxfcpy9k7paMytHtYLhRufEmeRmpNUtIowWil2yocDB61i3CvBdHy2KsrYOOK1bSKeQbjEz8daq3c0k9ea5d0s30cQ8oCSMeo5rXGs28KKblNjcA/LmqWnNcxuEjQqjnnIpdTtXmDq0Q6c4FXGKbOKo+ZkOv+IbKW3dbflsY3YxXl+rajKWbDTeZ0UBu9dPfJ9kmMkybwgzs+7nnvXAapcvcXjToCqM55U8AeldKXKtDin2I7C7NsJZ5o/Ncq20k9D61QQtceaZclm5BJ6VFG+Z8OWYDPAbtU8MhkG1UwqnJ96lszRatIwsqA8ueAR0rThVpHbzCUjHynA/SqMcZEO8Bg3TpWxAI47QlmYt15qIlF6JDNZqsS5CkAke1UEleBpoyXw3yrt6Veil+z26ysNzsSWwcAVTCeZlmcmHcSgIwTVN2QrajCiJboAGDsCQQe4pgUtFukJBORk+lIMlhtXlST83QjNStsyqPlQvQfWkgI4chhl0AI4U9cetTCNWjJUsd3XH+fpTzDH9mjMZ+dWwT7H0phBUDBzIO/tTQIflZLaPZkhOeeO9BHzndk7CD9PWm7QhjJYlJFPGB1qQMyxbxgNswoFCXQPMp3KB2lYk4+8DnGR6UixeYHkGSuMkZwcYqJ0WTaOxOR24P/6qa4WIDJblQGGepzTepO5HKGQtu2rtGADgc0bQq4Iz0PXqRSypkbogDu5z16cUn+rVdrFQOSCPzpWGdWrRy2iq6sQrHoRwOamihiK4DYl2g5wcEVWt5EiLRSKdzHjnG0571NvZC23G1P4iATyOlSasmiVd5JCqSNwz+nNTO4WOQLhwOAT27/nUEMaF44GdVTOV28k+xp8rlQFLfd4RQPT/APWaCSxOpiCO2Rj2xzToZPLcyj5stgnpiop3EjFEYgEDJPqaYY33FcliOoXv70/MEXLwjfHJEMrnkd6gknDx7YsOMemfrSwKJ2dCwXndjPOcUTReXcDY4KuvRRnFFh3C1l2DYE78ior0M6Ao33ASDjrQFxOTCpJHTjqab825uQAfvg+tG4MfEGMW1WcN1ANSQKsRzPkNjovWlkdW25/dnpxzx6UrSLnhSHGMevpQwa01IJsxLKyMHjb7vAJH+eaZcQkTRdRFt5AHIp21mZt8ZO4/Lx0OKBujVViIxIAhJPIP+c0CbHwsqlDGnTBJK9s9cVLcJ50z+YudoyMnhufSqxcxbI5QRsOCQe39KnNyySrwGBU7cNkgUeg9h0UkcoFvIPlxhSwGapC2ZlKwksAf4hg59qublmWUxjDYH0xUUIZlDcfKOCOOfSqtqK7Fs7yS3nWN0Cg+vrW5NftJFmQhnVflZh/CO1YF6mCszRhlz82D0PqKlS7EisvAyMYPFClpYGkXrYGeISKCFcdTUF/YxXUTo4COn3WA6n3pNMuhBbNEcFWG3B6j6GtMQh4AeMDgmhq+gul0cjtaNJhexkbT1z2H86xZLB33uqNtPILDtXZXtk16kkJGE4K59adaCOMNH5YUD5eRnmplHoi467nn81iY5I3tyd2c5HAFSaXqd9o18ZIJHjZ+HA6EV2V7bQQ3cyw7JkPGOmTjqPxrAu7OQsynHzdT1qU3EppNHT+GfFlnpV6guZobxSokYvGTgnqvPcV6Jp/ifSdYKsY9sGegXnGa+fX014pAwIC/zrpNAuRphiMwYxjjAOKqVp6WFHmR7jf3SzxKbfBGfkPU4NN1C0gtIbeONg045lYHO4+tcdZ+KYJWWG0BbJzk8V0+WmtdxcOXHYdDUOLjqzejVcWRmdQ6Ro29gecU7UZUSDa2Vk7g1a0yxFvIs74LryOOK5nxRcNDNId+5ick04PmZ1TxC6F+0WIMWUgnvTpyu4EH61z2jXTzkuTtPoe9bUSFgxySx6c8VU0loi6VXmXMype/OMj1xVXU7DfbZJGcZFXJY8SBW4PfJqeBEY4c7lSudwe5vOolFWPMNXt7iG4DkMyd8HpV7THZGBGCDyK3dZhie5dFxsJ/KuUgmkt717cnAycH1pSjbc5nJPRG9qIaWeNxgA9farFrazR3CGPc8Skbtp61No4S4XbMoOasWNyNMuZEmBaA/dIHShXJ9o/hRU1azMcxkJyknqOlWdI1ExERyZ28AH0rP1XVBc3TiAHyOPlNWdOVZ7g+WoA28g1duhUk+Rc52sPzQrt246g4qjrK3TLvtyDx/Cax5NRubKAxg5QdB3xWXH4k8mciUyPGx+Ve4qoQsrnmuTgzJ8XXM0dm/mEBz8pJIzivPjcrGQYmLOvXH3RXT+N9Wh1GbKRyRom5CGHIbHXFcRbRzSqQeB14FbXstTFvmdxDE7SiaTGD2XjNbunJaNp7Fhtlzy2eCKpQooAVl+Qdu9SxYWN433AgjoOgqLgX7ZBJMEkwETkcdTir8UWVfzCxUjAIHFUIg0cKn7wY5Hrir+4IoCt97grggA0KxWw27uYHt9hDDbGcYHfPFOvJxcabCgAVk5yfem6jbMnkRF49si87D1H+NR3/AJaIkYX7gPTrz0p9RKxCjsj+Zg7WH3uv61KX8x8rwQcZNVzIJLSIbdu08ipIg3zkDHfOee1JX6Bckl3KQFBPyjOfY/8A16ereZgL1QjPPXtTShnmRcHA5xnGalg8rex2qiuc9eRVC2JHZQrs2Q8BBKkc+/8ASoPLDKvJwHyfbPanRjmRmOQylWJboe1EkLNHK7bkYKOR0JFPyCxVn3qJEA7BlB4x6/41TnHmiPzfugYwPUd6ttK27eVVwFHT9aqSJ+4ZkxtU4BA7H0/z2o9BCQtv2KNy45AxnHtTpQgl3biwbk5HrTU3xsig5KjJJI4/yacxDu6seWBzx144NIDqJY0lWN4wEaPOeeSc1IsZlaSVeYyRu5JIXsfrVdmZQVdmZSScD6n9KlW5njt9o6tgYU9RgUjVruMZ/JMTAZ2nlu+f85qzJJ96QfcHAHce1U2kHmFwGwSflParSyqxkODv43d6AbFV2ECggBuoIPp/+urjOrTjac7RsJHHJ5FZ0jAxrkblAyOOR2qaYn7TiTbuZd2AchTimLYlyRIC5C4IBx1OcVbdmRuRgr0+h4qpKRJgHAcfMBjqehp5ZniiJAIYYP8A9elqPYQzFLlF52DuPWrtzEskYdTtYjGAMA+9ZrHbcBVIO7j3FXwA5kVWK7eRn0o6BuQRkyIXJAdflYEVLHbvPBlypeMblwePpUBHnRgIcNzn3NKkrDmPPT5s9zQImgifcrsCxb5sBuhqIxmOVMngtweoOfftUiSNn5cCQcY9Rj1pzt8gXAVCTjn/AD60aoZHOEAa5Dr14B7mmRmMuoPzLu/u9Minq6uTuwoY5OB1/wAKZgQK6738skkfL+VCVg2JZoxChKygZwfTpxTHdZFYQg+ZnA+X73bIpJQTcMHy3G7KjJoYNG0C8phdwPfpTuuoW6jvMzEUkYAgg5/Co7qNZRHIQVf36Gh1WcRoDtZnwxz1qX5Yt0QwhTA27sk07CK9oCbghlLBjg8VuwvHaRspDPnHFUrmRZrRl+UFBncvWmWkrSrBuzlhgNnr6ihLuDXVF2Rh5uF5A6Y/rVWQzFFKYz1HH86vps3kE7WHA44am2jK1xjCgqDxQ02JabmYbf7Vv+dUfbxx+dQx3KKhjYKe2cda1NThi84NCdobgqD0rJuraS2LlMbQR2qHbqWiq8cOZPuhW4AIzUHlIwVSdpHBzV6Ha4khuQQc43elOijha6ZLhsAL971qbXdi7tFSzsZI2DwtnB655r0HwxrotYmgvGV0JAEjDBFcLa3YiuBGkmUzWpJJtJDKrf3SRxTW2oPXRnoWp6siWf8Ao5GT0965O6zezEysVz1z3rOtlG1mkdiw4XnjNX1jFzIAg+ReARTTURxg7DrQR2sgUscHgbhya03vBFGWXBAHFYOpQXMbhlG7jr7VTiaaWJvMcswOFzwBWqcb3Q+aUY8p0SXs1xB5cgVgOVIHIqg1xNHMU+bHc9qr2dyIbRpiwZ1qve6pbrMPtCEDZyqHGSalxuzVVHTRJHKjtKzHcOxrl7tjFqLBkLgnKn0qezvE+0uiq6ws2RvPIFS3cgN4Ui2sgXJJrKcb6k+1sr2NXQbsfaUYgBehFdFMsMdyVbBVx8u7nmuS0tvPVkVds/Vcd66rTZlmt1a5AMkZ79QaxtYHJblB7e2aORDDtduQwHQio9PglEge3J3IMsK2jbfaFMgILHnjpWYbO6humeNgEI6qcGnEiVZpGfrl3KiK218dNpHUVwuvaqI3AjiBQc8kiuy1CIyXypcXmScqVIxtrzbxSLP7Y8Fm8ssa8b2Pf2FdKjynI3czrjV7q7kWPcAucjjp/jV63yYsSE7ieXqlbWgjY79ucZFacUeOc/KKTdxpWG7SSMfeXOSO9XDEZAruSC5wMUyIRksxiGW6HkUKGxhsBTkA9xUoZZs4SUILZIOAOlXrWSMTASJuAPQnpxUKODCu7YTjHHtTpWRAWGMfXtTS7D6EVxLuvQyZznjvio7oxmVi45zg+tSW4G3zFAyD1703yJJlaTqmCcA85pvUNiGJcpvYEjPSrsEP7hmDA8dB39qGCrbRrgEEce2KbvMKllIZg2SvUdadhCW8nlzb8gjAzTEfFwJQDtbsee9Szcq3T5j0PYH39qht1GxlZSWXjinZBsWYCfMIkATgxuMdR2omDpbwvI+4SAx49AOh+mKmhRnckIAGjGQe5FRagoEMWXyqncoHQKeDTC+hmwgSxsmOdpwMH9PypHmcWzJGAQcoPx6frUr/ACsV3fdOM9Oaj+bynSEAgqCuQOT1xU7CK+VXG4lSex5Bz1FNG3yEkDkBc57nryKcyq0iBlBJ6ZPTPemufKkdF2hW+fb7jrQFzrZrZAUKNlCOT1we9JsKopXaAFO3B6j3FQxkEZd+xUA8ZNSEIHKgB1OMBRx9KVrGtxbSNHfG1jhQT0p8ahLtQhJXJGevHSoopNhVgoAPGw8f56U9N7x7l27Qd2Bx0ximS0TxuphCgZ2jDDHP+etTW8WQjyqAxPlkDseKpXMgSR2xkk/Nn36GpY1ZiGaQcnggdx7U2CHswWULI2VUtjHbNXbVEkjc5OAcL6N/h2rOQCNSGQl+HY57CrO5xFNIuFZTvUDuDSHuP2IXXcm1VJY/T3piHZKxIIwp2jOcinRt5ki4HznDHPTHrTYkKXhUg+YASAfQjkU1uL0LFy0Zg3on3sEEc/lUUcQYOY87lI+QdKdCqJblXUkbuntjNLEWSeNY8BMEe+KXXQBLc4Y7w+UOSMc4qzKAqCRCT0bB5BFRSuWl8xcfKvTtToyJII1YkgEjjt7U+UTfRClEQBosgk5UHp7iow8k6LCzBVUfdGM1YmCSlvJP3ece9RSrsBCp8wORn/Gi1gepXh/dRpguCPlJbP5/yqxOzTIrFA4D8fQc09ojc7woCOxyMjvVWWNweXUkNjGaXkMWFgDuiG4nqMYGc9qnEDzBzhVKk4TufrSwQEQBGkVcsSPzpVma3YBdp2nJYemetPfQPUgt2KtkEYbKsCaAvkjpweUK9s0kqNHLHIq8FuMnqPpViKYNDIkjKA4yvb9aWrKTFZt5Vi54PTpmreYyFMeEYg5PXmq8H76Dfty6DnPerlqsCjzC+Vx0xVakkM5WRTuXLYx9D2rPlnkMMsMjZJAGPYVcmBIaSIbhj7vtVCRgXTtg9elS0NSKs5UxghyCv3veqgYH94ykkcYPpWzf2aoHk3ZxjqOPeqNwA1uzGTLD5QO+Km5pvuUWnCrzjAONwrVt74GDZnGP4qxdxwoI4GT0qS2miVXEozxxt9aQ1ZbM6azljB8wSDgfdPrWzpt1D9pSMA5I5+tcPZzKk2ZWbbnj3rdecC9WS2PyAA59aVktTSLvudRfSIT5b/eNYF9Cy70X5Qoz6ZqTVNQ85ofKzuPLH0rQ1aFcrKh3I8a+3alqtStNDipmmRTEuSD0OeKoSPMJPNmfcVGBx6VuampdgIlwPXFZ9/EptSudxA5IHer5+YiVkZcF4rMzSkA5z9ahfxMi6gsEkQRG+UPj+dRxwr5jByVGKyNagS7uYhCu0r1P9afN5HNJW1O+0q4MMqSx4Zgdw5q3PrW+cyeV5Zz26EVh+Hj51kEyDLHxu9auwyCSIxTAFwT0/nWXXQ0jKMmdra6nGtsAhX514INZseuiKR4/L+rGucE5gO0FsduaZ50CK4mmzu6YPNbwpWWphNroZHinVCt+ptfnw+TnpVWTS1vIzeWKcH5indfWkkEOyUMdxZ+OOabb6g1soWLcIgcEUpakFaExIsiSDLleOO9SadbS3MvkxYDNznIAquxVp5GGfm6e1Nid4nHl56g5BqTSxYRXDuDwFODU1uPMYY4wcDNRTh87mIJPJwODUwj8kBmwwY5GKHqOzJrV2iXGN3BzSnYWJIAQjkc0sIQ7Ac8tggdqWWJYVki27mPQ96FsNjFIijO0HB4zVm1CwqxO7JBxSKC0QQkHqRx3pzMDHAsYVpMEkH0qkTcIyhKrsBAOd2fWmv5SCQHdkjHvQp8vygyjBOBxj8KLkFxKw4RsHg9BTsIbC2dsbZOQR06Gn3K+VKwQc8cdgaRY2iQMzBs8Kcdc05G3BZDwp+VuCfpTtcAgciASKxLhgTxzzwaS98tbYA/KAT+GeD+tPikEIba2d3DcdM96ZdwtJcuiqyrKhIz2YUJA7soHkBSN2cMagnJhmbcP3an17GrAy6eYGIYY3cYz2qKfbK21j85446DH+R+dLyDUrhAkLBiVdCVz6A9KY4WVjxwF3ocHqOtSk4+fIVJGCHcM7SO/0qJiVYAEMoPB6/X+VAjq1t3KBlwSO+eelIoeXHlD585Jz0xUrzrGpwfl6EVCrsrEDoP5f5FDNE+xZTdHJhtpfgZGD1otXNu5Vxkkng8g1AX/AHrMMfNyp9B/nNPlLEsRgDd8oUdfrSG2OmjDhpCQVGPlB684p1kzeaNhO07g2R+tR27F3j+XALZY9cdsYpYwgB8vPyKSM+tPYSLjIkM7N1GMbc5/H+VBWRbSbjc2Rux0AH/68UyXeyxyKu0SZYqe3QYH5UsbtLFPGCSzgPg8EHNILjI52gmjZQSBjd9D6/rVmdm83zAQSmOT6d6rKC7BVJZpFPf2/wA/nUhZC0gJzn2/OnuJlmIMQ5Qhjn8qhnBJjMZ+YcEA9cCpbUbJJdqkhR69RRLEEtopwdx74osDZLG4QRklgcYIxkk0kmEffGcAvkD1GKcSCwZAMBgPz/8A10woDuJbIVt3HvQOwsICMNnLp83P8Qp8m90O/hN3Xpjimw/vVL7QGPygg+1LGzYC5+bOCPpQhCsVeYyLlOM4IzTbht8B2g7xg8CpVVo3fI3BDxgdR60u1kVmSRQCOme3PFOwig0o8uNBvMhHAycd6mW3/wBGVtgDKAWYHvStAROsjHbGR1x+n86dGoLgCPcoAIH4UrlIlhhjLKvmExsufTmoZhtZEXOBkrgfpT4VZSNwU45xuzgdealeFpSrR4wSAGzwBS0eoNlS0uPIclsqpbnH0q+G2KF24JHPvzVK+s/ssDXKEY43qTUljIJIFCD3XjJxVJiZZhJgCq42kZK59PeqF4SJHLLtBIwOgqzIwD7XUFBwS3fNN/cyptlzgr1A9Kmw010IZ5JbhF9dvTPpWe6nBjQHLA9asRxsSVjzn7wHX8KR4GljM0Y+79/I6HNJo0GpNGluI2UM+3GazBDkEL8x6n0NSyfeZCckncOOenSm258uTIXoOc1DKiTW0TbA7AFSMDIq1azlYmQn/wCtUe4so2fxZ4xVZ87ySduOvvSuatGgCBIpLdOmKvyX80lssSsTjp9KxEkZhnt64q2ZP3QIPI6U7iHTXrYKkAHHIrLZpHQhX9yKWUndub15pFmFtMTHw549apETKWFYsWFY96BGzMnDdM1tXf3mVcYY88dKztWgSKKNsA8Zp21MpbGj4P1eHSrjMyCRGQoykeverUV4huy3G3tiuFa/8udQ+Q544NXYtQ+YGLHy9qaSMlpsddf3IxkYx7965/z1+1ByTgdM0ya58xFkD4OeY6rTcktgj0xVzncViw02QCRk5NXLuCH7FbiDlnPP1rMTH2d2LZOeFHWl8wfZhtzxzzxis2CRNNay28gjkDKcZ5GajkLI/HCjrippLp5VXzmLMMAZqGQlAP7vekyvUsIxYNuB5HFPjJICg/MCMVWRvkVQePU1bWP5ScjbgEetBVx8TlZgpwOccc1Y1D5iJFZgAoOKZbhBJkDLH1p0Tjy5gwy2QoHrVIOhJpweXZJuAB4H170+5UxXqHgbARwBTbBWgIjLDKsWX3HpUt7lmZ8jcCBnpiqWxJGzZXf94Rnp/I1I6D7MJFywY5we3r/OiAqbN43A3epHamOvyOgHUAikNBIGZAgztBAA6flSpIVEsYwBJ83zDOf8mponCwujYzjIYHpVaRQVBOMg5znp/k0+lybhGqkbuMuNx5/SrF2u5Y3OdyncuDwfUfjVeJj5jKUxtwx+bqO4qa+cNarEgzs/eIfXH/66aHuZTDaMDA+ZsHr37/yqHdtmXlWCE8nnH+RTrtvmDKAFBDfgacqq9s5bPmg5I+lJi3IbjhJVyAWG4ex65quVfCOwClsgHJIqR9zuGJ+6MgjuO/8AWo32xwGNi5GAVzzwfT6UrK4dDp7hRGrBehG457nNEzkRlRxk5P40UUuhVyxEoeORj1VgB+lNjZixyT/FxRRQupQ+FijkL/d3/jtplgSyo+cHrx9RRRTl1IZNGxktyGPRyBUpyt1AFZhvUA8+q0UUi2TWjl7hVPRJWA/WmTYguWMQC8N+gooqnuiXuSaeMXZOTlo/6H/CnQk/YymflDkD86KKGJbD4eZpQeRG421bVcjJ6kgUUVLKXQj8tfPzzzxj86I1AlbvlRz6c0UVcegmRTXMjoCzZ4/wqaQAjfgBgm7jiiil0Et0Ts7PCCx7/wCNQQMVuEwTnO3PtiiipkXEdKMyKw43LkgdOtLboBbQPkksSDk/WiinHcUh8oEltKjgMCuOe3Ws7SZWimwhHIzyPrRRWn2iYmjOA90WYZ3IWI96pI7NHkn8O3Wiis2UtxEctK2cfKQR7VLFIyWsu09TyKKKl7Fx1aMu4iVUBGcg5zn2qoB8rE8nGaKKhlPcs2TkqM44pNVbbHGQB6UUVDNuhBGSI+DT4pG8snrRRT6lrZFm5w1qpIGTWOx2suMdaKKcTKoDDMakk5zis/VWOw+wooqjOJx+tczxnoQOMVLY/wCrVx94Y70UVS3OeW5s2xLsQ30p1udylT0HT25oopoTZGGOyVc8E809ehOOhHFFFITLF6BmMgYwo6fSphGjWzMR8wcAH2xRRQ9wj0KlsPMuMPyABgVq2Ch5ZIyPlCfyoopdSx75DLz7Z/CooRukyfRfxoopgy4nyuuCcquQfxqxMBuBHG7g+9FFUiktCupzHIx6hGH5dKk2hopmI+ZSpB9OKKKbM1uReazXWOMMMkfpUhgQpEOcMCD+WaKKHoy+pGzeXISvUEqPwFSbR9nL90cAe4LY5ooqpbCe5kXYC74wPl3soz2ANLIoWPePvbM5/P8AwooqWS9yr5jFJQf4ZOD6Zzx+lJIB9mteOhwDmiik9wR//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christine Johnston, MD, MPH and Anna Wald, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8596=[""].join("\n");
var outline_f8_25_8596=null;
var title_f8_25_8597="Diagnosis of cytomegalovirus";
var content_f8_25_8597=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of cytomegalovirus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/25/8597/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8597/contributors\">",
"     Timothy J Friel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/25/8597/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8597/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/25/8597/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8597/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/25/8597/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) generally produces an asymptomatic or minimally symptomatic acute illness in immunocompetent patients. In the immunocompromised host, however, CMV infection can result in a broad array of clinical presentations, including retinitis, pneumonia, encephalitis, hepatitis, and gastrointestinal tract ulceration -- complications associated with significant morbidity and mortality.",
"   </p>",
"   <p>",
"    The diagnosis of CMV infections will be reviewed here. The manifestations of CMV in immunocompetent and immunocompromised patients are discussed separately. (See appropriate topic cards). The diagnosis of CMV during pregnancy is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link\">",
"     \"Cytomegalovirus infection in pregnancy\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;All testing methods described below have their advantages and disadvantages and need to be interpreted in the context of the clinical presentation and other diagnostic assessments. In the past, serologic testing and viral cultures from multiple sites were the cornerstones of diagnosis of CMV infection. However, more recently, molecular amplification methods have gained prominence as diagnostic tools.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SEROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serology provides indirect evidence of recent CMV infection based upon changes in antibody titers at different time points during a clinical illness. Many different antibody detection techniques are available, including complement-fixation techniques, enzyme-linked immunosorbent assays (ELISA), latex agglutination, radioimmunoassays, and indirect hemagglutination assays [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/1\">",
"     1",
"    </a>",
"    ]. Investigators have also developed liquid-phase luciferase immunoprecipitation systems to provide qualitative assessments of anti-CMV antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In early studies, a diagnosis of recent or acute CMV was considered probable (though not definite) in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The detection of CMV-specific IgM antibodies (suggesting recent seroconversion)",
"     </li>",
"     <li>",
"      The observation of at least a fourfold increase in CMV-specific IgG titers in paired specimens obtained at least two to four weeks apart",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the sensitivity and specificity of serologic tests are adequate, the requirement for paired serum samples limits the utility of these tests in establishing a timely diagnosis. CMV-specific IgM antibodies are typically detectable within the first two weeks after the development of symptoms and may persist for several months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/3\">",
"     3",
"    </a>",
"    ]. CMV-specific IgG antibodies are often not detectable until two to three weeks following the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/3\">",
"     3",
"    </a>",
"    ]. Among a subset of patients with acute CMV infection who had serial serum samples available for analysis, CMV-specific IgM antibodies were detectable for a period of four to six months after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/3\">",
"     3",
"    </a>",
"    ]. Therefore, a positive CMV-specific IgM antibody alone may provide misleading information if a prior baseline test is not available.",
"   </p>",
"   <p>",
"    Serologies are also helpful in determining past exposure to CMV infection. This information is particularly relevant to the management of immunosuppressed hosts at risk for CMV reactivation syndromes. As an example, HIV-infected patients with serologic evidence of past exposure to CMV warrant monitoring for CMV retinitis with progressive immunosuppression. Likewise, serologies are also helpful in determining risk of acquisition of infection. For example, a seronegative patient is not at risk for CMV reactivation; on the other hand, the same patient is at high risk for new acquisition of infection if transplanted with a CMV seropositive organ. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CULTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using human fibroblast cultures, CMV can be isolated from multiple sites, including the blood, urine, throat washings, cerebrospinal fluid, bronchial washings, and biopsy specimens. However, there are several limitations of cell culture techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CMV grows slowly in cell culture; depending on the level of virus present, one to six weeks must pass before characteristic cytopathic changes can be detected [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/1\">",
"       1",
"      </a>",
"      ]. Thus, cultures cannot be relied upon as a rapid confirmatory test.",
"     </li>",
"     <li>",
"      The detection of CMV in culture indicates the presence of the virus but does not confirm active CMV disease. CMV may be shed from the urine and throat intermittently for several months after acute CMV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/4\">",
"       4",
"      </a>",
"      ]. Immunosuppressed patients often shed virus for prolonged periods of time.",
"     </li>",
"     <li>",
"      Though generally more sensitive than urine cultures, even isolation of CMV from the blood (peripheral blood leukocytes) is not diagnostic since viremia can persist in the absence of clinical disease, especially in the immunocompromised patient [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/5\">",
"       5",
"      </a>",
"      ]. The overall sensitivity is limited, especially in comparison to newer techniques like CMV antigenemia assays and molecular amplification.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, cultures are not often performed, but can be useful when determining the presence of drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EARLY ANTIGEN DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV early antigen detection (shell vial cultures) allows clinicians to detect CMV in culture before the development of characteristic cytopathic effects, thus accelerating the time to diagnosis. Following centrifugation of clinical samples (eg, urine, blood, bronchial washings) to increase the absorption of virus, cell monolayers are exposed to monoclonal antibodies. Binding of antibodies is indicative of \"early\" CMV replication within the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/1\">",
"     1",
"    </a>",
"    ]. Results are typically available within two to three days after specimens are obtained.",
"   </p>",
"   <p>",
"    Monoclonal antibodies are also used to detect CMV proteins in tissue specimens submitted for pathologic evaluation by immunocytochemical techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CMV ANTIGENEMIA ASSAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV antigenemia assays permit the rapid detection of CMV proteins in peripheral blood leukocytes. This technique employs tagged monoclonal antibodies specific to the pp65 lower matrix protein of CMV in peripheral blood polymorphonuclear leukocytes. Positive results are reported as the number of cells with staining per total number of cells counted. Results are generally available within 24 hours and the test performs well in patients with HIV infection and recipients of solid organ transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In these patients, antigenemia appears to correlate with viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Though extensively evaluated in immunosuppressed patients, the role of the CMV antigenemia assay in the diagnosis of CMV disease in immunocompetent patients has not been rigorously explored. One study evaluated this test in 40 patients with a suspected CMV mononucleosis-like syndrome over a two-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/11\">",
"     11",
"    </a>",
"    ]. CMV infection was ultimately confirmed in 10 patients; a positive CMV antigenemia assay was obtained in 9 of these 10 patients. Seven of the nine patients had low level antigenemia (less than 20 positive cells). Of the 30 remaining patients with other diagnoses, only one patient with systemic lupus erythematosus had detectable antigenemia. In this study the sensitivity and specificity of the test was 90 and 96 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MOLECULAR AMPLIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular amplification assays are fast and reliable. Commercially available tests include the COBAS AMPLICOR CMV Monitor test (Roche Diagnostics, Indianapolis, IN), the Hybrid Capture System (Digene Corporation, Gaithersburg, MD) and the NucliSens CMV Test, a nucleic acid sequence-based amplification assay (NASBA, Organon Teknika Corporation, Durham, North Carolina).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The COBAS Amplicor test is a PCR assay that amplifies a 365 base pair region of the CMV polymerase gene. The manufacturer reports that the dynamic range of the assay is between 400 and 100,000",
"      <span class=\"nowrap\">",
"       copies/mL.",
"      </span>",
"      The assay has been designed for use with plasma, leukocyte, and whole blood specimens.",
"     </li>",
"     <li>",
"      The Hybrid Capture System CMV DNA test is a signal amplification method using an RNA probe that targets 17 percent of the CMV genome. The target is detected employing antibodies that specifically bind RNA:DNA hybrids. The dynamic range is 1400 to 600,000",
"      <span class=\"nowrap\">",
"       copies/mL.",
"      </span>",
"      The assay has been designed for whole blood specimens.",
"     </li>",
"     <li>",
"      Nucleic acid sequence-based amplification (NASBA) was developed to detect both immediate-early gene UL123 (IE1) and late gene expression (pp67) of CMV infection. This assay can also be performed on whole blood samples. Unlike quantitative PCR and signal amplification techniques, NASBA provides a qualitative result.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity and specificity of NASBA was evaluated in a study of 21 solid organ transplant recipients; 90 percent of clinical samples that were positive by culture or immunofluorescence were positive by NASBA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/12\">",
"     12",
"    </a>",
"    ]. In contrast, NASBA was negative in 50 CMV seronegative and 50 seropositive asymptomatic blood donors. In another study of 30 renal transplant recipients, the sensitivity of the assay was 100 percent, but the specificity was only 76 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like the antigenemia assay, molecular amplification techniques have been studied most extensively in immunocompromised patients. Multiple reports cite a high sensitivity and specificity in patients with the acquired immunodeficiency syndrome (AIDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/14\">",
"     14",
"    </a>",
"    ] or following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/15\">",
"     15",
"    </a>",
"    ]. The use of molecular amplification assays in transplant patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=see_link\">",
"     \"Viral load testing for cytomegalovirus in solid organ transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Little data exist on the use of these assays in immunocompetent hosts. One investigation compared the performance of peripheral blood leukocyte (PBL) cultures, CMV PCR, and antigenemia assays in a group of 52 immunocompetent patients with primary CMV infection diagnosed by serology [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/16\">",
"     16",
"    </a>",
"    ]. CMV DNA was detected in 100 percent of the 25 patients who had the PCR assay performed within one month of symptoms, but in none of the controls. In comparison, antigenemia assays and PBL cultures were much less sensitive, with positive results in only 50 percent and 21 percent of patients, respectively, during the first four weeks of symptoms. However, assays remained positive by PCR in 81 percent of patients two months after presentation. The prolonged detection of CMV DNA may decrease the specificity of the test when used to detect active disease.",
"   </p>",
"   <p>",
"    Not all studies have supported the utility of CMV PCR assays in the diagnosis of acute CMV infections in immunocompetent individuals. Using serum obtained from 34 patients with confirmed CMV mononucleosis, investigators detected CMV DNA in the sera of only seven (20.5 percent) patients using three different commercially available assays. The case patients had clinical findings suggestive of acute mononucleosis and laboratory evidence of CMV seroconversion or CMV-specific IgM; diagnostic testing for EBV and HHV-6 were negative [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8597/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, the comparison of quantitative results obtained using different techniques is not possible. Therefore, it is important to use the same test method when monitoring changes in viral load in patients over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444144\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytomegalovirus (CMV) generally produces an asymptomatic or minimally symptomatic acute illness in immunocompetent patients. In the immunocompromised host, however, CMV infection can result in a broad array of clinical presentations, including retinitis, pneumonia, encephalitis, hepatitis, and gastrointestinal tract ulceration -- complications associated with significant morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the past, serologic testing and viral cultures from multiple sites were the cornerstones of diagnosis of CMV infection. However, more recently, molecular amplification methods have gained prominence as diagnostic tools. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A diagnosis of recent or acute CMV is considered probable (though not definite) in the following circumstances:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The detection of CMV-specific IgM antibodies (suggesting recent seroconversion)",
"     </li>",
"     <li>",
"      The observation of at least a fourfold increase in CMV-specific IgG titers in paired specimens obtained at least two to four weeks apart. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Serology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It should be noted that IgM antibody can persist for several months and, therefore, may provide misleading information if a prior baseline test is not available. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Serology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serologies are also helpful in determining past exposure to CMV infection. This information is particularly relevant to the management of immunosuppressed hosts at risk for CMV reactivation syndromes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Serology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV cultures are not often performed, but can be useful when determining the presence of drug resistance. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV early antigen detection (shell vial cultures) allows clinicians to detect CMV in culture before the development of characteristic cytopathic effects, thus accelerating the time to diagnosis. Following centrifugation of clinical samples (eg, urine, blood, bronchial washings) to increase the absorption of virus, cell monolayers are exposed to monoclonal antibodies. Binding of antibodies is indicative of \"early\" CMV replication within the cells. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Early antigen detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monoclonal antibodies are also used to detect CMV proteins in tissue specimens submitted for pathologic evaluation by immunocytochemical techniques. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Early antigen detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV antigenemia assays permit the rapid detection of CMV proteins in peripheral blood leukocytes. This technique employs tagged monoclonal antibodies specific to the pp65 lower matrix protein of CMV in peripheral blood polymorphonuclear leukocytes. Positive results are reported as the number of cells with staining per total number of cells counted. Results are generally available within 24 hours and the test performs well in patients with HIV infection and recipients of solid organ transplants. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'CMV antigenemia assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Molecular amplification assays are fast and reliable. Several testing methods are available, including the polymerase chain reaction, a hybrid capture assay, and nucleic acid sequence-based amplification (NASBA). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Molecular amplification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/1\">",
"      Chou S. Newer methods for diagnosis of cytomegalovirus infection. Rev Infect Dis 1990; 12 Suppl 7:S727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/2\">",
"      Burbelo PD, Issa AT, Ching KH, et al. Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies. Virol J 2009; 6:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/3\">",
"      Wreghitt TG, Teare EL, Sule O, et al. Cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 2003; 37:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/4\">",
"      Klemola E, von Essen R, Wager O, et al. Cytomegalovirus mononucleosis in previously healthy individuals. Five new cases and follow-up of 13 previously published cases. Ann Intern Med 1969; 71:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/5\">",
"      Zurlo JJ, O'Neill D, Polis MA, et al. Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection. Ann Intern Med 1993; 118:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/6\">",
"      Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/7\">",
"      Bek B, Boeckh M, Lepenies J, et al. High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol 1996; 34:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/8\">",
"      van den Berg AP, Klompmaker IJ, Haagsma EB, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991; 164:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/9\">",
"      van den Berg AP, van der Bij W, van Son WJ, et al. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation--a report of 130 consecutive patients. Transplantation 1989; 48:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/10\">",
"      van der Bij W, Schirm J, Torensma R, et al. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 1988; 26:2531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/11\">",
"      Lesprit P, Scieux C, Lemann M, et al. Use of the cytomegalovirus (CMV) antigenemia assay for the rapid diagnosis of primary CMV infection in hospitalized adults. Clin Infect Dis 1998; 26:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/12\">",
"      Witt DJ, Kemper M, Stead A, et al. Analytical performance and clinical utility of a nucleic acid sequence-based amplification assay for detection of cytomegalovirus infection. J Clin Microbiol 2000; 38:3994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/13\">",
"      Degr&eacute; M, Kristiansen KI, Rollag H, et al. Detection of human cytomegalovirus (HCMV) pp67-mRNA and pp65 antigenemia in relation to development of clinical HCMV disease in renal transplant recipients. Clin Microbiol Infect 2001; 7:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/14\">",
"      Shinkai M, Bozzette SA, Powderly W, et al. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis 1997; 175:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/15\">",
"      Brytting M, Xu W, Wahren B, Sundqvist VA. Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol 1992; 30:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/16\">",
"      Revello MG, Zavattoni M, Sarasini A, et al. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J Infect Dis 1998; 177:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8597/abstract/17\">",
"      Navalpotro D, Gimeno C, Navarro D. PCR detection of viral DNA in serum as an ancillary analysis for the diagnosis of acute mononucleosis-like syndrome due to human cytomegalovirus (HCMV) in immunocompetent patients. J Clin Virol 2006; 35:193.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8291 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8597=[""].join("\n");
var outline_f8_25_8597=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H444144\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SEROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CULTURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EARLY ANTIGEN DETECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CMV ANTIGENEMIA ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MOLECULAR AMPLIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444144\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=related_link\">",
"      Cytomegalovirus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=related_link\">",
"      Viral load testing for cytomegalovirus in solid organ transplant recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_25_8598="EP study tracings preablation mapping WPW";
var content_f8_25_8598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 609px\">",
"   <div class=\"ttl\">",
"    Intracardiac and surface electrocardiogram (ECG) recordings during electrophysiologic (EP) study in Wolff-Parkinson-White syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 589px; height: 419px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are five surface ECG leads (I, aVF, V1, V3, V6) and intracardiac recordings from the high right atrium (HRA), lateral mitral annulus (HBE1-2 and HBE 3-4), coronary sinus (proximal to distal, CS9-10, CS7-8, CS5-6, CS3-4, and CS1-2), and the right ventricular apex (RVA3- 4). During the diagnostic electrophysiology study, orthodromic atrioventricular reentrant tachycardia was induced. Recordings from the CS demonstrated that the earliest site of ventricular activation was at CS7-8, indicating a left lateral location of the accessory pathway (arrow). The mapping catheter (HBE1-2,3-4) was advanced through a patent foramen ovale to the lateral mitral annulus. Activation mapping was used to select the ablation site; during sinus rhythm, the ablation catheter was maneuvered to the site along the mitral annulus which recorded earliest ventricular activity (HBE1-2), ie, the atrial (A) and ventricular (V) electrograms recorded from the ablation catheter tip were continuous and the local ventricular activity preceded the onset of the delta wave on the surface ECG.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8598=[""].join("\n");
var outline_f8_25_8598=null;
var title_f8_25_8599="Huntington disease: Genetics and pathogenesis";
var content_f8_25_8599=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Huntington disease: Genetics and pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/25/8599/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8599/contributors\">",
"     Huda Y Zoghbi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8599/contributors\">",
"     Harry T Orr, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/25/8599/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8599/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8599/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/25/8599/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8599/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/25/8599/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unstable trinucleotide repeats are associated with a variety of neurodegenerative diseases. Nine of these disorders are associated with expansion of cytosine-adenine-guanine (CAG) repeats that encode for polyglutamine tracts in the protein products. Included in this group are Huntington disease (HD), spinobulbar muscular atrophy, dentatorubral pallidoluysian atrophy, and some of the spinocerebellar ataxias.",
"   </p>",
"   <p>",
"    The most common presenting symptom of HD in adults is chorea (hence the name Huntington chorea). Other usual findings at presentation include memory deficits, affective disturbances, personality changes, and other manifestations of motor dysfunction such as parkinsonism and dystonia. Patients with juvenile-onset HD have minimal or no chorea, but develop myoclonus and seizures as well as cognitive and behavioral problems. Children also have a more rapidly progressive disease.",
"   </p>",
"   <p>",
"    The genetics and pathogenesis of HD will be reviewed here. Clinical aspects and management of HD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29832?source=see_link\">",
"     \"Huntington disease: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39385?source=see_link\">",
"     \"Huntington disease: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Huntington disease (HD) is caused by expansion of the cytosine-adenine-guanine (CAG) trinucleotide repeats in the HTT gene (also known as the HD or IT15 gene) located on chromosome 4p16.3 that encodes the protein huntingtin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Mutant huntingtin contains an expanded tract of glutamine residues, which is located near its amino terminal. The disease is transmitted in an autosomal dominant manner.",
"   </p>",
"   <p>",
"    HD shares several clinical features with the other polyglutamine diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They typically present in middle age, with progressive neuronal dysfunction and eventual neuronal loss over the ensuing 10 to 20 years.",
"     </li>",
"     <li>",
"      The greater the number of CAG repeats on expanded alleles, the earlier the age of onset and more severe the disease.",
"     </li>",
"     <li>",
"      The repeats show both somatic and germline instability. As a result of the latter, there can be expansion of the CAG repeat number over successive generations. This may cause earlier disease onset and a progressive worsening of the phenotype in subsequent generations, a phenomenon termed anticipation. Anticipation is more common following paternal transmission of the disease allele.",
"     </li>",
"     <li>",
"      Only a certain subset of neurons is vulnerable to dysfunction, even though the relevant protein is widely expressed throughout the brain and other tissues [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Wild-type HD alleles have 6 to 34 CAG repeat units. More than 35 repeats results in an unstable, expanded, disease-causing allele [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/3\">",
"     3",
"    </a>",
"    ]. However, there is variable penetrance for expression of the HD phenotype with 35 to 39 CAG repeats. Full penetrance occurs with more than 40 repeats.",
"   </p>",
"   <p>",
"    Trinucleotide repeat size is estimated to account for 30 to 70 percent of the variance in age of HD symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/3,5-7\">",
"     3,5-7",
"    </a>",
"    ]. Alleles with 40 to 50 CAG repeats are found in most patients with the adult form of HD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/3\">",
"     3",
"    </a>",
"    ]. Juvenile HD is typically associated with alleles containing more than 60 CAG repeats, and some patients have more than 100 repeats. Additional factors predicting age of onset are thought to be environmental and other genetic determinants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its effect on the age of presentation, it is generally believed that CAG repeat length is positively correlated with the rate of clinical disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. There also appears to be a positive correlation between CAG repeat length and the severity of neuropathologic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/15\">",
"     15",
"    </a>",
"    ]. These findings suggest that large CAG expansions produce more widespread injury than smaller expansions and may affect neuronal subtypes that would otherwise be spared with smaller repeat sizes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anticipation and transmitting parent effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expansion of the CAG repeat number over successive generations causes an earlier and more severe phenotype, termed anticipation.",
"   </p>",
"   <p>",
"    Intergenerational transmissions are associated with either slight increases of one to four CAG units or slight decreases of one to two units [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/1\">",
"     1",
"    </a>",
"    ]. However, paternal transmission can sometimes produce much larger increases, on the order of seven or more CAG repeats [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The high number of cellular divisions that occur during spermatogenesis may account for the pronounced paternal-repeat instability [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the tendency for paternal transmission to result in greater expansion of the CAG repeat size, anticipation shows a major transmitting parent effect, as approximately 70 to 88 percent of symptomatic patients with juvenile HD inherit the mutant HD gene from their father [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Toxic gain of function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expansion of CAG repeats is thought to cause toxicity through a \"gain of function\" mechanism (ie, disease develops because the mutant form of the protein gains a function that is deleterious to the cell).",
"   </p>",
"   <p>",
"    Three observations are compatible with HD being caused by a dominant gain of function rather than loss of function mechanism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with homozygous disease have clinical manifestations and age of onset similar to those of heterozygous siblings [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. In contrast, the data conflict on whether the clinical course is more severe with more rapid progression in those with homozygous disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduction of normal huntingtin activity does",
"      <strong>",
"       not",
"      </strong>",
"      cause HD in both animal models and in humans. The clinical manifestations in mice with deletion or complete inactivation of wild-type Hdh, the homologue of the HD gene, are different from those in humans with HD. These mice die in gestation between days 8.5 and 10.5, before the emergence of the nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. Thus, huntingtin is critical for early embryonic development. Mice heterozygous for Hdh inactivation are phenotypically normal [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Similar findings have been noted in humans, providing further support for a gain-of-function mechanism. In addition, a patient with a breakpoint in the HD gene that led to reduced expression of huntingtin was phenotypically normal [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In mice, replacing wild-type Hdh with a mutant Hdh allele containing 50 glutamine repeats results in normal embryonic and brain development [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/28\">",
"       28",
"      </a>",
"      ]. This finding indicates that the HD defect in humans does not mimic complete or partial Hdh inactivation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, htt residues outside of the polyglutamine tract impact disease severity, suggesting that the toxic gain of function is related to a normal function of huntingtin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Distribution and function of huntingtin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Huntingtin is widely expressed throughout the brain, and is present in a large number of tissues throughout the body. However, pathology appears to be limited to the central nervous system, with neuronal cell loss and atrophy of the caudate and putamen (the neostriatum) being most prominent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, the distribution of huntingtin does not correlate with the pattern of neuronal cell loss seen in HD.",
"   </p>",
"   <p>",
"    Wild-type huntingtin exists primarily as a soluble cytoplasmic protein in somatodendritic regions and in axons [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/4,31\">",
"     4,31",
"    </a>",
"    ]. It is associated with cellular organelles including the Golgi apparatus, mitochondria, endoplasmic reticulum, cytoskeleton, and synaptic vesicles, and is also present to a lesser degree in the nucleus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it is essential for normal embryonic development, the role of wild-type huntingtin in the adult is poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/2\">",
"     2",
"    </a>",
"    ]. Huntingtin interacts with numerous proteins, raising the possibility that huntingtin is involved in multiple cellular events. Proposed functions for wild-type huntingtin include roles in the regulation of ciliogenesis, protein trafficking, vesicular transport and anchoring to the cytoskeleton, endocytosis, and postsynaptic signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/3,32-34\">",
"     3,32-34",
"    </a>",
"    ]. In addition, wild-type huntingtin may have a prosurvival (anti-apoptotic) function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mutant huntingtin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutant huntingtin is expressed in the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/4,35,36\">",
"     4,35,36",
"    </a>",
"    ]. A key neuropathologic feature of HD is selective neuronal loss in the caudate and putamen (striatum).",
"   </p>",
"   <p>",
"    In HD, electron microscopy reveals both cytoplasmic and nuclear abnormalities, including the presence of large neuronal intranuclear inclusions or aggregates similar to those in other polyglutamine disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The aggregates are also found in dystrophic neurites. The aggregates consist of amino-terminus fragments of the expanded mutant huntingtin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/37,40\">",
"     37,40",
"    </a>",
"    ]. The degree of aggregation varies with the length of the polyglutamine expansion (ie, the number of CAG repeats) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Formation of mutant huntingtin aggregates may occur by one or both of two proposed mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal tertiary protein conformation of huntingtin may be destabilized by the presence of the expanded polyglutamine tract, leading to the formation of insoluble beta pleated sheets",
"     </li>",
"     <li>",
"      The expanded polyglutamine tract may result in increased transglutaminase-mediated crosslinking with other polyglutamine-containing proteins, including mutant and wild-type huntingtin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While aggregation of mutant huntingtin is a pathologic hallmark of the disease process, the precise role of aggregates in the pathogenesis of HD is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/3,41-43\">",
"     3,41-43",
"    </a>",
"    ]. As discussed below, the interaction of Rhes with mutant huntingtin results in both neurotoxicity and diminished aggregation of mutant huntingtin. This finding suggests that aggregation is a protective rather than a deleterious mechanism. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Rhes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although the pathophysiology of neuronal loss is incompletely understood, there is evidence that mutant huntingtin may disrupt a number of intracellular pathways and thereby cause cellular demise by interfering with key components of these pathways",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by sequestrating of normal proteins into the huntingtin aggregates [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proteins and pathways that are potentially disrupted by mutant huntingtin include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation of proteases, leading to proteolysis",
"     </li>",
"     <li>",
"      Inhibition of essential native proteins that contain polyglutamine repeats",
"     </li>",
"     <li>",
"      Reduction in protein degradation, perhaps by blocking or overloading the proteosome degradation system [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/44\">",
"       44",
"      </a>",
"      ]; the importance of this mechanism is related to the central role of the ubiquitin protease system in the removal of damaged, mutated, mislocated or misfolded proteins that could be toxic to the cell [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Transcription deregulation",
"     </li>",
"     <li>",
"      Interference with axonal transport",
"     </li>",
"     <li>",
"      Increased ciliogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Disruption of synaptic transmission",
"     </li>",
"     <li>",
"      Interference with the normal action of wild-type huntingtin [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not necessarily a direct consequence of mutant huntingtin, a variety of additional mechanisms may contribute to neurodegeneration and the clinical manifestations of HD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/3,47,48\">",
"     3,47,48",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excitotoxicity",
"     </li>",
"     <li>",
"      Metabolic dysfunction, mitochondrial dysfunction and oxidative stress",
"     </li>",
"     <li>",
"      Promotion of apoptosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      autophagy",
"     </li>",
"     <li>",
"      Dysfunction of neuronal interaction and circuits, primarily involving the corticostriatal and nigrostriatal pathways",
"     </li>",
"     <li>",
"      Abnormal cerebrospinal fluid flow and impaired neuroblast migration [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rhes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible explanation for the restriction of HD pathology mainly to the neostriatum involves the role of Rhes (Ras homolog enriched in striatum), a small guanine nucleotide-binding protein that is selectively localized to the striatum. Rhes interacts with both wild-type and mutant huntingtin, but binds more strongly with mutant huntingtin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/49\">",
"     49",
"    </a>",
"    ]. In cultured lines of human embryonic and murine brain cells, Rhes induces the small ubiquitin-like modifier (SUMO) protein to covalently attach to mutant huntingtin in a process known as sumoylation. This process reduces the aggregation of mutant huntingtin and elicits neurotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NEUROPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic pathologic change in HD is diffuse, marked atrophy of the neostriatum that may be worse in the caudate than in the putamen [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/15,50\">",
"     15,50",
"    </a>",
"    ]. The caudate atrophy can often be detected on brain imaging with CT scan or MRI. Caudate and putamen volume measurements by MRI suggest that striatal atrophy begins 9 to 20 years before the clinical diagnosis of HD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a general correlation exists between clinical severity of motor impairment and the degree of neuronal loss [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/53,54\">",
"     53,54",
"    </a>",
"    ], some symptomatic patients (5 of 163 in one postmortem series) with HD have no pathologic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/50\">",
"     50",
"    </a>",
"    ]. Symptoms in such patients presumably are caused by cellular dysfunction related to mutant huntingtin and its associated biochemical changes.",
"   </p>",
"   <p>",
"    The pathologic changes are more dramatic in early onset HD. Affected patients typically show generalized brain atrophy and loss of cerebellar Purkinje cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8599/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the cellular level, protein aggregates are seen both in the cytoplasm and nucleus. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Mutant huntingtin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/56/27521?source=see_link\">",
"       \"Patient information: Huntington disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Huntington disease (HD) is caused by expansion of the cytosine-adenine-guanine (CAG) trinucleotide repeats in the HTT gene (also known as the HD or IT15 gene) located on chromosome 4p16.3 that encodes the protein huntingtin. The disease is transmitted in an autosomal dominant manner. Wild-type HD alleles have 6 to 34 CAG repeat units. More than 35 repeats results in an unstable, expanded, disease-causing allele. However, there is variable penetrance for expression of the HD phenotype with 35 to 39 CAG repeats. Full penetrance occurs at repeat sizes greater than 40. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with early-onset HD tend to have a large number of CAG repeats, while those developing HD late in life typically have a low repeat number. Alleles with 40 to 50 CAG repeats are found in most patients with the adult form of HD. In comparison, juvenile HD is typically associated with alleles containing more than 60 CAG repeats. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Expansion of the CAG repeat number over successive generations may cause an earlier and more severe phenotype, termed anticipation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anticipation and transmitting parent effect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Expansion of CAG repeats is thought to produce a toxic \"gain of function\" (ie, disease develops because the mutant form of the protein gains a new function that is deleterious to the cell). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Toxic gain of function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wild-type huntingtin is essential for normal embryonic development. While its role in adults is not completely understood, wild-type huntingtin participates in the regulation of ciliogenesis, protein trafficking, vesicular transport and anchoring to the cytoskeleton, endocytosis, and postsynaptic signaling. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Distribution and function of huntingtin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aggregation of mutant huntingtin is a pathologic hallmark of the disease process. However, the precise role of aggregates in the pathogenesis of HD is controversial. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mutant huntingtin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While the pathophysiology of neuronal loss is incompletely understood, there is evidence that mutant huntingtin may disrupt a number of intracellular pathways and thereby cause cellular demise by interfering with key components of these pathways",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      by sequestration of normal proteins into the huntingtin aggregates. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mutant huntingtin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The predominant localization of HD neuropathology to the striatum may be explained by the interaction of mutant huntingtin with Rhes, a small guanine nucleotide-binding protein that is selectively localized to the striatum. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Rhes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The characteristic pathologic change in HD is diffuse, marked atrophy of the neostriatum that may be worse in the caudate than in the putamen. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Neuropathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/1\">",
"      A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993; 72:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/2\">",
"      Walker FO. Huntington's disease. Lancet 2007; 369:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/3\">",
"      Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 2008; 27:2803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/4\">",
"      Trottier Y, Devys D, Imbert G, et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 1995; 10:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/5\">",
"      Andrew SE, Goldberg YP, Kremer B, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993; 4:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/6\">",
"      Stine OC, Pleasant N, Franz ML, et al. Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet 1993; 2:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/7\">",
"      Lee JM, Ramos EM, Lee JH, et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 2012; 78:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/8\">",
"      Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 2004; 101:3498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/9\">",
"      Arning L, Kraus PH, Valentin S, et al. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics 2005; 6:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/10\">",
"      Furtado S, Suchowersky O, Rewcastle B, et al. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 1996; 39:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/11\">",
"      Brandt J, Bylsma FW, Gross R, et al. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 1996; 46:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/12\">",
"      Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997; 48:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/13\">",
"      Mahant N, McCusker EA, Byth K, et al. Huntington's disease: clinical correlates of disability and progression. Neurology 2003; 61:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/14\">",
"      Rosenblatt A, Liang KY, Zhou H, et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 2006; 66:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/15\">",
"      Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/16\">",
"      Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 1993; 4:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/17\">",
"      Z&uuml;hlke C, Riess O, Bockel B, et al. Mitotic stability and meiotic variability of the (CAG)n repeat in the Huntington disease gene. Hum Mol Genet 1993; 2:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/18\">",
"      Telenius H, Almqvist E, Kremer B, et al. Somatic mosaicism in sperm is associated with intergenerational (CAG)n changes in Huntington disease. Hum Mol Genet 1995; 4:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/19\">",
"      Z&uuml;hlke C, Riess O, Schr&ouml;der K, et al. Expansion of the (CAG)n repeat causing Huntington's disease in 352 patients of German origin. Hum Mol Genet 1993; 2:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/20\">",
"      Brinkman RR, Mezei MM, Theilmann J, et al. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997; 60:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/21\">",
"      Nahhas FA, Garbern J, Krajewski KM, et al. Juvenile onset Huntington disease resulting from a very large maternal expansion. Am J Med Genet A 2005; 137A:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/22\">",
"      Wexler NS, Young AB, Tanzi RE, et al. Homozygotes for Huntington's disease. Nature 1987; 326:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/23\">",
"      Squitieri F, Gellera C, Cannella M, et al. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 2003; 126:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/24\">",
"      Duyao MP, Auerbach AB, Ryan A, et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995; 269:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/25\">",
"      Nasir J, Floresco SB, O'Kusky JR, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995; 81:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/26\">",
"      Zeitlin S, Liu JP, Chapman DL, et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995; 11:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/27\">",
"      Persichetti F, Carlee L, Faber PW, et al. Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol Dis 1996; 3:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/28\">",
"      White JK, Auerbach W, Duyao MP, et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 1997; 17:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/29\">",
"      Graham RK, Deng Y, Slow EJ, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006; 125:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/30\">",
"      Gu X, Greiner ER, Mishra R, et al. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 2009; 64:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/31\">",
"      DiFiglia M, Sapp E, Chase K, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995; 14:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/32\">",
"      Keryer G, Pineda JR, Liot G, et al. Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease. J Clin Invest 2011; 121:4372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/33\">",
"      Liu JP, Zeitlin SO. The long and the short of aberrant ciliogenesis in Huntington disease. J Clin Invest 2011; 121:4237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/34\">",
"      Caviston JP, Holzbaur EL. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol 2009; 19:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/35\">",
"      Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 1995; 378:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/36\">",
"      Jou YS, Myers RM. Evidence from antibody studies that the CAG repeat in the Huntington disease gene is expressed in the protein. Hum Mol Genet 1995; 4:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/37\">",
"      DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/38\">",
"      Davies SW, Beardsall K, Turmaine M, et al. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet 1998; 351:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/39\">",
"      Ross CA. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 1997; 19:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/40\">",
"      Krobitsch S, Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci U S A 2000; 97:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/41\">",
"      Michalik A, Van Broeckhoven C. Pathogenesis of polyglutamine disorders: aggregation revisited. Hum Mol Genet 2003; 12 Spec No 2:R173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/42\">",
"      Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998; 95:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/43\">",
"      Okamoto S, Pouladi MA, Talantova M, et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 2009; 15:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/44\">",
"      Seo H, Sonntag KC, Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol 2004; 56:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/45\">",
"      Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001; 292:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/46\">",
"      Zuccato C, Ciammola A, Rigamonti D, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001; 293:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/47\">",
"      Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J Clin Invest 2011; 121:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/48\">",
"      Song W, Chen J, Petrilli A, et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med 2011; 17:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/49\">",
"      Subramaniam S, Sixt KM, Barrow R, Snyder SH. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009; 324:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/50\">",
"      Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/51\">",
"      Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004; 63:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/52\">",
"      Kipps CM, Duggins AJ, Mahant N, et al. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry 2005; 76:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/53\">",
"      Guo Z, Rudow G, Pletnikova O, et al. Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Mov Disord 2012; 27:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8599/abstract/54\">",
"      Rosenblatt A, Abbott MH, Gourley LM, et al. Predictors of neuropathological severity in 100 patients with Huntington's disease. Ann Neurol 2003; 54:488.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6182 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8599=[""].join("\n");
var outline_f8_25_8599=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anticipation and transmitting parent effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Toxic gain of function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Distribution and function of huntingtin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mutant huntingtin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rhes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NEUROPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29832?source=related_link\">",
"      Huntington disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39385?source=related_link\">",
"      Huntington disease: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/56/27521?source=related_link\">",
"      Patient information: Huntington disease (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_25_8600="Pathophysiology, clinical features, and diagnosis of migraine in children";
var content_f8_25_8600=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology, clinical features, and diagnosis of migraine in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/25/8600/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8600/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/25/8600/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8600/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/25/8600/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8600/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/25/8600/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is the most common acute and recurrent headache syndrome in children. It is characterized by periodic episodes of paroxysmal headache accompanied by nausea, vomiting, abdominal pain, and relief with sleep.",
"   </p>",
"   <p>",
"    The epidemiology, pathophysiology, clinical features, and diagnosis of migraine headaches in children are reviewed here. Classification and treatment of migraine headaches in children and an approach to the general evaluation of headaches in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link\">",
"     \"Classification of migraine in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18490?source=see_link\">",
"     \"Management of migraine headache in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35977?source=see_link\">",
"     \"Approach to the child with headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine occurs at all ages and may even begin in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The disorder begins before age 20 years in 50 percent of cases.",
"   </p>",
"   <p>",
"    The onset of migraine tends to be earlier in boys than girls (7 versus 10 years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, before age seven, affected boys outnumber girls. The male preponderance persists until puberty; by 10 to 14 years of age, more females are affected [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of migraine may be as high as 2.5 percent of children less than seven years of age (",
"    <a class=\"graphic graphic_figure graphicRef58152 \" href=\"UTD.htm?2/55/2942\">",
"     figure 1",
"    </a>",
"    ). By age 17 years, as many as 8 percent of males and 23 percent of females have experienced migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ]. Family history is positive in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical and demographic characteristics of migraine were evaluated by a survey of parents of schoolchildren aged 5 to 13 years in Cleveland [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/9\">",
"     9",
"    </a>",
"    ]. Migraine was reported in 222 of 2572 respondents (8.6 percent). Onset of migraine at four to five years of age was reported in 30.6 percent, and family history was positive in 65.8 percent. Although others have reported that approximately 60 percent of patients affected before age 12 years are male [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/10\">",
"     10",
"    </a>",
"    ], the ratio of males to females in this study was 1:1.2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 1988 classification of headaches by the International Headache Society (IHS) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/11\">",
"     11",
"    </a>",
"    ] did not specifically address children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/12\">",
"     12",
"    </a>",
"    ]. This system replaced the terms \"classic and common\" with the terms \"with and without aura.\" The IHS subsequently revised the classification and diagnostic criteria for migraine in children younger than 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/13\">",
"     13",
"    </a>",
"    ], and a major overall revision was published in 2004 (",
"    <a class=\"graphic graphic_table graphicRef50876 \" href=\"UTD.htm?11/31/11773\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classification of migraine in children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link\">",
"     \"Classification of migraine in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is thought to have a polygenetic and multifactorial etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/15\">",
"     15",
"    </a>",
"    ]. No consistent genetic basis has been established for migraine, with the exception of familial hemiplegic migraine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=see_link&amp;anchor=H81876416#H81876416\">",
"     \"Hemiplegic migraine\", section on 'Familial hemiplegic migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No single theory or hypothesis can explain all of the phenomena that occur with migraine. The popular vascular theory of migraine, which suggested that the headaches were caused by the dilatation of blood vessels while the aura resulted from vasoconstriction, is no longer considered correct. Vasodilatation appears to play an important role in the characteristic severe throbbing head pain, but is probably is an epiphenomenon, resulting from instability in the central neurovascular control mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism appears to be a primary neuronal dysfunction that leads to a sequence of intracranial and extracranial changes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/18\">",
"     18",
"    </a>",
"    ]. A genetic predisposition can make individuals susceptible to an acute migraine attack, depending upon the balance between excitation and inhibition at various levels of the nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. Both genetic and environmental factors are important [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A primary event may occur in the brainstem involving diffuse projections from the locus ceruleus to other parts of the brain. This causes an unstable trigeminovascular reflex, and allows excessive discharge of part of the spinal nucleus of the trigeminal nerve and basal thalamic nuclei. Support for this role of the brainstem is derived from a study that used positron emission tomography to examine changes in regional cerebral blood flow as an index of neuronal activity in the human brain during spontaneous migraine attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/19\">",
"     19",
"    </a>",
"    ]. During the attacks, increased blood flow was found in the cerebral hemispheres in the cingulate, auditory, and visual association cortices, and in the brainstem. However, only the brainstem activation persisted after the injection of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    had induced complete relief from headache, phonophobia, and photophobia. These findings support the idea that the pathogenesis of migraine is related to an imbalance in activity between brainstem nuclei regulating antinociception and vascular control.",
"   </p>",
"   <p>",
"    Antidromic stimulation of the trigeminal nerve results in the release of substance P, calcitonin gene-related peptide, and other vasoactive polypeptides that cause pain and vasodilatation in experimental models, and lead to the sequence of events labeled as \"neurogenic inflammation.\" Locus ceruleus projections to the cerebral cortex may initiate cortical hypoperfusion and spreading depression, which can explain the aura of migraine. One group of investigators has established a causal link between the aura and headache by providing evidence that cortical spreading depression, a wave of neuronal depolarization that spreads across the cerebral cortex and causes the aura, activates trigeminal nerve afferents that, through central and peripheral reflex mechanisms, cause inflammatory changes in the pain-sensitive meninges to generate the headache [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/21\">",
"     21",
"    </a>",
"    ]. A second group has also reported temporary sensitization of central trigeminal neurons during acute migraine attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cortical spreading depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A causal association between migraine aura and headache is supported by evidence that both are linked to the phenomenon known as cortical spreading depression (CSD) of Leao [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/23\">",
"     23",
"    </a>",
"    ]. CSD is a self propagating wave of neuronal and glial depolarization that spreads across the cerebral cortex. CSD appears to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cause the aura of migraine",
"     </li>",
"     <li>",
"      Activate trigeminal nerve afferents",
"     </li>",
"     <li>",
"      Alter blood-brain barrier permeability by matrix metalloproteinase (MMP) activation and upregulation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The activation of trigeminal afferents by CSD in turn causes inflammatory changes in the pain-sensitive meninges that generate the headache of migraine through central and peripheral reflex mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of serotonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serotonin (released from brainstem serotonergic nuclei) also plays an important role in the pathogenesis of migraine; this is probably mediated via its direct action upon the cranial vasculature, through its role in central pain control pathways, and through cerebral cortical projections of brainstem serotonergic nuclei [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/25\">",
"     25",
"    </a>",
"    ]. The exact mechanism of serotonin action is obscure. A decline in serotonergic function has been noted during acute migraine attacks in adults, resulting in vasodilation of cranial vessels and sensitization of meningeal afferents of the trigeminal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/26\">",
"     26",
"    </a>",
"    ]. Between attacks, patients who have migraine without aura appear to have increased brain serotonin synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylactic antimigraine drugs may act via centrally modulating serotonergic neuronal networks, while abortive medications terminate migraine attacks through their effects upon intracranial and extracranial vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/28\">",
"     28",
"    </a>",
"    ]. Beta blocking drugs used for migraine prophylaxis may regulate serotonin synthesis through action at the serotonin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Role of CGRP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcitonin gene-related peptide (CGRP) may also play a central role in migraine pathophysiology. CGRP is a 37 amino acid neuropeptide that is expressed in trigeminal ganglia nerves and is a potent vasodilator of cerebral and dural vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CGRP may mediate trigeminovascular pain transmission from intracranial vessels to the central nervous system as well as neurogenic inflammation. However, the evidence is conflicting. Stimulation of the trigeminal ganglion induces the release of CGRP [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/32\">",
"     32",
"    </a>",
"    ], and CGRP infusion can trigger a migraine attack in migraineurs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/33\">",
"     33",
"    </a>",
"    ]. Although an earlier study found elevation of CGRP levels in external jugular venous blood during migraine attack [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/34\">",
"     34",
"    </a>",
"    ], this result was not reproduced in a subsequent study [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, CGRP did not activate or sensitize meningeal nociceptors in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated CGRP levels are normalized in migraine patients following administration of the serotonin",
"    <span class=\"nowrap\">",
"     1b/1d",
"    </span>",
"    receptor agonist",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/37\">",
"     37",
"    </a>",
"    ], suggesting that triptans may act to control migraine at least in part by reducing CGRP levels. Modulation of CGRP levels by other means also offers the promise of future treatment options for acute migraine attacks. As an example, the investigational agent BIBN 4096, a CGRP receptor antagonist, was significantly superior to placebo for treating acute migraine attacks in a phase II, double-blind, randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Right to left cardiac shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few studies in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/39-41\">",
"     39-41",
"    </a>",
"    ] and children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/42,43\">",
"     42,43",
"    </a>",
"    ] have suggested that migraine with aura is associated with right to left cardiac shunts, usually in the setting of a patent foramen ovale or, much less often, an atrial septal defect.",
"   </p>",
"   <p>",
"    The mechanism of the possible association between right to left cardiac shunt and migraine is not known. One theory is that the venous circulation contains vasoactive substances capable of triggering migraine; these are normally inactivated in the lungs but gain access to the cranial circulation in the presence of a right to left shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/44\">",
"     44",
"    </a>",
"    ]. Another hypothesis is that the existence of the shunt provides a pathway for paradoxical embolism and subsequent cerebral ischemia, which in turn triggers migraine.",
"   </p>",
"   <p>",
"    However, there is no compelling evidence that closure of a patent foramen ovale or atrial septal defect is effective treatment for migraine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H27#H27\">",
"     \"Preventive treatment of migraine in adults\", section on 'Closure of right-to-left cardiac shunt'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of migraine vary with age. In toddlers, symptoms appreciated by caregivers include episodic pallor, unusual decreased activity, and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/2,45\">",
"     2,45",
"    </a>",
"    ]. In young children, the headache often begins in the late afternoon, in contrast to adults, in whom migraine typically starts in the early morning. It may be bifrontal, temporal, generalized, or unilateral, and is often accompanied by nausea and sensitivity to light and noise. Many children have vomiting that occurs once or repetitively.",
"   </p>",
"   <p>",
"    In adolescents, the headaches tend to be more typical of those seen in adults. The headache is lateralized during severe migraine attacks in 60 to 70 percent of patients; bifrontal or global headache occurs in up to 30 percent. The pain is usually gradual in onset, following a crescendo pattern with gradual but complete resolution. The headache is usually dull, deep, and steady when mild to moderate; it becomes throbbing or pulsatile when severe. Migraine headaches are typically worsened by rapid head motion, sneezing, straining, constant motion, or physical exertion. Patients typically want to lie down in a dark, quiet room as they obtain relief with sleep.",
"   </p>",
"   <p>",
"    The duration of the headaches tends to be shorter in younger compared to older children or adults. The duration is less than two hours in 11 to 81 percent and less than one hour in 8 to 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/46\">",
"     46",
"    </a>",
"    ]. The acute headache may be followed by a milder aching headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Aura",
"    </span>",
"    &nbsp;&mdash;&nbsp;An aura, when it occurs, is most often visual, and may be monocular or binocular. A typical visual aura consists of spots or colored lights but may include scotomata or complex visual images. The aura evolves gradually and lasts a few minutes before the onset of headache. An aura does not have prognostic or therapeutic implications.",
"   </p>",
"   <p>",
"    Children should be asked specifically if they see anything unusual at the beginning of their headache. Some are embarrassed to mention their experience spontaneously or do not associate it with their headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of migraine is made on the basis of a typical history of paroxysmal headaches; the child is normal between episodes. However, the diagnosis may be difficult in young children who may not be able to describe their symptoms or in patients with migraine variants who may not have typical symptoms.",
"   </p>",
"   <p>",
"    Because of the unique features of migraine in children, the quality of the headache and associated symptoms are more important than specific clinical criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/47\">",
"     47",
"    </a>",
"    ]. In general, three of the following criteria should be present for the diagnosis of childhood migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal pain, nausea, or vomiting with headache",
"     </li>",
"     <li>",
"      Hemicrania (unilateral headache)",
"     </li>",
"     <li>",
"      Throbbing, pulsating pain",
"     </li>",
"     <li>",
"      Complete relief after a brief rest",
"     </li>",
"     <li>",
"      An aura, either visual, sensory, or motor",
"     </li>",
"     <li>",
"      A history of migraine headaches in one or more family members",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the revised International Headache Society (IHS) diagnostic criteria (",
"    <a class=\"graphic graphic_table graphicRef50876 \" href=\"UTD.htm?11/31/11773\">",
"     table 1",
"    </a>",
"    ) note that certain features of migraine in children may differ from typical features in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Migraine attacks may last one to 72 hours",
"     </li>",
"     <li>",
"      Migraine headache is commonly bilateral in children, and an adult pattern of unilateral pain usually emerges in late adolescence or early adulthood",
"     </li>",
"     <li>",
"      Occipital headache in children is rare and raises diagnostic caution, as many cases are attributable to structural lesions.",
"     </li>",
"     <li>",
"      Photophobia and phonophobia may be inferred by behavior in young children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These revisions to the IHS criteria provide a reasonable guide to migraine headache characteristics in children (",
"    <a class=\"graphic graphic_table graphicRef50876 \" href=\"UTD.htm?11/31/11773\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Headache drawings may be a useful adjunct to the history and physical examination in differentiating migraine from nonmigraine headaches. In one study, pediatric neurologists masked to the clinical history evaluated pictures drawn by 226 children, ages 4 to 19 years, illustrating how their headache felt [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/49\">",
"     49",
"    </a>",
"    ]. Drawings with features consistent with migraine (eg, pounding pain,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    photophobia) had a sensitivity and specificity of 93.1 and 82.7 percent and a positive predictive value of 87.1 percent for migraine.",
"   </p>",
"   <p>",
"    The child should have normal general physical and neurologic examinations. Children with an established history (more than six months) of typical intermittent headaches and a normal examination usually do not need testing. Testing should be performed if the headaches are focal, relentless, or worsening over time or if the clinical evaluation reveals atypical features that may suggest other diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with a history of migraine headaches and no signs or symptoms of neurologic dysfunction or increased intracranial pressure do not need neuroimaging. However, many parents and children are concerned that the headaches are caused by a brain tumor or other life-threatening illness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/51\">",
"     51",
"    </a>",
"    ]. In these cases, brain imaging may be required to relieve apprehensions.",
"   </p>",
"   <p>",
"    The American Academy of Neurology, American Academy of Family Physicians, American College of Physicians-American Society of Internal Medicine, and four other groups formed a consortium that took an evidence-based approach to, among other things, evaluating the need for brain imaging in patients with headache [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/52\">",
"     52",
"    </a>",
"    ]. This report noted that the odds of finding a significant abnormality on neuroimaging in patients with nonacute headache were increased by the following symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapidly increasing headache frequency",
"     </li>",
"     <li>",
"      History of lack of coordination",
"     </li>",
"     <li>",
"      History of localized neurologic signs or subjective numbness or tingling",
"     </li>",
"     <li>",
"      History of headache causing awakening from sleep (although this can occur with migraine headache)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the odds of finding a significant abnormality were not lowered by the absence of these symptoms.",
"   </p>",
"   <p>",
"    The consortium recommended that neuroimaging is usually not warranted in patients with migraine headache and a normal neurologic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/52\">",
"     52",
"    </a>",
"    ]. In addition, data were insufficient to make a specific recommendation regarding the relative sensitivity of magnetic resonance imaging (MRI) compared with CT in patients who have an imaging study performed. However, many clinicians prefer MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link\">",
"     \"Approach to neuroimaging in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Electroencephalogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;EEG is not indicated in the routine evaluation of headache [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/53\">",
"     53",
"    </a>",
"    ]. An EEG is performed if seizures are suspected.",
"   </p>",
"   <p>",
"    Rolandic spike and wave discharges occur more in children with migraine than unaffected children. In one study of 100 children with migraine, benign focal epileptiform discharges occurred in 9 percent, significantly higher than the normal population (1.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/54\">",
"     54",
"    </a>",
"    ]. These are thought to have no clinical significance in children without nocturnal seizures. Focal slowing may occur in the hemimigraine syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing rarely is helpful in the evaluation of childhood headache [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8600/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. In children with complicated syndromes or migraine variants, testing will depend upon the differential diagnosis. Lumbar puncture (LP) may be necessary to diagnose an intracranial infection or increased intracranial pressure. Other studies might include metabolic testing (amino acids, organic acids, lactic acid), coagulation studies, echocardiogram, lipid profile, amylase, or gastrointestinal series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/9/33938?source=see_link\">",
"       \"Patient information: Migraine headaches in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/29/27090?source=see_link\">",
"       \"Patient information: Headaches in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36086?source=see_link\">",
"       \"Patient information: Headache in children (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173512567\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Migraine is the most common acute and recurrent headache syndrome in children. It is characterized by periodic episodes of paroxysmal headache accompanied by nausea, vomiting, abdominal pain, and relief with sleep.",
"     </li>",
"     <li>",
"      Migraine occurs at all ages and may even begin in infancy. The disorder begins before age 20 years in 50 percent of cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Migraine is thought to have a polygenetic and multifactorial etiology. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of migraine vary with age. In toddlers, symptoms include episodic pallor, unusual decreased activity, and vomiting. In young children, the headache may be bifrontal, temporal, generalized, or unilateral, and is often accompanied by nausea, vomiting, and sensitivity to light and noise. In adolescents, the headache tends to be more typical of those seen in adults, and is lateralized during severe migraine attacks in 60 to 70 percent of patients. The pain is usually gradual in onset. Patients typically want to lie down in a dark, quiet room as they obtain relief with sleep. An aura, when it occurs, is most often visual, and may be monocular or binocular. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of migraine is made on the basis of a typical history of paroxysmal headaches; the child is normal between episodes. Diagnostic criteria (",
"      <a class=\"graphic graphic_table graphicRef50876 \" href=\"UTD.htm?11/31/11773\">",
"       table 1",
"      </a>",
"      ) provide a reasonable guide to the clinical diagnosis. However, the diagnosis may be difficult in young children who are unable to describe their symptoms or in patients with migraine variants who may not have typical symptoms. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/1\">",
"      Mortimer MJ, Kay J, Jaron A. Epidemiology of headache and childhood migraine in an urban general practice using Ad Hoc, Vahlquist and IHS criteria. Dev Med Child Neurol 1992; 34:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/2\">",
"      Elser JM, Woody RC. Migraine headache in the infant and young child. Headache 1990; 30:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/3\">",
"      Sillanp&auml;&auml; M. Changes in the prevalence of migraine and other headaches during the first seven school years. Headache 1983; 23:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/4\">",
"      Zwart JA, Dyb G, Holmen TL, et al. The prevalence of migraine and tension-type headaches among adolescents in Norway. The Nord-Tr&oslash;ndelag Health Study (Head-HUNT-Youth), a large population-based epidemiological study. Cephalalgia 2004; 24:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/5\">",
"      Bigal ME, Lipton RB, Winner P, et al. Migraine in adolescents: association with socioeconomic status and family history. Neurology 2007; 69:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/6\">",
"      Dalsgaard-Nielsen T. Some aspects of the epidemiology of migraine in Denmark. Headache 1970; 10:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/7\">",
"      Deubner DC. An epidemiologic study of migraine and headache in 10-20 year olds. Headache 1977; 17:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/8\">",
"      Congdon, PJ, Forsythe, Wl. Migraine in childhood: a study of 300 children. Dev Med Child Neurol 1979; 21:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/9\">",
"      Lee LH, Olness KN. Clinical and demographic characteristics of migraine in urban children. Headache 1997; 37:269.",
"     </a>",
"    </li>",
"    <li>",
"     Prensky, AL. Headache. In: Oski's Pediatrics. Principles and Practice, 4th ed, McMillan, JA, Feigin, RD, DeAngelis, C, Jones, MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.2388.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/11\">",
"      Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988; 8 Suppl 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/12\">",
"      Seshia SS, Wolstein JR, Adams C, et al. International headache society criteria and childhood headache. Dev Med Child Neurol 1994; 36:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/13\">",
"      Olesen J. International Headache Society classification and diagnostic criteria in children: a proposal for revision. Dev Med Child Neurol 1997; 39:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/14\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/15\">",
"      Ducros A, Tournier-Lasserve E, Bousser MG. The genetics of migraine. Lancet Neurol 2002; 1:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/16\">",
"      Welch KM. Drug therapy of migraine. N Engl J Med 1993; 329:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/17\">",
"      Welch KM, Barkley GL, Tepley N, Ramadan NM. Central neurogenic mechanisms of migraine. Neurology 1993; 43:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/18\">",
"      Langemark M, Olesen J. Drug abuse in migraine patients. Pain 1984; 19:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/19\">",
"      Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/20\">",
"      Gervil M, Ulrich V, Kaprio J, et al. The relative role of genetic and environmental factors in migraine without aura. Neurology 1999; 53:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/21\">",
"      Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/22\">",
"      Kaube H, Katsarava Z, Przywara S, et al. Acute migraine headache: possible sensitization of neurons in the spinal trigeminal nucleus? Neurology 2002; 58:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/23\">",
"      Le&atilde;o AAP. Pial circulation and spreading depression of activity in cerebral cortex. J Neurophysiol 1944; 7:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/24\">",
"      Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004; 113:1447.",
"     </a>",
"    </li>",
"    <li>",
"     Martignoni, E, Solomon, S. The complex chronic headache, mixed headache and drug overuse. In: The Headaches, Olesen, J, Tfelt-Hansen, P, Welch, KM (Eds), Raven, New York 1993. p.849.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/26\">",
"      Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/27\">",
"      Chugani DC, Niimura K, Chaturvedi S, et al. Increased brain serotonin synthesis in migraine. Neurology 1999; 53:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/28\">",
"      Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache: analysis of factors. Headache 1982; 22:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/29\">",
"      Rosenfeld MG, Mermod JJ, Amara SG, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 1983; 304:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/30\">",
"      Skofitsch G, Jacobowitz DM. Calcitonin gene-related peptide coexists with substance P in capsaicin sensitive neurons and sensory ganglia of the rat. Peptides 1985; 6:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/31\">",
"      Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996; 16:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/32\">",
"      Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/33\">",
"      Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002; 22:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/34\">",
"      Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/35\">",
"      Tvedskov JF, Lipka K, Ashina M, et al. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 2005; 58:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/36\">",
"      Levy D, Burstein R, Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005; 58:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/37\">",
"      Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/38\">",
"      Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/39\">",
"      Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke 2002; 33:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/40\">",
"      Anzola GP, Magoni M, Guindani M, et al. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology 1999; 52:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/41\">",
"      Del Sette M, Angeli S, Leandri M, et al. Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study. Cerebrovasc Dis 1998; 8:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/42\">",
"      Sar��soy S, Ayd��n &Ouml;F, Sungur M, et al. The relationship between migraine and right-to-left shunt in children. Eur J Pediatr 2011; 170:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/43\">",
"      McCandless RT, Arrington CB, Nielsen DC, et al. Patent foramen ovale in children with migraine headaches. J Pediatr 2011; 159:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/44\">",
"      Meier B, Lock JE. Contemporary management of patent foramen ovale. Circulation 2003; 107:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/45\">",
"      Barlow CF. Migraine in the infant and toddler. J Child Neurol 1994; 9:92.",
"     </a>",
"    </li>",
"    <li>",
"     Winner, P, Rothner, AD. Headaches in children and adolescents. BC Decker, Hamilton, ON 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/47\">",
"      Rothner, AD. Headaches in children: How to determine whether they are organic or functional. Consultant 1986; 26:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/48\">",
"      Prensky AL, Sommer D. Diagnosis and treatment of migraine in children. Neurology 1979; 29:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/49\">",
"      Stafstrom CE, Rostasy K, Minster A. The usefulness of children's drawings in the diagnosis of headache. Pediatrics 2002; 109:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/50\">",
"      Prensky A. Childhood Migraine Headache Syndromes. Curr Treat Options Neurol 2001; 3:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/51\">",
"      Lewis DW, Middlebrook MT, Mehallick L, et al. Pediatric headaches: what do the children want? Headache 1996; 36:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/52\">",
"      Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/53\">",
"      Practice parameter: the electroencephalogram in the evaluation of headache (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1995; 45:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/54\">",
"      Kinast M, Lueders H, Rothner AD, Erenberg G. Benign focal epileptiform discharges in childhood migraine (BFEDC). Neurology 1982; 32:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/55\">",
"      Mets&auml;honkala L. Migraine and nonmigrainous headache--how to distinguish them. Cephalalgia 1999; 19 Suppl 25:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/56\">",
"      Rothner AD. Headaches in children and adolescents. Child Adolesc Psychiatr Clin N Am 1999; 8:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/57\">",
"      Forsyth R, Farrell K. Headache in childhood. Pediatr Rev 1999; 20:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8600/abstract/58\">",
"      Winner PK. Headaches in children. When is a complete diagnostic workup indicated? Postgrad Med 1997; 101:81.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6161 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-2A6F391156-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8600=[""].join("\n");
var outline_f8_25_8600=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H173512567\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cortical spreading depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of serotonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Role of CGRP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Right to left cardiac shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Aura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Electroencephalogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H173512567\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6161\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6161|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/55/2942\" title=\"figure 1\">",
"      Migraine prevalence in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6161|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/31/11773\" title=\"table 1\">",
"      Diagnostic criteria migraine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35977?source=related_link\">",
"      Approach to the child with headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=related_link\">",
"      Classification of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=related_link\">",
"      Hemiplegic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18490?source=related_link\">",
"      Management of migraine headache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36086?source=related_link\">",
"      Patient information: Headache in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/29/27090?source=related_link\">",
"      Patient information: Headaches in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/9/33938?source=related_link\">",
"      Patient information: Migraine headaches in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_25_8601="1st degree AV block tutorial";
var content_f8_25_8601=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1109px;\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    First degree atrioventricular (AV) block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 156px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    First degree AV block is caused by a prolongation or delay in impulse conduction through the AV node. It is defined as a PR interval &gt;0.20 seconds. In this case the PR interval (blue lines) is approximately 0.22 seconds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8601=[""].join("\n");
var outline_f8_25_8601=null;
var title_f8_25_8602="Treatment of transsexualism";
var content_f8_25_8602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of transsexualism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/25/8602/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8602/contributors\">",
"     Louis J G Gooren, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8602/contributors\">",
"     Vin Tangpricha, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/25/8602/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8602/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8602/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/25/8602/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/25/8602/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/25/8602/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transsexualism is the condition in which a person with apparently normal somatic sexual differentiation of one gender is convinced that he or she is actually a member of the opposite gender. It is associated with an irresistible urge to be that gender hormonally, anatomically, and psychosocially. The treatment of transsexualism will be discussed here, while its definition and diagnosis will be discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2630?source=see_link\">",
"     \"Transsexualism: Epidemiology, pathophysiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Standards of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The international organization involved with professional help to transsexuals, the World Professional Association for Transgender Health (WPATH), formerly known as the Harry Benjamin International Gender Dysphoria Association, has drafted Standards of Care for the diagnosis and treatment of individuals with transsexualism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major purpose of the Standards of Care (SOC) is to articulate this organization's professional consensus about the psychological, medical, and surgical management of transsexualism. Persons with transsexualism, their families, and social institutions may use the SOC as a means to understand the current thinking of professionals. The SOC undergo revisions approximately every five years. The most current version of the SOC can be found at the",
"    <a class=\"external\" href=\"file://www.wpath.org/\">",
"     WPATH website",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Counseling before treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before initiating hormonal or surgical treatment that will change a person's gender, the clinician should counsel the patient about:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Realistic expectations about treatment - The only benefit sex reassignment can bring is relief of gender dysphoria; all human problems outside the area of gender dysphoria will remain. Unrealistic expectations that subjects may have about the success of hormonal and surgical treatment for their transition to the desired sex must be addressed.",
"     </li>",
"     <li>",
"      Contacts with other transsexuals who are already in the process of changing over to the new sex or who have completed this process may be helpful in shaping a subject's expectations of what can be achieved and what problems, personally and socially, may arise in the transition to the new sex. However, this may not be possible for many individuals. A strong supportive network of family and friends is often important for a successful transition to the opposite gender.",
"     </li>",
"     <li>",
"      The patient should be aware of the risks and benefits of the hormonal or surgical therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/2\">",
"       2",
"      </a>",
"      ]. The patient should be able to understand and articulate the additional risks of these therapies and provide informed consent in proceeding with these therapies.",
"     </li>",
"     <li>",
"      The patient should be aware that there may be financial barriers to undergoing surgical sex reassignment because of insurance coverage. In the authors&rsquo; experience, approximately 90 percent of patients in western European countries are able to undergo sex reassignment surgery. In contrast, only 10 to 25 percent of patients in the US undergo sex reassignment surgery, primarily because of insurance coverage issues. Thus, there are transsexual individuals who seek partial adaptations to the desired sex that does not include surgery; others choose to undergo surgery in countries, such as Thailand, where costs are lower.",
"      <br/>",
"      <br/>",
"      In addition, GnRH agonists, one of the hormone therapy options for male-to-female transsexuals, may be prohibitively expensive for many individuals (see",
"      <a class=\"local\" href=\"#H354331202\">",
"       'GnRH agonists'",
"      </a>",
"      below). As a result, some patients obtain medications from non-medical sources (eg, internet). However, it is important to emphasize the risks of self-medication and self-dosing during counseling (see",
"      <a class=\"local\" href=\"#H578487429\">",
"       'Goals'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Transsexuals who undergo surgical sex reassignment lose their reproductive potential. Thus, before starting any treatment, patients should be encouraged to consider fertility issues, as some patients do eventually choose to have children [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/1,3\">",
"       1,3",
"      </a>",
"      ]. Male-to-female transsexuals may consider sperm cryopreservation, while female-to-male transsexuals may consider cryopreservation of oocytes or embryos [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link&amp;anchor=H15#H15\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\", section on 'Methods to preserve fertility in men'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      While these options may provide preservation of fertility, the associated costs are high, particularly for cryopreservation of oocytes or embryos, which requires ovarian stimulation and oocyte retrieval in addition to storage fees. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"       \"In vitro fertilization\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=see_link\">",
"       \"Oocyte donation for assisted reproduction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transitioning to the opposite gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;When possible, when hormone treatment starts, or perhaps even earlier, the individual should begin living in the role of the opposite gender. This was formerly known as the \"real life test\" or \"real life experience.\" The World Professional Association for Transgender Health Standards of Care requires a minimum of one year of living in the gender role that is desired prior to genital surgery.",
"   </p>",
"   <p>",
"    Transitioning to the opposite gender role may be done in a stepwise fashion; for instance, first in a trusted environment and later in public. As noted, the subject should have lived at least one full year full-time in the new sex before irreversible surgical reassignment is considered. The transition to the opposite gender role may be prolonged if too many hurdles present themselves during the test period. During this period, the subject should stay in contact with a mental health professional to allow assessment of the success of the test and to discuss how to overcome problems that almost inevitably arise during this period. In some instances, transitioning into the opposite gender role is not possible due to employment or other social issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H331478\">",
"    <span class=\"h1\">",
"     TREATMENT OF ADOLESCENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult transsexuals often recall that their gender dysphoria started early in life, well before puberty. However, among children with gender dysphoria, it is estimated that only about 15 percent will become transsexuals in adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link\">",
"     \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2630?source=see_link\">",
"     \"Transsexualism: Epidemiology, pathophysiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If, in an expert's opinion, an adolescent&rsquo;s cross-sex gender identity will not change during long-term follow-up, the individual may be spared the torment of (full) pubescent development of the \"wrong\" secondary sex characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/7\">",
"     7",
"    </a>",
"    ]. Depot forms of GnRH agonists, following the regimen used in the treatment of children with precocious puberty, can be used when clear signs of sexual maturation are evident in order to delay pubertal development until an age that a balanced and responsible decision can be made to transition to the other sex [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, as noted, this may be prohibitively expensive for some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=see_link&amp;anchor=H113274158#H113274158\">",
"     \"Overview of the management of gender nonconformity in children and adolescents\", section on 'Overview of hormonal interventions for adolescents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whenever possible, treatment is best performed in a specialized center. Treatment is usually started after Tanner stage 2 of puberty has been reached. Anthropometry, measurement of bone mineral density, metabolic parameters such as lipid profiles, insulin, glucose, and bone turnover, and psychometric testing should be followed up.",
"   </p>",
"   <p>",
"    This approach is consistent with the Endocrine Society's Clinical Guidelines, which suggest GnRH agonist suppression when girls and boys first exhibit physical changes of puberty, but no earlier than Tanner stages 2 to 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ]. They suggest that pubertal development of the desired opposite sex should be started at about age 16, with a gradually increasing dose of hormones. Surgery is usually delayed until at least age 18 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=see_link&amp;anchor=H113274158#H113274158\">",
"     \"Overview of the management of gender nonconformity in children and adolescents\", section on 'Overview of hormonal interventions for adolescents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HORMONAL THERAPY FOR ADULTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578487429\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial hormonal therapy phase of sex reassignment has two aims:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To suppress the endogenous hormones of the individual's natal sex",
"     </li>",
"     <li>",
"      To induce the secondary sex characteristics of the new sex [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once this has been accomplished, the goal is to maintain cross-sex hormone levels in the normal physiological range for the individual&rsquo;s desired gender. Hormonal therapy must be continued, even after surgical sex reassignment.",
"   </p>",
"   <p>",
"    Of note, many individuals self-medicate with cross-sex hormones for a variety of reasons, including fear of rejection by health care providers, delays in initiation of hormone therapy and, for the uninsured, the cost of undergoing treatment at a multidisciplinary center. Therefore, some patients obtain hormones from other sources, including the internet. Morbidity due to excessive doses has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Involvement of a mental health professional in all stages of the patient's evaluation, diagnosis, endocrine therapy, and surgical reassignment is essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Male-to-female",
"    </span>",
"    &nbsp;&mdash;&nbsp;To male-to-female (MTF) transsexuals, elimination of sexual hair growth, induction of breast formation, and a more female fat distribution are essential. To accomplish this, a near-complete reduction of the biological effects of androgens is required. Administration of estrogens alone will suppress gonadotropin output and therefore androgen production, but dual therapy with one compound that suppresses androgen secretion or action and a second compound that supplies estrogen is more effective. In addition, dual therapy may permit use of lower doses of estrogen. (See",
"    <a class=\"local\" href=\"#H768005246\">",
"     'Major adverse events'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H331025\">",
"    <span class=\"h3\">",
"     Suppression of androgen secretion or action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several agents are available to inhibit androgen secretion or action. We suggest the antiandrogens",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    as first-line therapy given their effectiveness and low cost. Both are also widely used in women for the treatment of hirsutism (",
"    <a class=\"graphic graphic_table graphicRef69460 \" href=\"UTD.htm?40/58/41900\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hirsutism\", section on 'Antiandrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GnRH agonists are another effective option but, given their high cost, they are our second choice for initial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H331058\">",
"    <span class=\"h4\">",
"     Antiandrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     Spironolactone",
"    </a>",
"    , a mineralocorticoid receptor antagonist, is also a competitive inhibitor of the androgen receptor and an inhibitor of 5-alpha reductase activity, and an inhibitor of testicular steroidogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The recommended dose of spironolactone is 100 to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef69460 \" href=\"UTD.htm?40/58/41900\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ]. This is the most widely used drug in the US for male-to-female transsexuals. While GnRH agonists are likely to be more effective for suppressing androgens, they are used less often because of their higher cost (see",
"    <a class=\"local\" href=\"#H354331202\">",
"     'GnRH agonists'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     Cyproterone acetate",
"    </a>",
"    (CPA) is both a progestin and androgen receptor antagonist that is available in most countries, but not the United States. The recommended dose of CPA as an antiandrogen for male-to-female transsexuals is 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H236088609\">",
"    <span class=\"h4\">",
"     Progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     Medroxyprogesterone acetate",
"    </a>",
"    , another progestin, at a dose of 5 to 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    has also been used as a strategy to suppress gonadotropin and, therefore, testosterone secretion. However, it appears to be less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    , and we suggest against its routine use.",
"   </p>",
"   <p>",
"    After orchiectomy, antiandrogens and progestational compounds are no longer needed to suppress testosterone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354331202\">",
"    <span class=\"h4\">",
"     GnRH agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-acting GnRH agonists, used as monthly injections, inhibit gonadotropin secretion and, as result, suppress testicular testosterone production. In one series of 60 MTF transsexual individuals receiving a GnRH agonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    acetate) plus estrogen therapy, testosterone levels were suppressed from a mean at baseline of 542",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (18.8",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    to 15",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (0.53",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    at 12 months with few adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/15\">",
"     15",
"    </a>",
"    ]. However, as noted, the cost of long-acting GnRH agonists often prohibits the use of these agents in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354331209\">",
"    <span class=\"h4\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other potential options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    or nonsteroidal antiandrogens. However, we suggest against the routine use of either.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    inhibits 5-alpha reductase type 2 activity and, therefore, partially inhibits conversion of testosterone to dihydrotestosterone. It has been used in the management of benign prostatic hyperplasia, prostate cancer, hair loss in men and women, and occasionally for hirsutism in women. There are no available data for its use in MTF transsexuals, but in our experience, some patients choose this therapy. The recommended dose is 5",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link&amp;anchor=H10#H10\">",
"     \"Medical treatment of benign prostatic hyperplasia\", section on '5-alpha-reductase inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of androgenetic alopecia in men\", section on 'Finasteride'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hirsutism\", section on 'Antiandrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonsteroidal antiandrogens, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33204?source=see_link\">",
"     nilutamide",
"    </a>",
"    , are occasionally used, but they increase gonadotropin secretion, causing increased secretion of testosterone and estradiol (only the latter would be desirable). We do not suggest their use as they are expensive, and flutamide has been associated with hepatotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hirsutism\", section on 'Antiandrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many MTF transsexuals also undergo laser hair removal treatment for additional cosmetic benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37014?source=see_link&amp;anchor=H11#H11\">",
"     \"Removal of unwanted hair\", section on 'Laser and intense pulsed light'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to suppressing endogenous androgen secretion, exogenous estrogen must be given to induce breast formation and a more female fat distribution.",
"   </p>",
"   <p>",
"    There is a wide range of estrogens from which to choose (",
"    <a class=\"graphic graphic_table graphicRef69460 \" href=\"UTD.htm?40/58/41900\">",
"     table 1",
"    </a>",
"    ). However, we suggest 17 beta-estradiol as first-line therapy. We suggest a route of administration and dosing that is consistent with the Endocrine Society Guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transdermally, 100 to 400 mcg twice a week, or",
"     </li>",
"     <li>",
"      Orally, 2 to 6",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      In Europe, oral 17 beta-estradiol valerate 2 to 4 mg per day is also used",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral ethinyl estradiol, the estrogen used in oral contraceptives, a potent and inexpensive estrogen, has been used in doses of 50 to 100",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    in male-to-female transsexuals, but it is associated with an excess risk of venous thrombosis, particularly in subjects over 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/12,16,17\">",
"     12,16,17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H768005322\">",
"     'Venous thromboembolism'",
"    </a>",
"    below.) It has also been associated with an increased risk of cardiovascular death [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/18\">",
"     18",
"    </a>",
"    ]. We therefore suggest against its use.",
"   </p>",
"   <p>",
"    Oral estrogens should be avoided in patients with familial hypertriglyceridemia, as they may cause severe elevations in triglycerides (&gt;2000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [22.59",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and subsequent acute pancreatitis. We therefore suggest measuring lipids before initiating hormone therapy.",
"   </p>",
"   <p>",
"    Clinical monitoring of the patient&rsquo;s response to exogenous estrogen includes assessment of breast development, which is typically complete after two years of hormone therapy. Serum estradiol concentrations are monitored to avoid supraphysiologic levels for young healthy women (eg, &lt;200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [734",
"    <span class=\"nowrap\">",
"     pmol/L])",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef67967 \" href=\"UTD.htm?42/43/43707\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H578486635\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clinical outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the goal of therapy is to reduce the hormonally-induced male secondary sex characteristics as much as possible, complete elimination is not possible. In male-to-female (MTF) transsexuals, the previous effects of androgens on the skeleton, such as the greater height of men than women, the size and shape of hands, feet, jaws, and pelvis, cannot be reversed.",
"   </p>",
"   <p>",
"    However, there are many changes that do occur (",
"    <a class=\"graphic graphic_table graphicRef54189 \" href=\"UTD.htm?27/61/28636\">",
"     table 3",
"    </a>",
"    ). The initial changes (over the first three to six months) that one can expect include a decrease in libido, facial and body hair, some initial growth of breast tissue, a decrease in oiliness of the skin, and early redistribution of fat mass [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main clinical outcomes include (",
"    <a class=\"graphic graphic_table graphicRef54189 \" href=\"UTD.htm?27/61/28636\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sexual hair &mdash; Adult male beard growth is very resistant to inhibition by combined hormonal intervention, and in Caucasian subjects additional measures such as laser hair removal or electrolysis to eliminate facial hair are necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"       3",
"      </a>",
"      ]. Sexual hair growth on other parts of the body responds more favorably [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Breast development &mdash; Breast formation starts almost immediately after initiation of estrogen administration. Androgens have an inhibitory effect on breast formation and, therefore, estrogens will be most effective in a milieu devoid of androgen action. Breast development is typically maximal at two years, and no further development can be expected. [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/12,20\">",
"       12,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Skin &mdash; Androgen deprivation leads to a decreased activity of the sebaceous glands, and may result in a dry skin or brittle nails [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Body composition &mdash; Following androgen deprivation there is an increase in subcutaneous fat and a decrease in lean body mass [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/21\">",
"       21",
"      </a>",
"      ]. Body weight usually increases.",
"     </li>",
"     <li>",
"      Testes &mdash; Atrophy of the testes (if not surgically removed) occurs over many years [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"       3",
"      </a>",
"      ]. Lacking gonadotropic stimulation, the testes become atrophic and may occasionally enter the inguinal canal, which may cause discomfort.",
"     </li>",
"     <li>",
"      Prostate &mdash; Atrophy of the prostate also occurs over many years [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Voice &mdash; Antiandrogens and estrogens have no effect on the properties of the voice, so male-to-female transsexuals may choose to consult a specialized phoniatric center for speech therapy. Maleness of the voice is not so much determined by the pitch of the voice as by chest resonance and volume. Speech therapy may lead to more feminine speech [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/22\">",
"       22",
"      </a>",
"      ]. Laryngeal surgery may change the pitch of the voice but reduces its range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Long-term maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After sex reassignment surgery, including orchiectomy, antiandrogen therapy must be continued because MTF transsexuals will otherwise continue to experience growth of sexual hair in a male pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/2\">",
"     2",
"    </a>",
"    ]. Although there are no data, antiandrogens appear to help manage this, and we typically use only one-half the starting dose [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ]. This is consistent with the approach of the Endocrine Society.",
"   </p>",
"   <p>",
"    Continuous estrogen therapy is also required to avoid symptoms of hormone deprivation and, most importantly, to prevent bone loss and osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. The appropriate doses of estrogen are described above and in the table (",
"    <a class=\"graphic graphic_table graphicRef69460 \" href=\"UTD.htm?40/58/41900\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Estrogen'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768005246\">",
"    <span class=\"h3\">",
"     Major adverse events",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768005322\">",
"    <span class=\"h4\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective study of over 1000 transsexual individuals, the incidence of venous thromboembolic complications was 2 to 6 percent in male-to-female transsexuals (MTF) treated with oral ethinyl estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/16\">",
"     16",
"    </a>",
"    ]. In a follow-up study of the same cohort, no increased risk was seen in users of estrogen preparations other than ethinyl estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/18\">",
"     18",
"    </a>",
"    ]. In vitro studies show that this thrombogenic effect is typical of oral ethinyl estradiol but not of oral 17 beta-estradiol valerate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/17\">",
"     17",
"    </a>",
"    ]. We suggest that ethinyl estradiol not be used for any MTF transsexuals given its higher thrombogenicity and association with venous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because immobilization is also a risk factor for venous thromboembolic events, estrogen administration should be discontinued three to four weeks before elective surgical interventions. Once subjects are fully mobilized again, estrogen therapy may be resumed.",
"   </p>",
"   <p>",
"    The incidence of thrombophilias appears to be the same in the transsexual population as the general population. Therefore, routine pretreatment screening for thrombophilias is not suggested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768005489\">",
"    <span class=\"h4\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the considerable sex difference in the prevalence of cardiovascular disease between men and women would lead one to expect an effect of hormonal treatment, the actual risk remains to be established. The effects of estrogen administration to male-to-female and of androgens to female-to-male transsexuals on biochemical risk markers are somewhat mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/26\">",
"     26",
"    </a>",
"    ]. But two studies with cardiovascular endpoints showed that cardiovascular mortality in MTF patients treated with anti-androgens and estrogens is higher than in FTM patients treated with testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/18\">",
"     18",
"    </a>",
"    ]. This observation may be due in part to the use of ethinyl estradiol, which has a more thrombotic effect than other oral estrogens. However, in a second report of transgender subjects with low rates of ethinyl estradiol use, a similar pattern of higher cardiovascular morbidity in MTF compared with FTM transsexuals was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 16 studies concluded that cross-sex hormone therapies increase serum triglycerides [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/28\">",
"     28",
"    </a>",
"    ]. We suggest obtaining a fasting lipid panel prior to initiating hormone therapy as patients with familial hypertriglyceridemia could be at risk for severe hypertriglyceridemia (and possible acute pancreatitis) with oral estrogen therapy.",
"   </p>",
"   <p>",
"    We agree with the Endocrine Society guidelines that transsexual persons treated with hormones should be evaluated for cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768005442\">",
"    <span class=\"h4\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates are increased in male-to-female (MTF), but not female-to male (FTM) transsexuals. In a report of 966 male-to-female transsexuals and 365 female-to-male transsexuals, the mortality rate was 51 percent higher in the male-to-female population, mainly due to drug abuse, HIV, cardiovascular disease, and suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/18\">",
"     18",
"    </a>",
"    ]. These findings underscore the need for continued long-term follow-up with a mental health professional and screening for high risk behaviors (unprotected intercourse) in MTF transsexual population. Users of oral ethinyl estradiol had a threefold excess risk of cardiovascular death. As noted, we suggest against the use of ethinyl estradiol in MTF transsexuals (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Estrogen'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768005631\">",
"    <span class=\"h4\">",
"     Hyperprolactinemia/lactotroph adenoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male-to-female transsexuals treated with high dose estrogen (ethinyl estradiol 100",
"    <span class=\"nowrap\">",
"     mcg/day)",
"    </span>",
"    may develop hyperprolactinemia. In a report of 214 MTF transsexuals, 46 (21 percent) experienced an increase in serum prolactin to &gt;48",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (2.1",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/29\">",
"     29",
"    </a>",
"    ]. The incidence of prolactin levels &gt;48",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (2.1",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    was 3.7 to 7.2 percent per year; for most patients, the elevated prolactin levels decreased either spontaneously or after reducing the estrogen dose. Five patients with persistently elevated serum prolactin (even after reduction of the estrogen dose) had enlargement of the pituitary on CT scan. With the lower doses of estrogen that are currently recommended, hyperprolactinemia is likely to be less common.",
"   </p>",
"   <p>",
"    Four cases of lactotroph adenoma (prolactinoma) following high dose estrogen administration have been reported in subjects who had normal serum prolactin concentrations before therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Though causality has not been established, we agree with the Endocrine Society and suggest measuring serum prolactin at baseline, yearly for the first two years, and then every two years in MTF transsexuals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ]. Pituitary MRI is indicated in patients whose prolactin levels do not normalize with reduction of the estrogen dose [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768005895\">",
"    <span class=\"h4\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is very rare in male-to-female (MTF) transsexuals. In a series of 2200 patients accrued between 1975 and 2005, no case of breast cancer had been observed, [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/30\">",
"     30",
"    </a>",
"    ]. However, there have been a total of six published cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/31\">",
"     31",
"    </a>",
"    ] and one unpublished case. Although this is a rare event, routine mammography is suggested for MTF individuals because of their exposure to long-term high doses of estrogen (",
"    <a class=\"graphic graphic_table graphicRef67967 \" href=\"UTD.htm?42/43/43707\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3,32-36\">",
"     3,32-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three cases of prostate cancer in male-to-female transsexuals taking estrogen have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/37\">",
"     37",
"    </a>",
"    ]. It is not clear whether these cancers were estrogen-sensitive or whether they were present before estrogen administration started and progressed to become hormone-independent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578486635\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male-to-female transsexuals taking an estrogen should undergo clinical and laboratory monitoring every three months during the first year and then once or twice yearly (",
"    <a class=\"graphic graphic_table graphicRef67967 \" href=\"UTD.htm?42/43/43707\">",
"     table 2",
"    </a>",
"    ). Serum estradiol concentrations are monitored to avoid supraphysiologic levels for young healthy women (eg, &lt;200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [734",
"    <span class=\"nowrap\">",
"     pmol/L]).",
"    </span>",
"    In addition to measuring estradiol and testosterone, serum prolactin should be monitored because some individuals develop hyperprolactinemia (see",
"    <a class=\"local\" href=\"#H768005631\">",
"     'Hyperprolactinemia/lactotroph adenoma'",
"    </a>",
"    above). This approach is consistent with the approach of the Endocrine Society Clinical Practice Guideline (",
"    <a class=\"graphic graphic_table graphicRef67967 \" href=\"UTD.htm?42/43/43707\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MTF transsexuals treated with estrogen but without other risk factors for breast cancer should follow standard breast screening guidelines for biological women. Prostate cancer is very rare in MTF transsexuals who have undergone gonadectomy. However, it is still suggested that they follow screening guidelines for prostate cancer for biological men [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ]. Bone density should be preserved as long as they continue taking estrogen therapy, even after gonadectomy. However, if they stop estrogen therapy, bone mineral density testing should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Female-to-male",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment in female-to-male transsexuals is to stop menses and induce virilization, including a male pattern of sexual hair, male physical contours, and clitoral enlargement. The principal hormonal treatment is a testosterone preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Androgen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many available testosterone preparations and routes of administration, including injectables, gels, and buccal tablets. We suggest starting with one of the testosterone ester preparations (eg, testosterone enanthate or cypionate), administered intramuscularly in doses of 100 to 200 mg every two weeks, or testosterone undecanoate 1000 mg every 12 weeks (available in Europe, but not the United States) (",
"    <a class=\"graphic graphic_table graphicRef69460 \" href=\"UTD.htm?40/58/41900\">",
"     table 1",
"    </a>",
"    ). Some clinicians start with a lower dose of testosterone (eg, 100 mg testosterone enanthate every two weeks), and then titrate up depending upon the response.",
"   </p>",
"   <p>",
"    Testosterone gel (1 percent, 2.5 to 10",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    or a more concentrated preparation) may also be used [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ], but virilization tends to be somewhat slower initially because of the lower serum testosterone concentrations achieved with the gels. Some clinicians switch to gels once initial virilization is complete. This may help to avoid supraphysiologic testosterone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link&amp;anchor=H12#H12\">",
"     \"Testosterone treatment of male hypogonadism\", section on 'Serum testosterone concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Masculinizing effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of consequences of hormonal therapy in female-to-male (FTM) transsexuals (",
"    <a class=\"graphic graphic_table graphicRef75101 \" href=\"UTD.htm?6/38/6764\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hair &mdash; The development of sexual hair follows essentially the pattern observed in pubertal boys: first the upper lip, then chin, then cheeks, etc [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/19\">",
"       19",
"      </a>",
"      ]. The degree of hirsutism can usually be predicted from the degree and pattern in male members of the same family. The same applies to the occurrence of androgenetic alopecia, &ldquo;male pattern baldness.&rdquo;",
"     </li>",
"     <li>",
"      Voice &mdash; Deepening of the voice occurs after 6 to 10 weeks of androgen administration and is irreversible [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Body composition &mdash; Androgen administration leads to a reduction of subcutaneous fat but increases abdominal fat [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/21\">",
"       21",
"      </a>",
"      ]. The increase in lean body mass is on average 4 kilograms and the increase in body weight is usually greater [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acne &mdash; Acne eventually occurs in approximately 40 percent, similar to that observed in hypogonadal men starting androgen treatment past the age of normal puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clitoral enlargement &mdash; Clitoral enlargement occurs in all, but the degree varies.",
"     </li>",
"     <li>",
"      Libido &mdash; Most subjects will note an increase in libido [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Breasts &mdash; Androgen administration causes a decrease in glandular tissue, resulting in prominent fibrous connective tissue, similar to menopausal mammary changes [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ovaries show polycystic-like changes but they do not appear to meet stringent criteria for polycystic ovary morphology [",
"      <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the goal of therapy is to reduce the female secondary sex characteristics as much as possible, complete elimination is rare. The relatively lower height and the broader hip configuration of FTM transsexuals compared to men will not change with testosterone treatment. Menses usually stop within a few months of starting testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/12\">",
"     12",
"    </a>",
"    ]. However, in some individuals, bleeding may continue. This is almost always the case in patients taking transdermal preparations (such as the gels). If this occurs, we suggest first adding an oral progestin such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (5 to 10 mg daily) or lynestrenol 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (not available in the US) to stop the menstrual bleeding. Some clinicians suggest endometrial ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ]. Other options if bleeding persists include endometrial ablation, a GnRH agonist, or depot medroxyprogesterone acetate. Our approach is consistent with that of the Endocrine Society [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one trial of 35 FTM transsexuals receiving testosterone undecanoate 1000 mg every 12 weeks for one year, mean endometrial thickness (on pelvic ultrasound) decreased from 9.9 to 5.7 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/40\">",
"     40",
"    </a>",
"    ]. In a second study, histologic analysis found inactive, atrophic endometrium in FTM individuals taking long-term testosterone therapy, similar to that seen in postmenopausal women not taking estrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23534981\">",
"    <span class=\"h4\">",
"     Metabolic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of adverse effects are associated with testosterone use in FTM transsexuals, but most occur when serum testosterone concentrations are supraphysiologic. These include erythrocytosis, hypertension, lipid changes, liver dysfunction, and adverse psychological changes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ]. This highlights the importance of maintaining serum levels in the normal physiologic male range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H331201\">",
"    <span class=\"h4\">",
"     Routine monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;After bilateral oophorectomy, testosterone therapy must be continued to maintain virilization and prevent osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/23\">",
"     23",
"    </a>",
"    ]. To make sure that hormone serum testosterone concentrations are maintained in the physiologic range of the desired sex and to minimize the risk of adverse events, endocrine monitoring should include measurement of serum estradiol and testosterone, with a goal of maintaining estradiol &lt;50",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    and testosterone approximately 400 to 800",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (13.9-27.7",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    For patients on testosterone injections, trough levels should be towards the lower end of this range while peak levels should not exceed 1000",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (34.7",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    We agree with the monitoring schedule recommended by the Endocrine Society: evaluate the patient every two to three months in the first year, and then one to two times per year thereafter (",
"    <a class=\"graphic graphic_table graphicRef78811 \" href=\"UTD.htm?24/1/24604\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Women who have undergone mastectomy do not require mammograms. However, if mastectomy is delayed, or not performed, mammography should be performed, particularly if there is a family history of breast cancer.",
"   </p>",
"   <p>",
"    In addition to monitoring weight and blood pressure, other lab testing should include CBC, liver function tests, lipids, and fasting blood glucose (if family history of diabetes). Details of biochemical testing, bone mineral density testing, and need for mammograms are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef78811 \" href=\"UTD.htm?24/1/24604\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Adverse events'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     Adverse events",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h5\">",
"     Heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the effects of androgens on female-to-male transsexuals on biochemical risk markers are somewhat mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/26\">",
"     26",
"    </a>",
"    ]. A meta-analysis of 16 studies concluded that cross-sex hormone therapies increase serum triglycerides in both male-to-female and female-to-male transsexuals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/28\">",
"     28",
"    </a>",
"    ]. However, data about patient important outcomes such as venous thromboembolism and atherosclerosis were limited and inconclusive. Mortality rates are increased in male-to-female (MTF), but not female-to male (FTM) transsexuals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H768005442\">",
"     'Mortality'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We agree with the Endocrine Society guidelines that transsexual persons treated with hormones should be evaluated for cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h5\">",
"     Breast and ovarian cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only two cases of breast cancer have been reported in FTM transsexuals, and they were being treated with supraphysiologic doses of testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two cases of ovarian cancer in female-to-male transsexuals have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. FTM patients who choose surgical sex reassignment typically undergo oophorectomy, hysterectomy, and vaginectomy. In addition, many or most patients undergo mastectomy. In this case, monitoring for breast cancer is not necessary. (See",
"    <a class=\"local\" href=\"#H331201\">",
"     'Routine monitoring'",
"    </a>",
"    above.) However, if mastectomy is delayed, or not performed, mammography should be performed, particularly if there is a family history of breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Contraindications to hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the potential side effects described above, hormonal treatment is contraindicated in certain situations. Contraindications to estrogen use are history of severe thromboembolic disease (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    ), and to androgen use, erythrocytosis, breast or uterine cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several relative contraindications for estrogen use in male-to-female transsexuals associated with moderate to high risk of adverse outcomes include history of breast cancer, cardiovascular disease, cerebrovascular disease, history of severe migraine headaches or severe liver dysfunction. Lactotroph adenomas should be treated before starting estradiol therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relative contraindication for testosterone use in female-to-male transsexuals associated with moderate to high risk of adverse outcomes include liver function test abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SURGICAL SEX REASSIGNMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital sex reassignment surgery is the final step for many transsexual individuals to live successfully in their preferred gender role. The steps that are required before initiating surgical treatment are reviewed above (",
"    <a class=\"graphic graphic_table graphicRef60865 \" href=\"UTD.htm?39/35/40507\">",
"     table 6",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Transitioning to the opposite gender'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Counseling before treatment'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Prior to surgery, the clinician should continue to counsel the patient to acknowledge the limitations of what surgical sex reassignment can achieve. In addition, the patient should continue to work closely with a mental health professional during the surgical intervention and continue hormonal maintenance therapy.",
"   </p>",
"   <p>",
"    The most important procedures to consider are removal of the gonads and genital cosmetic surgery. Cosmetic results of genital surgery have improved and neurological sensation is now typically preserved, resulting in better patient satisfaction with sexual function [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Male-to-female",
"    </span>",
"    &nbsp;&mdash;&nbsp;In male-to-female transsexuals (MTF), a bilateral orchiectomy is performed to remove the main source of endogenous testosterone. In addition to gonadectomy, other procedures include penectomy, cosmetic surgery to create a clitoris, and surgical construction of a vagina, usually using the penile skin for vaginal lining and scrotal skin for the labia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3,49\">",
"     3,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaginal dilators should be used on a regular basis postoperatively to maintain the vaginal length until successful and consistent sexual intercourse has been established.",
"   </p>",
"   <p>",
"    Some individuals choose to have breast augmentation, but this should be delayed until after at least two years of estrogen therapy (when estrogen-induced breast growth is likely to be complete) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Clinical outcomes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cosmetic facial surgery is also sometimes performed to create more feminine features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Female-to-male",
"    </span>",
"    &nbsp;&mdash;&nbsp;For female-to-male transsexuals, an oophorectomy, hysterectomy, and vaginectomy are usually performed after one to two years of androgen therapy, although practice patterns vary [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, genital surgery is required. One option is creation of a neopenis but the surgery is complex and requires multiple stages [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3,50\">",
"     3,50",
"    </a>",
"    ]. In other cases a metoidioplasty may be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. With this technique the urethra is lengthened using an anterior vaginal wall flap to reach the tip of the phallic glans, and the clitoris is partially released and stretched by resection of the ventral chordae. From the labia majora a scrotum can be constructed in which testicular prostheses can be implanted. This surgical intervention allows the patient to urinate standing. Alternatively, free flaps removed from arms or legs can be used to construct a neophallus.",
"   </p>",
"   <p>",
"    Breast size does not decrease much with androgen therapy, and glandular tissue remains [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/42\">",
"     42",
"    </a>",
"    ]. Thus, the other important surgical procedure is mastectomy (chest contouring is sometimes done as well to provide a more masculine upper body habitus) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/50\">",
"     50",
"    </a>",
"    ]. These procedures are typically performed within two to three years of initiating testosterone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Sexual function after sex reassignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little attention has been given to this subject and all research has been based on self-reports. As expected, there is a correlation between sexual function and the quality of the neovagina or neophallus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/52\">",
"     52",
"    </a>",
"    ]. While not all postoperative transsexuals are orgasmic, many more report sexual satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/41,53-56\">",
"     41,53-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A hormonal factor to consider may be the androgen depletion of male-to-female transsexuals. It may be that women need a small amount of androgens to have normal libido, although this is not proven. By contrast, female-to-male transsexuals receiving androgens generally note an increase in sexual interest. Systematic investigation is needed to gain more insight into sexual functioning of postoperative transsexuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Regrets after sex reassignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the irreversibility of sex reassignment surgery, and to a lesser degree of cross-sex hormone administration, it would be desirable to have insight into factors that spell success or failure. Prospective controlled studies specifically designed to assess outcome and its prognostic factors are difficult with this relatively rare condition and are still lacking. However, sex reassignment surgery does appear to improve gender dysphoria and psychological functioning in most individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/53,57\">",
"     53,57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H158223846\">",
"     'Psychosocial outcomes of treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are estimates that 1 to 2 percent will have regrets [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/58\">",
"     58",
"    </a>",
"    ]. Some of these subjects will have experienced gender dysphoria late in adult life, without strong manifestations in childhood; others have difficulty in transitioning to the new sex because of their appearance or limited social skills. Therefore, the importance of the period of transitioning to the opposite gender (the period when hormonal treatment starts and subjects are, with trial and error, required to live socially the life of the desired sex) cannot be overemphasized (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Transitioning to the opposite gender'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158223846\">",
"    <span class=\"h1\">",
"     PSYCHOSOCIAL OUTCOMES OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex reassignment that includes hormonal therapies results in significant improvements in quality of life and psychosocial outcomes. This was illustrated in a meta-analysis of 28 studies that enrolled 1833 individuals with gender identity disorder (1093 male-to-female, 801 female-to-male) who underwent sex reassignment that included hormonal therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/25/8602/abstract/53\">",
"     53",
"    </a>",
"    ]. In the pooled analysis, the percentage of patients reporting improvements in symptoms included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gender dysphoria &mdash; 80 percent",
"     </li>",
"     <li>",
"      Psychological symptoms &mdash; 78 percent",
"     </li>",
"     <li>",
"      Quality of life &mdash; 80 percent",
"     </li>",
"     <li>",
"      Sexual function &mdash; 72 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/41/7826?source=see_link\">",
"       \"Patient information: Transsexualism (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H331321\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transsexualism is the condition in which a person with apparently normal somatic sexual differentiation of one gender is convinced that he or she is actually a member of the opposite gender. It is associated with an irresistible urge to be that gender hormonally, anatomically, and psychosocially.",
"     </li>",
"     <li>",
"      The international organization involved with professional help to transsexuals, the World Professional Association for Transgender Health (WPATH), has drafted Standards of Care for the diagnosis and treatment of individuals with transsexualism (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Standards of care'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      If, in an expert's opinion, a child's cross-sex gender identity will not change during long-term follow-up, the individual may be treated with GnRH agonists to delay the onset of puberty until an age that a balanced and responsible decision can be made to transition to the other sex (see",
"      <a class=\"local\" href=\"#H331478\">",
"       'Treatment of adolescents'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Before initiating hormonal or surgical treatment that will change a person's gender, the clinician should counsel the patient about risks and benefits of the hormonal or surgical therapy, as well as realistic expectations about outcomes (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Counseling before treatment'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In addition, before undergoing surgical reassignment, individuals are expected to undergo a social transition into the desired gender role by living full-time as a member of the desired gender that is typically initiated before or with hormone therapy (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Transitioning to the opposite gender'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      For male-to-female transsexuals we suggest antiandrogen therapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"       cyproterone acetate",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), and transdermal estradiol or oral 17 beta-estradiol for estrogen replacement (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Male-to-female'",
"      </a>",
"      above.) We suggest against the use of ethinyl estradiol (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For female-to-male transsexuals, we suggest either testosterone esters administered intramuscularly or transdermal preparations of testosterone, depending upon patient preference (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, initially, clinical results are typically more rapid with parenteral therapy (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Female-to-male'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Male-to-female transsexuals treated with estrogen should follow the same screening guidelines for breast cancer as biological women. This may apply also to female-to-male transsexuals whose breast ablation is delayed particularly if there is a family history of breast cancer (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Breast and ovarian cancer'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We agree with the Endocrine Society guidelines that male-to-female transsexuals treated with estrogen should follow the screening guidelines for prostate disease and prostate cancer recommended for men (see",
"      <a class=\"local\" href=\"#H578486635\">",
"       'Monitoring'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Surgical sex reassignment is considered after living one year in the desired gender role and after one year of continuous hormone therapy. Details of surgery are described above (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Surgical sex reassignment'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Professional Association for Transgender Health. Standards of care for gender identity disorders. file://wpath.org/publications_standards.cfm (Accessed on September 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/2\">",
"      Gooren LJ. Clinical practice. Care of transsexual persons. N Engl J Med 2011; 364:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/3\">",
"      Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/4\">",
"      De Sutter P. Gender reassignment and assisted reproduction: present and future reproductive options for transsexual people. Hum Reprod 2001; 16:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/5\">",
"      Wierckx K, Van Caenegem E, Pennings G, et al. Reproductive wish in transsexual men. Hum Reprod 2012; 27:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/6\">",
"      Houk CP, Lee PA. The diagnosis and care of transsexual children and adolescents: a pediatric endocrinologists' perspective. J Pediatr Endocrinol Metab 2006; 19:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/7\">",
"      Cohen-Kettenis PT, van Goozen SH. Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent. Eur Child Adolesc Psychiatry 1998; 7:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/8\">",
"      Delemarre-van de Waal, Cohen-Kettenis PT. Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. Eur J Endocrinol. 2006; 155 Suppl 1:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/9\">",
"      Spack NP. Management of transgenderism. JAMA 2013; 309:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/10\">",
"      Gooren L. Hormone treatment of the adult transsexual patient. Horm Res 2005; 64 Suppl 2:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/11\">",
"      Becerra Fern&aacute;ndez A, de Luis Rom&aacute;n DA, Pi&eacute;drola Maroto G. [Morbidity in transsexual patients with cross-gender hormone self-treatment]. Med Clin (Barc) 1999; 113:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/12\">",
"      Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003; 88:3467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/13\">",
"      Tangpricha V, Ducharme SH, Barber TW, Chipkin SR. Endocrinologic treatment of gender identity disorders. Endocr Pract 2003; 9:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/14\">",
"      Zitzmann M, Erren M, Kamischke A, et al. Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. J Clin Endocrinol Metab 2005; 90:6603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/15\">",
"      Dittrich R, Binder H, Cupisti S, et al. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2005; 113:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/16\">",
"      van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997; 47:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/17\">",
"      Toorians AW, Thomassen MC, Zweegman S, et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab 2003; 88:5723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/18\">",
"      Asscheman H, Giltay EJ, Megens JA, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011; 164:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/19\">",
"      Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 2000; 85:2913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/20\">",
"      Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf) 2003; 59:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/21\">",
"      Lapauw B, Taes Y, Simoens S, et al. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone 2008; 43:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/22\">",
"      de Bruin MD, Coerts MJ, Greven AJ. Speech therapy in the management of male-to-female transsexuals. Folia Phoniatr Logop 2000; 52:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/23\">",
"      van Kesteren P, Lips P, Gooren LJ, et al. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf) 1998; 48:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/24\">",
"      Mueller A, Dittrich R, Binder H, et al. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. Eur J Endocrinol 2005; 153:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/25\">",
"      Ruetsche AG, Kneubuehl R, Birkhaeuser MH, Lippuner K. Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study. Osteoporos Int 2005; 16:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/26\">",
"      Elbers JM, Giltay EJ, Teerlink T, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf) 2003; 58:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/27\">",
"      Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med 2012; 9:2641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/28\">",
"      Elamin MB, Garcia MZ, Murad MH, et al. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf) 2010; 72:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/29\">",
"      Asscheman H, Gooren LJ, Assies J, et al. Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals. Clin Endocrinol (Oxf) 1988; 28:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/30\">",
"      Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008; 93:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/31\">",
"      Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008; 159:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/32\">",
"      Grabellus F, Worm K, Willruth A, et al. ETV6-NTRK3 gene fusion in a secretory carcinoma of the breast of a male-to-female transsexual. Breast 2005; 14:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/33\">",
"      Symmers WS. Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. Br Med J 1968; 2:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/34\">",
"      Pritchard TJ, Pankowsky DA, Crowe JP, Abdul-Karim FW. Breast cancer in a male-to-female transsexual. A case report. JAMA 1988; 259:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/35\">",
"      Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg 1995; 82:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/36\">",
"      Dhand A, Dhaliwal G. Examining patient conceptions: a case of metastatic breast cancer in an African American male to female transgender patient. J Gen Intern Med 2010; 25:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/37\">",
"      van Haarst EP, Newling DW, Gooren LJ, et al. Metastatic prostatic carcinoma in a male-to-female transsexual. Br J Urol 1998; 81:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/38\">",
"      Dobs AS, McGettigan J, Norwood P, et al. A novel testosterone 2% gel for the treatment of hypogonadal males. J Androl 2012; 33:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/39\">",
"      Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med 2008; 5:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/40\">",
"      Mueller A, Kiesewetter F, Binder H, et al. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab 2007; 92:3470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/41\">",
"      Wierckx K, Elaut E, Van Caenegem E, et al. Sexual desire in female-to-male transsexual persons: exploration of the role of testosterone administration. Eur J Endocrinol 2011; 165:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/42\">",
"      Slagter MH, Gooren LJ, Scorilas A, et al. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. J Histochem Cytochem 2006; 54:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/43\">",
"      Futterweit W, Deligdisch L. Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab 1986; 62:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/44\">",
"      Ikeda K, Baba T, Noguchi H, et al. Excessive androgen exposure in female-to-male transsexual persons of reproductive age induces hyperplasia of the ovarian cortex and stroma but not polycystic ovary morphology. Hum Reprod 2013; 28:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/45\">",
"      Perrone AM, Cerpolini S, Maria Salfi NC, et al. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med 2009; 6:3193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/46\">",
"      Shao T, Grossbard ML, Klein P. Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management. Clin Breast Cancer 2011; 11:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/47\">",
"      Hage JJ, Dekker JJ, Karim RB, et al. Ovarian cancer in female-to-male transsexuals: report of two cases. Gynecol Oncol 2000; 76:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/48\">",
"      Dizon DS, Tejada-Berges T, Koelliker S, et al. Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Invest 2006; 62:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/49\">",
"      Karim RB, Hage JJ, Mulder JW. Neovaginoplasty in male transsexuals: review of surgical techniques and recommendations regarding eligibility. Ann Plast Surg 1996; 37:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/50\">",
"      Monstrey SJ, Ceulemans P, Hoebeke P. Sex Reassignment Surgery in the Female-to-Male Transsexual. Semin Plast Surg 2011; 25:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/51\">",
"      Hage, JJ. Metaidoioplasty: an alternative phalloplasty technique in transsexuals. Plast Reconstr Surg 1009; 97:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/52\">",
"      Green R. Sexual functioning in post-operative transsexuals: male-to-female and female-to-male. Int J Impot Res 1998; 10 Suppl 1:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/53\">",
"      Murad MH, Elamin MB, Garcia MZ, et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol (Oxf) 2010; 72:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/54\">",
"      Lawrence AA, Latty EM, Chivers ML, Bailey JM. Measurement of sexual arousal in postoperative male-to-female transsexuals using vaginal photoplethysmography. Arch Sex Behav 2005; 34:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/55\">",
"      Klein C, Gorzalka BB. Sexual functioning in transsexuals following hormone therapy and genital surgery: a review. J Sex Med 2009; 6:2922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/56\">",
"      Wierckx K, Van Caenegem E, Elaut E, et al. Quality of life and sexual health after sex reassignment surgery in transsexual men. J Sex Med 2011; 8:3379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/57\">",
"      Weyers S, Elaut E, De Sutter P, et al. Long-term assessment of the physical, mental, and sexual health among transsexual women. J Sex Med 2009; 6:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/25/8602/abstract/58\">",
"      Lawrence AA. Factors associated with satisfaction or regret following male-to-female sex reassignment surgery. Arch Sex Behav 2003; 32:299.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7456 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8602=[""].join("\n");
var outline_f8_25_8602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H331321\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Standards of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Counseling before treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transitioning to the opposite gender",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H331478\">",
"      TREATMENT OF ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HORMONAL THERAPY FOR ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H578487429\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Male-to-female",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H331025\">",
"      - Suppression of androgen secretion or action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H331058\">",
"      Antiandrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H236088609\">",
"      Progestins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H354331202\">",
"      GnRH agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H354331209\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clinical outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Long-term maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H768005246\">",
"      - Major adverse events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H768005322\">",
"      Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H768005489\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H768005442\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H768005631\">",
"      Hyperprolactinemia/lactotroph adenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H768005895\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H578486635\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Female-to-male",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Androgen therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Masculinizing effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23534981\">",
"      Metabolic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H331201\">",
"      Routine monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Adverse events",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Breast and ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Contraindications to hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SURGICAL SEX REASSIGNMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Male-to-female",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Female-to-male",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Sexual function after sex reassignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Regrets after sex reassignment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H158223846\">",
"      PSYCHOSOCIAL OUTCOMES OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H331321\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7456\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7456|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/58/41900\" title=\"table 1\">",
"      Hormone regimens in the transsexual persons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/43/43707\" title=\"table 2\">",
"      Monitoring of MTF transsexual persons on cross-hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/61/28636\" title=\"table 3\">",
"      Feminizing effects in male-to-female transsexual persons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/38/6764\" title=\"table 4\">",
"      Masculinizing effects in female-to-male transsexual persons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/1/24604\" title=\"table 5\">",
"      Monitoring of FTM transsexual persons on cross-hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/35/40507\" title=\"table 6\">",
"      Sex reassignment surgery eligibility and readiness criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=related_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=related_link\">",
"      Overview of gender development and clinical presentation of gender nonconformity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=related_link\">",
"      Overview of the management of gender nonconformity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/41/7826?source=related_link\">",
"      Patient information: Transsexualism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37014?source=related_link\">",
"      Removal of unwanted hair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2630?source=related_link\">",
"      Transsexualism: Epidemiology, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=related_link\">",
"      Treatment of androgenetic alopecia in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=related_link\">",
"      Treatment of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_25_8603="Causes of elevated ICP";
var content_f8_25_8603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of intracranial hypertension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Traumatic brain injury/Intracranial hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Subdural, epidural, or intraparenchymal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ruptured aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diffuse axonal injury&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Arteriovenous malformation or other vascular anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system infections (eg, encephalitis, meningitis, abscess)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemic stroke&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocephalus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic intracranial hypertension (pseudotumor cerebri)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8603=[""].join("\n");
var outline_f8_25_8603=null;
var title_f8_25_8604="Major causes of thyroid nodules";
var content_f8_25_8604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of thyroid nodules",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Benign",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multinodular (sporadic) goiter (\"colloid adenoma\")",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hashimoto's (chronic lymphocytic) thyroiditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cysts: colloid, simple, or hemorrhagic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Follicular adenomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Macrofollicular adenomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Microfollicular or cellular adenomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Hurthle-cell (oxyphil-cell) adenomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Macro- or microfollicular patterns",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Malignant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Papillary carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Follicular carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Minimally or widely invasive",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Oxyphilic (Hurthle-cell) type",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Medullary carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anaplastic carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primary thyroid lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metastatic carcinoma (Breast, renal cell, others)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8604=[""].join("\n");
var outline_f8_25_8604=null;
var title_f8_25_8605="Nonoccupat HIV exposure labs";
var content_f8_25_8605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended laboratory evaluation for nonoccupational postexposure prophylaxis (nPEP) of HIV infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Baseline",
"       </td>",
"       <td class=\"subtitle1\">",
"        During nPEP*",
"       </td>",
"       <td class=\"subtitle1\">",
"        4-6 weeks after exposure",
"       </td>",
"       <td class=\"subtitle1\">",
"        3 months after exposure",
"       </td>",
"       <td class=\"subtitle1\">",
"        6 months after exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV antibody testing",
"       </td>",
"       <td>",
"        E, S&bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        E",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete blood count with differential",
"       </td>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum liver enzymes",
"       </td>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood urea nitrogen/ creatinine",
"       </td>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sexually transmitted diseases screen (gonorrhea, chlamydia, syphilis)",
"       </td>",
"       <td>",
"        E, S",
"       </td>",
"       <td>",
"        E&Delta;",
"       </td>",
"       <td>",
"        E&Delta;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B serology",
"       </td>",
"       <td>",
"        E, S",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        E&Delta;",
"       </td>",
"       <td>",
"        E&Delta;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis C serology",
"       </td>",
"       <td>",
"        E, S",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        E",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy test (for women of reproductive age)",
"       </td>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        E&Delta;",
"       </td>",
"       <td>",
"        E&Delta;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV viral load",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        E&loz;",
"       </td>",
"       <td>",
"        E&loz;",
"       </td>",
"       <td>",
"        E&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV resistance testing",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        E&loz;",
"       </td>",
"       <td>",
"        E&loz;",
"       </td>",
"       <td>",
"        E&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD4+T lymphocyte count",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        E&loz;",
"       </td>",
"       <td>",
"        E&loz;",
"       </td>",
"       <td>",
"        E&loz;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     E: exposed patient; S: source.",
"     <br>",
"      * Other specific tests might be indicated dependent on the antiretrovirals prescribed. Literature pertaining to individual agents should be consulted.",
"      <br>",
"       &bull; HIV antibody testing of the source patient is indicated for sources of unknown serostatus.",
"       <br>",
"        &Delta; Additional testing for pregnancy, sexually transmitted diseases, and hepatitis B should be performed as clinically indicated.",
"        <br>",
"         &loz; If determined to be HIV infected on follow-up testing; perform as clinically indicated once diagnosed.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     CDC. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. MMWR 2005; 54(RR-02):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8605=[""].join("\n");
var outline_f8_25_8605=null;
var title_f8_25_8606="Lisinopril reduces mortality in patients with diabetes after MI";
var content_f8_25_8606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lisinopril reduces mortality in patients with diabetes after acute MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 240px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The GISSI-3 trial enrolled 18,131 patients of whom 2790 were diabetics. Treatment with lisinopril was associated with a significant 29.8 percent reduction in the six-week mortality among diabetics after myocardial infarction (MI), translating into 37 lives saved per 1000 patients. Lisinopril was less effective in nondiabetics; there was only a 5 percent reduction in mortality or three lives saved per 1000 patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Zuanetti G, Latini R, Maggioni AP, et al, for the GISSI-3 Investigators. Circulation 1997; 96:4239.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8606=[""].join("\n");
var outline_f8_25_8606=null;
var title_f8_25_8607="Silver stain lung 1B answer";
var content_f8_25_8607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumocystis carinii",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Giemsa stain of impression smear of lung tissue (x1000). With this stain, the trophozoites of Pneumocystis carinii appear as small, reddish oval forms (arrow), while the unstained cysts of P. carinii appear as clear haloes. P. carinii can also be identified in specimens using fluorescent antibody techniques.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_25_8607=[""].join("\n");
var outline_f8_25_8607=null;
